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Epstein-Barr virus (EBV) asymptomatically infects >90% of the world population but is 
also associated with multiple malignancies. The EBV latent nuclear proteins EBNA2, 3A, 
3B and 3C orchestrate changes in host gene transcription to drive B-cell immortalisation 
by hijacking cellular DNA-binding transcription factors. This project set out to obtain 
thermodynamic and structural information on host transcription factor RBP-Jkappa, the 
DNA-binding mediator of the Notch pathway, and its interactions with the EBNAs. 
EBNA2 activates transcription by binding RBP-Jkappa through the same WΦP motif 
found in Notch proteins. EBNA3 proteins bind RBP-Jkappa through a distinct motif 
(TΦGC) and compete with EBNA2 for binding, inhibiting EBNA2-mediated gene 
activation, but can also use RBP-Jkappa to bind DNA independently. Interestingly, 
EBNA3C also contains an adjacent WΦP motif (WTP) that can bind RBP-Jkappa in vitro. 
We used Isothermal Titration Calorimetry (ITC) to measure binding affinities of EBNA2 
and EBNA3C peptides containing these motifs to RBP-Jkappa. We found that EBNA2 
peptides bound RBPJ-kappa via its WWP motif with an affinity 10-fold less than the WLP 
motif of Notch 2. Surprisingly, we found that EBNA3 peptides containing TΦGC motifs 
did not bind to RBP-Jkappa in vitro. Phosphorylation of the threonine in this motif did 
not lead to any detectable binding. However, EBNA3C peptides containing both the 
TFGC and WTP motifs bound RBP-Jkappa with a similar affinity to EBNA2 peptides, but 
this interaction was entirely mediated by the WTP motif. We also demonstrated that the 
EBNA3C TFGC peptide could not compete with EBNA2 for RBP-Jkappa binding using a 
fluorescent polarisation binding assay. Interestingly, we found that an EBNA3A peptide 
bound weakly to RBP-Jkappa via a motif with similar physiochemistry to the Notch WTP 
motif (FKL) and not its TLFC motif. These data indicate that TΦGC motifs in EBNA3 
proteins may only direct RBPJ-kappa binding in the context of other EBNA3C residues in 
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Chapter 1 : Introduction 
1.1 : Epstein-Barr virus 
1.1.1 : Discovery of Epstein-Barr virus 
Anthony Epstein had originally worked on viruses which caused tumours to grow in 
animals. A chance attendance at a lecture being given by Denis Burkitt would set the 
discovery of the first cancer causing virus in humans in motion. Denis Burkitt identified 
tumours growing on children’s jaws whilst serving as a doctor in Uganda after World 
War II. After searching for records of similar cases he identified that there was a 
geographical correlation between high incidences of Burkitts lymphoma and the 
altitude and microclimate of the homes of the patients (Burkitt, 1958, Burkitt, 1962). 
Denis Burkitt identified that, in the malaria belt of equatorial Africa, Burkitts lymphoma 
was the most common childhood cancer. Secondly, he identified that a higher number 
of cases of Burkitts lymphoma manifested in humid low lands compared to highlands 
which, had drier climates. He hypothesised that the Burkitts lymphoma was being 
transferred by an infectious agent being administered by mosquitos in a similar 
manner to malaria (Burkitt, 1962).  
Upon learning this, Anthony Epstein applied and won a grant from the British Empire 
Cancer Campaign to go to East Africa to collect samples of Burkitts lymphoma to 
elucidate if there was an infectious agent. Initial attempts to identify a virus from the 
Burkitts lymphoma tissues samples were unsuccessful, most likely due to the tissue 
eliciting an immune response. Epstein hypothesised that by culturing Burkitts cells this 
could be avoided. They achieved this by accident when a sample of cells being flown 
from Uganda was delayed by fog. The following week Epstein observed a cloudy 
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substance had formed in the tissue fluid but inspection under a microscope revealed 
that cloudy fluid was proliferating lymphoblasts not bacterial contamination (Epstein, 
2012). The cells (then referred to as EB (Epstein-Barr) cells) were cultured by Yvonne 
Barr which, Anthony Epstein and Bert Achong used to take the first images of Epstein-
Barr viral capsids using Electron Microscopy in 1964 (Epstein et al., 1964a, Epstein and 
Barr, 1964). The capsid’s morphology and shape appeared to be that of a herpes virus 
but analysis with fluorescently tagged antibodies grown against known herpes viruses 
of the time, tested negative in the EB cell line suggesting the virus was novel. In 
addition to this, globulins, grown against EB cells, only bound to small proportion of EB 
cells (1-3%) but were found in over 90% of serum donations (from US donors) 
suggesting that a large proportion of the population had the virus (Epstein et al., 1965, 
Henle et al., 1969). Later studies would show that EBV predominantly exists as an 
episome in persistent infections explaining why so few of the lymphoblasts were 
shown to contain EBV (Babcock et al., 1999). However, there was still scepticism that 
the EBV was causing cancers in humans and was suggested to be a passenger rather 
than a driver of metastasis. However, detection of EBV DNA in Nasopharyngeal 
carcinomas from south east Asia in 1970 and EBV being associated with Non-Hodgkins 
lymphoma and oral hairy leukoplakia in acquired immune deficiency syndrome (AIDS) 
patients in the subsequent decade built a strong case for EBV being a cancer causing 
virus (zur Hausen et al., 1970, Greenspan et al., 1985, Jones et al., 1988). In addition to 
this the association of Kaposi’s sarcoma in human immunodeficiency virus (HIV) 
patients with Kaposi's sarcoma-associated herpesvirus (KSHV) in 1994 and Human 
papilloma virus being proven to cause cervical cancer in 2002, demonstrated that 
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Anthony Epstein had been correct and viruses could cause cancers in humans (Bosch et 
al., 2002, Gonçalves et al., 2017). 
The discovery of the link between infectious mononucleosis and EBV similarly relied on 
a fruitful accident. Anthony Epstein had sent the EB cells to the Henle laboratory in 
Philadelphia for analysis as British laboratories refused to collaborate on a project that 
insinuated a virus could cause human cancers. Their technician had donated 
lymphocytes for experiments that did not immortalise in culture (Levine 1985, H, 
2005). However, one week later she fell ill with infectious mononucleosis, potentially 
from the EB cells, after which her lymphocytes immortalised in culture and she had 
also developed EBV-specific antibodies. Samples donated from Yale university from 
students before and after suffering from infectious mononucleosis were later used to 
confirm the link between EBV and infectious mononucleosis (Henle et al., 1968). As 
EBV is spread by the exchange of saliva amongst adolescents and infectious 
mononucleosis manifests from an over reactive T cell response to an EBV infection, 
infectious mononucleosis gained the nickname ‘the kissing disease’ (Balfour et al., 
2013, Balfour et al., 2015).   
The decades of research into EBV has not only contributed vast amounts of 
information into EBV biology and potential pathways to human cancer development, 
but has also produced EBV immortalised B cell lines, which have proven invaluable to B 
cell biology and genomic studies (Pope et al., 1968, Menezes et al., 1975, Ben-Bassat et 





1.1.2 : EBV infection 
EBV is spread to new hosts through the exchange of saliva (Niederman et al., 1976). 
EBV is a gamma herpes virus that establishes a persistent infection in B cells (Epstein et 
al., 1964a, Moghaddam et al., 1997). There is debate as to whether the primary site of 
infection is in epithelial oropharyngeal cells or in circulating B cells in the oropharynx 
(Sixbey et al., 1984, Allday and Crawford, 1988). The lytic model of infection starts 
when EBV enters the oropharyngeal tissues via interactions between EBV glycoprotein 
BMRF-2 and epithelial cell integrin 1 receptors (Xiao et al., 2009). EBV, upon infecting 
the oropharynx, intiates the lytic programme of expression expressing 80 genes which 
manufacture new virus leading to shedding of EBV virus (Yao et al., 1985, Farrell, 
2001). However, to enter host B cells during infection EBV major envelope glyco-
protein gp350, binds to B cell protein CD21 (Fingeroth et al., 1984, Nemerow et al., 
1987). HLA class II molecules have also been shown to act as co-receptors via 
interactions with the EBV glycol-protein gp42 whilst EBV docks to B cells (Li et al., 
1997). Upon entry to B cells the EBV capsid disassembles releasing the EBV genome. 
EBV switches its linear genome to a circular genome expressing 9 latent genes and a 
number of untranslated mRNAs initially from the C promoter (Cp) or W promoter (Wp) 
and then from the LMP, EBER and BART promoters (Adams and Lindahl, 1975, Baer et 
al., 1984, Farrell, 2001). This makes treatment of EBV diseases by the common antiviral 
drug aciclovir, which targets linear viral genome replication, not possible (Sixbey and 
Pagano, 1985).  
Latency genes are expressed upon infection of naïve B cells and memory B cells 
circulating underneath the nasopharyngeal epithelium (Miyashita et al., 1997, Babcock 
et al., 1999)(Figure 1.1). During Latency III EBV expresses 6 Epstein-Barr Nuclear 
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Antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP), 3 Latent Membrane 
Proteins (LMP1, LMP2A, LMP2B) and non-coding RNAs (EBERs) (Babcock et al., 2000, 
Babcock and Thorley-Lawson, 2000)(Figure 1.1). In vitro only EBNA-LP, EBNA2, EBNA3A 
and EBNA3C are required to immortalise B cell lines. However, in vivo EBV latency III 
EBV transcription factors mediate B cell expression to promote B cell growth, mediate 
cell-cell contacts, drive B cell maturation and encourage immune evasion (Sinclair et 
al., 1994, Stewart et al., 2004, McClellan et al., 2012). Latency III expression is thought 
to be brief as EBV viral proteins have been shown trigger immune responses from 
cytotoxic T cells. Cytotoxic T cells are thought to control the progress of EBV latency 
infections and prevent excessive outgrowth of EBV infected cells (Niedobitek et al., 
1997, MacArthur et al., 2007)(Figure 1.1). Latency II expression (EBNA1, EBNA-LP, 
LMP1, LMP2A, LMP2B and EBERs) is thought to protect EBV infected B cells from 
germinal centre selection as LMP1 and LMP2 have been shown to mimic CD40 and B 
cell receptor (BCR) respectively cloaking the cells from autoreactive immune 
surveillance (Wang et al., 1985, Gires et al., 1997, Caldwell et al., 1998)(Figure 1.1.). 
Following migration through the germinal centre EBV infected B cells migrate to B cell 
memory pool adopting minimalistic EBV expression programmes latency I (EBNA1 and 
EBERs) and latency 0 (EBERs) (Babcock et al., 2000)(Figure 1.1). In addition to this B 
memory cells infected by EBV in the oropharynx have been suggested to migrate 
directly to the B cell memory pool (Babcock et al., 1999). The EBV genome has been 
shown to persist as an episome in the nucleus of infected B cells in the B cell memory 
pool (Babcock et al., 2000). It is suggested that EBV reactivates or partially reactivates 
lytic expression programmes in order to produce virus to infect new hosts however, 

















































































































































































































1.1.3 : EBNA1  
EBNA1 was the first EBNA discovered and is essential for sustaining immortalisation in 
B cells (Reedman and Klein, 1973, Humme et al., 2003, Altmann et al., 2006). EBNA1 is 
required for the maintenance of the EBV genome through host cell division (Yates et 
al., 1984, Yates and Guan, 1991). To do this, EBNA1 associates with the latent origin of 
replication as a dimer via 18bp palindromic sequences in DS element of the oriP during 
the S phase of the cell cycle (Rawlins et al., 1985, Yates et al., 1985, Jones et al., 1989, 
Ambinder et al., 1990, Shah et al., 1992, Wu et al., 1996). As EBNA1 possesses no 
helicase or DNA melting activity of its own, it recruits host DNA polymerase to facilitate 
the replication of the EBV genome (Frappier and O'Donnell, 1991, Schepers et al., 
2001). EBNA1 has been shown to recruit origin of complex (ORC) to the DS element to 
facilitate EBV DNA replication (Dhar et al., 2001, Schepers et al., 2001). During cell 
division EBNA1 mediates the even distribution of the EBV episome between the 
daughter cells by tethering the episome to host chromatin (Hodin et al., 2013). EBNA1 
has also been shown to activate the expression of Cp and LMP1 promoters via binding 
through the Fr element (Sugden and Warren, 1989, Gahn and Sugden, 1995). EBNA1 
can also downregulate its own expression from the Q promoter (Nonkwelo et al., 
1996). Additionally, 903 EBNA1 binding sites on the host genome in B cells have been 
identified and approximately 7% of these sites were proximal to transcription start 
sites (TSS) (Lu et al., 2010). However, the mechanism of how EBNA1 mediates 
transcription is not yet understood. EBNA1 has been shown to promote cell survival 
and immortalisation through its effects on host proteins such as USP70 where it 
competes with with p53 for USP70 binding (Humme et al., 2003, Altmann and 
Hammerschmidt, 2005, Altmann et al., 2006). EBNA1 is thought to prevent p53 binding 
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resulting in decreased levels of p53 which is suggested to prevent cell cycle arrest 
during infection (Holowaty et al., 2003, Saridakis et al., 2005). EBNA1 has also been 
shown to interfere with NFκB and TGFβ signalling (Wood et al., 2007, Valentine et al., 
2010).  
1.1.4 : LMPs 
Latent membrane protein 1 (LMP1) expression is controlled by its bidirectional 
promoter, which expresses LMP1 and LMP2B in opposite directions (Laux et al., 
1994b). RBP-Jκ and PU.1 sites in the promoter allow EBNA2 and EBNA3C to mediate 
the expression of LMP1 and LMP2B (Allday et al., 1993b, Allday and Farrell, 1994, 
Henkel et al., 1994, Sjoblom et al., 1995, Sjoblom et al., 1998b). However, during an 
established infection, LMP1 co-ordinates multiple host signalling pathways to regulate 
its own expression (Sjoblom et al., 1998a, Rowe et al., 2014). LMP1 has been shown to 
mimic CD40 receptors which is suggested  to prevent autoreactive immune responses 
destroying the EBV infected cell in the germinal centre (Uchida et al., 1999). LMP1 has 
6 membrane spanning domains which tether LMP1 to the cell membrane (Fennewald 
et al., 1984). Upon associating with the cell membrane LMP1 clusters into aggregates, 
which intercalate into lipid rafts to provide a platform for signalling (Mann et al., 1985, 
Gires et al., 1997, Ardila-Osorio et al., 1999, Higuchi et al., 2001). The LMP1 C-terminal 
activation region 1 transformation effector site 1 (CTAF-TES1) is bound by the Tumour 
necrosis factor receptor associated factors (TRAF) 1,2,3 and 5 at a PXQXT motif which  
activates the non-canonical NFκB signalling pathway (Devergne et al., 1996, Gires et 
al., 1997, Devergne et al., 1998). TRAF6 binds to the LMP1 CTAF-TES2 via TRADD or 
RIP1, which activates the canonical NFκB signalling pathway (Izumi and Kieff, 1997, 
Schultheiss et al., 2001, Luftig et al., 2003, Huye et al., 2007). NFκB signalling promotes 
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cell survival of EBV infected cells during their journey through the germinal centre 
(Devergne et al., 1998, Babcock et al., 2000, Cahir-McFarland et al., 2004). LMP1 is also 
shown to activate the PI3K/AKT and JNK signalling pathways which are thought to 
promote longevity of the EBV infected cell via telomerase activity after it has migrated 
through the germinal centre (Ding et al., 2007, Shair et al., 2007, Yang et al., 2014). 
Latent membrane protein 2 (LMP2) is expressed as 2 proteins LMP2A and LMP2B (Laux 
et al., 1988, Rowe et al., 1988, Laux et al., 1989, Sample et al., 1989, Rowe et al., 
1990). After primary infection, LMP2 is suggested to self-regulate its expression using 
host factors it activates such as Notch (Anderson and Longnecker, 2008a). LMP2 
inserts into the cell membrane via its multiple hydrophobic α-helices and 
palmitoylation (Matskova et al., 2001, Katzman and Longnecker, 2004). Like LMP1, 
LMP2 aggregates in the membrane (Matskova et al., 2001). The N-terminal domains 
contain tyrosine residues, which are hyper-phosphorylated in order to bind to host 
proteins with SH3 domains (Longnecker et al., 1991, Burkhardt et al., 1992, Fruehling 
et al., 1998). The N-terminal domain also contains proline rich regions which can bind 
neural precursor cell expressed developmentally down-regulated protein (NEDD) 
ubiquitinases which tag the LMP2A for degradation reglulating LMP2A activity (Ikeda 
et al., 2003). Through these interactions with host proteins, LMP2 mimics B cell 
receptor (BCR) signalling by hijacking PI3K, Notch, Bcl2, ERK/MAPK and p27 signalling 
pathways to promote B cell growth, survival, maturation and migration during an EBV 
infection (Henderson et al., 1991, Caldwell et al., 1998, Fruehling et al., 1998, Babcock 
et al., 2000, Pegtel et al., 2005, Anderson and Longnecker, 2008a, Anderson and 
Longnecker, 2008b, Shair et al., 2012, Fish et al., 2014).   
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1.1.5 : EBNA-LP 
Epstein-Barr Nuclear Antigen Leader Protein (EBNA-LP) is expressed from the Wp 
during early infection and produces varying isoforms, which contain different numbers 
of the W1W2 repeats and Y1Y2 C-terminal repeats (Wang et al., 1987b, Nitsche et al., 
1997). EBNA-LP, via its bipartite nuclear localisation sequence (NLS), predominantly 
localises in the nucleus (Peng et al., 2000). EBNA-LP has been shown to co-activate 
expression of LMP1 with EBNA2 (Harada and Kieff, 1997a, Nitsche et al., 1997, McCann 
et al., 2001). However, the interaction between EBNA2 and EBNA-LP that facilitates co-
activation is not fully understood. EBNA-LP has also been shown to interact with 
tumour suppressors Retinoblastoma (Rb), p53 and p14ARF (Inman and Farrell, 1995, 
Portal et al., 2006). However, the physiological effects of these interactions with EBNA-
LP have yet to be elucidated. EBNA-LP has also been shown to interact with HDAC4 
and is suggested to activate gene expression using HDAC4 to facilitate epigenetic 
changes to the genes to promote gene expression (Portal et al., 2006, Portal et al., 
2013).  
1.1.6 : EBNA2 and EBNA3s 
EBNA2 and EBNA3 family of EBV proteins are expressed during the latency programme 
III and regulate the expression of EBV latency genes for a short time frame in EBV 
infected tonsillar tissue (Thorley-Lawson and Babcock, 1999, Babcock et al., 
2000)(Figure 1.1). EBNA2 and EBNA3s also orchestrate host cell expression and are 
essential, with exception of EBNA3B, for sustaining immortalised B cells in culture 
(Tomkinson and Kieff, 1992, Tomkinson et al., 1993). EBNA2 and EBNA3s cannot bind 
to DNA directly like EBNA1 and rely on host transcription factors to target them to viral 
and host regulatory elements (Ling et al., 1994, Sample and Parker, 1994, Hsieh and 
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Hayward, 1995). RBP-Jκ, the effector of the Notch signalling pathway, was the first 
host transcription factor shown to act as a DNA adaptor to EBNA2. RBP-Jκ was also 
shown to be essential to recruiting EBNA2 to EBV Cp promoter to trans-activate the 
expression of the EBV LMP proteins (Abbot et al., 1990, Wang et al., 1990, 
Woisetschlaeger et al., 1991, Randahl et al., 1992, He and Pear, 2003a). The EBNA3 
family were subsequently shown to require RBP-Jκ to regulate LMP2 expression and 
were also shown, using a CAT reporter assay, to inhibit EBNA2-transactivation (Le Roux 
et al., 1994, Marshall and Sample, 1995).  
Interactions between EBNA2, EBNA3s and RBP-Jκ have been shown to be essential for 
sustaining immortalised LCLs (Robertson et al., 1996b, Maruo et al., 2003, Maruo et 
al., 2005, Maruo et al., 2006, Lee et al., 2009). Mutating the RBP-Jκ binding motif to 
alanine residues in EBNA3C, fused to a 4-hydroxytamoxifen (4HT)-dependent 
oestrogen receptor (EBNA3C-HT) allowing for conditional expression of EBNA3C, was 
shown to prevent EBNA3C repression of host genes in LCLs. In addition to this the 
EBNA3C RBP-Jκ mutant was also shown to be unable to sustain LCL growth and in 
reporter assays failed to silence EBNA2 transactivation of a reporter construct 
regulated by RBP-Jκ (Waltzer et al., 1996, Lee et al., 2009, Maruo et al., 2009). 
Conversely a recent study showed that infecting primary CD19+ cells with EBV 
expressing EBNA3C with a mutated RBP-Jκ binding motif established an immortalised 
cell line suggesting EBNA3-RBP-Jκ interactions being essential to sustaining B cell lines 
may be cell-type specific (Wang et al., 2015, Kalchschmidt et al., 2016). Electro-
mobility-shift assays (EMSAs) showed that when EBNA3C was incubated with an 
EBNA2-RBP-Jκ-DNA complex the EBNA2 was displaced from RBP-Jκ, which also resulted 
in RBP-Jκ unbinding from the DNA (Waltzer et al., 1996). EBNA2 and EBNA3 competing 
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for RBP-Jκ binding was confirmed when ChIP-re ChIP of RBP-Jκ controlled genes 
showed EBNA2 and EBNA3s bound RBP-Jκ independently (McClellan et al., 2013b). 
However, genome wide ChIP-seq analysis of Mutu III and LCLs has confirmed that RBP-
Jκ is not displaced from DNA as previously suggested as EBNA3s are shown to be 
enriched at RBP-Jκ consensus sites (McClellan et al., 2013b, Wang et al., 2015).  
1.1.7 : EBNA2 
Most studies of EBNA2 have identified EBNA2 as a transactivator of EBV and host gene 
expression. However there are a small number of cases, such as the host regulator of B 
cell diversity activation-induced cytidine deaminase (AID), where EBNA2 inhibits gene 
expression via mechanisms that are not yet understood (Tobollik et al., 2006). EBNA2 
is expressed earlier on during an EBV infection and is not identified to be expressed at 
the later stages of infection in hosts capable of eliciting a healthy cytotoxic T cell 
response (Babcock et al., 2000, Kurth et al., 2003). However, EBNA2 has been shown  
to be expressed in malignancies in immunocompromised transplant patients (Thomas 
et al., 1990). Upon a primary EBV infection of B cells latent viral gene expression is 
directed from the W promoter (Wp) (Woisetschlaeger et al., 1990, Grossman et al., 
1994b). EBNA2 is required to switch viral expression to C promoter (Cp) which allows 
expression of all the EBNA genes as a long primary transcript (Grossman et al., 1994a). 
Immortalised B cell lines that do not express EBNA2 or had mutated EBNA2 enhancers 
upstream of the Cp were shown to continue to use Wp to direct expression (Yoo et al., 
1997, Yoo et al., 2002). EBNA2 binding at the Cp has also been shown to be essential 
for promotor stalling of RNA polymerase II (PolII) at the Cp, allowing for effective 
pTEFb recruitment, via Brd4, for phosphorylation of serine 5 of PollII CTD (Jang et al., 
2005, Palermo et al., 2011). EBNA2 induced PolII promoter stalling allows for efficient 
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transcription of the long Cp promotor transcript (Palermo et al., 2011). BL cells lacking 
EBNA2 expression (Mutu I), were shown, using Chip-Seq, to have significant 
nucleosome assembly around the Cp promoter compared to Burkitts lymphoma cells 
(Mutu III) expressing EBNA2. This suggested the stalled PolII complex protects the Cp 
promoter from nucleosome assembly to aid transcription (Palermo et al., 2011). 
EBNA2 also transactivates the expression of the viral LMP proteins, predominantly via 
RBP-Jκ binding. A combination of deletion analysis of reporter constructs of LMP1, 
LMP2A and LMP2B promoters and gel retardation assays have confirmed the presence 
of RBP-Jκ consensus sites in all LMP promoters (Abbot et al., 1990, Sung et al., 1991, 
Zimber-Strobl et al., 1991, Ling et al., 1993a, Zimber-Strobl et al., 1993, Henkel et al., 
1994, Laux et al., 1994b, Waltzer et al., 1994, Zimber-Strobl et al., 1994). However, 
RBP-Jκ binding at the LMP1 and LMP2B promoters is comparatively weak and it has 
been shown that EBNA2 requires PU.1 to be bound to facilitate effective 
transactivation of the LMP1 promoter (Laux et al., 1994a, Laux et al., 1994b, 
Johannsen et al., 1995).  
9 conserved regions (CR) were identified by comparative analysis of EBNA2 from EBV,  
baboon and rhesus lymphocryptovirus which searched for similarities in their 
sequences (Peng et al., 2000)(Figure 1.2). EBNA2 nuclear localisation sequences (NLS) 
in CR7 and CR9 were identified when deletion of both of these regions was shown, 
using immunofluorescent microscopy, to ablate EBNA2 migration to the nucleus 
(Cohen et al., 1991). A bacterially expressed polypeptide of EBNA2 CR6 was identified 
as being essential for RBP-Jκ interactions (Ling and Hayward, 1995). A competition 
binding assay using EMSA showed that a peptide of the EBNA2 CR6 WWP motif 
competed with EBNA2 for RBP-Jκ binding (Ling and Hayward, 1995)(Figure 1.2). This 
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revealed EBNA2 mimicked the Notch RAM domain WΦP RBP-Jκ binding motif, which is 
conserved across species in Notch, to interact with RBP-Jκ (Ling and Hayward, 1995, 
Johnson et al., 2010). CR5 has also been shown to bind to a mediator of co-activator 
and co-repressor binding to RBP-Jκ called SKIP. Reporter assays showed that deletion 
of this domain could prevent EBNA2 binding to RBP-Jκ and disrupt EBNA2 
transactivation (Sifang Zhou, 2000)(Figure 1.2). In addition to this EBNA2 can be 
phosphorylated by EBV kinase and cdc2/Cyclin B1 at serine 243 which leads to 
decreased activation of LMP1 in both cases (Cohen and Kieff, 1991a, Yue et al., 2005, 
Yue et al., 2006). CR1/2 and CR8 have been identified as N and C terminal TAD 










Figure 1.2. Domain map of EBNA2. At the top is an amino acid ruler. Below the ruler is 
a map of the conserved regions (CR) between the type1 and type 2 EBNA2 (dark blue 
boxes) (Cancian et al., 2011). Domain map shows the Self Association Domains (SAD) in 
yellow (Friberg et al., 2015) which contains EBNA2 N-terminal Domain (END) in light 
orange, proline rich region (PP) in purple (Wu et al., 1996),  kinase phosphorylation site 
(PKC) in dark orange (Yue et al., 2006), the RBP-Jκ binding region (RBP-Jκ) in red (Ling 
and Hayward, 1995), the WWP motif in black, an Arginine/ Glycine rich region(Voss et 
al., 2001), the PILF motif has been shown to associate with PU.1 in vivo (Zimber-Strobl 
and Strobl, 2001), a Trans Activation Domain (TAD) in green and a Nuclear localisation 
sequence (NLS) in brown (Ling et al., 1993b). Just below the domain the SKIP (Sifang 
Zhou, 2000) and another PU.1 binding region is highlighted (E Johannsen, 1995). At the 
bottom of the diagram is a map of the predicted secondary structure, the unstructured 
loops are shown in grey, the alpha helix regions are shown in blue and the beta sheet 







The EBNA2 C-terminal TAD that has been shown to have structural similarities to 
Human Simplex Virus (HSV) VP16 TAD. EBNA2 TAD (aa453-466) conjugated to Gal4 was 
shown to activate expression of CD23 and LMP1 in a reporter assay in Burkitts 
lymphoma (BL) cells (Cohen, 1992). The VP16 TAD (aa412-490) could be substituted 
with the EBNA2 TAD to transactivate expression in the same assay suggesting they had 
similar functions (Cohen, 1992). EBNA2 TAD and VP16 TAD have both been shown to 
interact with TFIIB and TAF4 which, open chromatin to facilitate gene expression (Tong 
et al., 1995a, Tong et al., 1995b, Tong et al., 1995c, Wu et al., 2000b). In addition to 
this NMR chemical shift perturbation studies showed that when the EBNA2 TAD binds 
to the plextrin homology domain of Tfb1/p62 subunit (Tfb1PH) of TFIIH this induces 
similar H1 N15 shifts to that seen when HSV V16 TAD and human p53 TAD interact with 
Tfb1PH (Chabot et al., 2014). The EBNA2 TAD is predicted to be an intrinsically 
disordered protein, however NMR chemical shift perturbation and the NMR structure 
of the EBNA2 TAD bound to Tfb1PH showed that the EBNA2 TAD (aa448-471) folded 
into a 9 residue α-helix flanked by disordered regions, which bound in a shallow 
hydrophobic pocket on the surface of the Tfb1PH (Chabot et al., 2014) (Figure 1.3A). 
The EBNA2 residues W458, I461 and F462 mimicked the ΦXXΦΦ motif used by p53 
and VP16 to interact with TFIIH. However, this structure showed that EBNA2 presented 
these hydrophobic residues in a conformation, unique to that of p53 and VP16 (Chabot 
et al., 2014). 
Consistent with EBNA2s role as an activator of gene expression ChIP data shows EBNA2 
binding coincides with the chromatin remodelling factor SWI/SNF (Wu et al., 2000a). In 
EBNA2 negative cell lines SWI/SNF binding to EBNA2 target genes is not detected 
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suggesting EBNA2 indirectly recruits SWI/SNF. No data has shown that the SWI/SNF 
complex and EBNA2 directly interact however, EBNA2 has been shown to bind to the 
SWI/SNF co-activator and Histone Acetylase (HAT) p300 (Wang et al., 2000, Wu et al., 
2000a). NMR chemical perturbation studies of the interactions between EBNA2 TAD 
(aa448-471) and the KIX domain of the CBP/p300 complex (residues 586-672) showed 
significant H1 and N15 shifts in the structure of EBNA2 when it was introduced to KIX 
suggesting the disordered EBNA2 TAD changes conformation upon binding to KIX 
potentially interacting with KIX in a similar manner as VP16 TAD and p53 TAD (Chabot 
et al., 2014). Together this suggests EBNA2 recruits SWI/SNF via its co-activators to 
modify histone tails and promotes open chromatin conformations at regulatory 
elements to transactivate gene expression (Wu et al., 2000a, Chabot et al., 2014). 
CR1/2 and CR3/4 were predicted to contain two EBNA2 self association domains (SAD1 
aa1-60 and SAD2 aa101-214) (Harada and Kieff, 1997a)(Figure 1.2). Additionally, yeast 
two hybrid assays had shown EBNA2 residues 122-344 could interact with full length 
EBNA2 (Tsui and Schubach, 1994). Recombinant EBNA2 expressed in insect cells and 
EBNA2 expressed in EBV infected B cells had also been shown to assemble into a 
440kDa polymer (Grässer et al., 1991, Tsui and Schubach, 1994). Co-
immunoprecipitations of truncations of EBNA2 and full length EBNA2 expressed in 
BJAB cells were analysed by western blot to identify regions 1-60 and 101-214 were 
essential for EBNA2 dimerisation (Harada and Kieff, 1997b). Due to EBNA2 binding 
sites on the LMP2A promoter being 11bp apart and multiple host transcription factor 
binding sites being identified in close proximity to the single EBNA2 binding site on the 
Cp promoter, it was suggested EBNA2 dimerised to bind multiple host transcription 
factors to mediate LMP regulatory elements (Sung et al., 1991, Zimber-Strobl et al., 
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1993, Zimber-Strobl et al., 1994, Harada and Kieff, 1997b). The NMR structure of 
EBNA21-58 confirmed that it dimerised and folded into a structure containing 4 β-
strands organised in an anti-parallel fashion and a short α-helix (Figure 1.3B)(Friberg et 
al., 2015). The EBNA2 dimer fold was identified as a novel topology that had not been 
seen in the protein data bank (PDB) before, so was named the END (EBNA2 N-terminal 
Dimerisation) domain. The hydrophobic interface of the dimer stabilises the END 
domain through inter-monomer hydrophobic interactions between the leucine, 
tyrosine, and valine residues creating a hydrophobic core (Figure 1.3B). EliBL cell lines 
transfected with EBNA2 END domain mutants showed that L16D and I50D mutations 
strongly attenuated EBNA2 activation of LMP expression (Friberg et al., 2015). RT-
QPCR analysis of host targets CCL3 and CD23 in ELiBL cells that L16D and I50D 
mutations caused a significant loss in EBNA2 induced activation of the genes, 
demonstrating that the EBNA2 dimerisation plays a key role in EBV hijacking of host 


























Figure 1.3. NMR structures of EBNA2. A. NMR structure of EBNA21-58 (in green) bound 
to Tfb1/p62 subunit of the host transcription factor TFIIH (in grey) (Chabot et al., 
2014). B. EBNA2 NTD transactivational domain dimerises. Structure has been rotated 
90o to show hydrophobic core (hydrophodic residues have been shown as sticks) of 
NTD EBNA2 dimer. EBNA2 monomer have been coloured yellow and orange to 














Due to EBNA2 binding sites being identified in the EBV Cp, LMP1p and the promotor of 
CD23 and reporter assays confirming EBNA2 transactivated these genes it was 
originally thought EBNA2 mediated gene expression via promoters (Wang et al., 1987a, 
Wang et al., 1990, Wang et al., 1991, Ling et al., 1994, Rymo, 1995). Microarrays in EBV 
positive cell lines not only confirmed CD23 to be upregulated by EBNA2 but also 
identified key B cell growth genes RUNX3 and MYC were also upregulated by EBNA2 
(Maier et al., 2006, Spender et al., 2006, Zhao et al., 2006). No EBNA2 binding sites 
were identified to transactivate at RUNX3 or MYC promoters, however genome wide 
ChIP-Seq analysis of EBNA2 binding in BL cells (Mutu III) identified that 75% of EBNA2 
binding was at distal regulatory elements (McClellan et al., 2013b, Gunnell et al., 2016, 
Wood et al., 2016). For example, EBNA2 relies on interactions with RBP-Jκ to bind to 
the RUNX3 -97kb super enhancer (SE) and to the -139kb and -250kb enhancers of 
RUNX1 (Gunnell et al., 2016). EBNA2 transactivation of RUNX3 leads to repression of 
RUNX1 and its inhibitory effects on B cell growth (Spender et al., 2005). Additionally, 
EBNA2 RBP-Jκ dependent binding at the -139kb and -250kb RUNX enhancers also 
resulted in decreased expression of RUNX1 (Gunnell et al., 2016). However, Notch 1 
has been shown in multiple cell systems to upregulate RUNX1 expression (Burns et al., 
2005, Nakagawa et al., 2006, Meier-Stiegen et al., 2010). This revealed EBNA2 bound 
distal enhancers, via interactions with RBP-Jκ, to down regulate RUNX1 expression and 
B cell growth inhibition, via a mechanism distinct from Notch to promote B cell growth 
during EBV infections (Gunnell et al., 2016). EBNA2 was also shown not to bind at the 
MYC promoter (Wood et al., 2016). However, in EREB cells with conditionally active 
EBNA2, increased EBNA2 binding was shown, using Capture HiC, at the -556, -428, -
186/168 SE of the MYC locus whilst reduced EBNA2 binding was shown at the +456, 
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+570, +1.8/9 upstream SE of the MYC locus (Wood et al., 2016). Chromatin 
conformation capture (CCC) was then used to confirm that the presence of EBNA2 
induced downstream enhancer-promoter interactions. Therefore, EBNA2 binding at 
the MYC locus created a unique looping profile bringing downstream enhancers and 
the MYC promoter together to turn on MYC expression whilst silencing other MYC 
elements (Wood et al., 2016).  
Motif searching of ChIP-Seq data of EBNA2 binding peaks confirmed EBNA2 bound at 
RBP-Jκ (80% of EBNA2 binding sites in LCLs), PU.1, RUNX and EBF1 sites (McClellan et 
al., 2013b, Wang et al., 2015). EBF1 has more recently been shown to bind EBNA2 to 
drive the assembly of EBNA2-EBF1-RBP-Jκ complexes at co-occupied sites and even 
anchor EBNA2 to DNA at EBNA2 sites independent of RBP-Jκ, to activate the 
expression of host genes (Lu et al., 2016, Glaser et al., 2017). When the chromatin 
landscape of GM12878 LCLs was mapped to the EBNA2 peaks, the majority of the 
EBNA2 peaks were shown to have Histone 3 Lysine 27 acetylation (H3K27ac) and 
Histone 3 lysine 4 monomethylation (H3K4me1) indicative of active gene expression 
(McClellan et al., 2013a). This confirmed the role of EBNA2 as a transcriptional 
activator and that EBNA2 utilised host factors to bind distal regulatory elements to 








1.1.8 : EBNA3 family 
EBNA1, EBNA2 and LMP1 had already been identified however a 142kDa protein was 
also shown to react with EBV exposed human antisera (Hennessy et al., 1985). The 
protein, dubbed EBNA3, was identified to be expressed from the BamHI E fragment of 
the rightward open reading frame (BERF1) of the EBV genome (Hennessy et al., 1985, 
Hennessy et al., 1986). The gene was cloned into a bacterial vector and expressed in 
rodent cells, however EBNA3 antisera was also shown to react with other 
incrementally larger proteins (Hennessy et al., 1986). Subsequently, EBNA3C (155kDa) 
and EBNA3B (165kDa) were discovered forming the EBNA3 family of EBV transcription 
factors (Petti and Kieff, 1988, Petti et al., 1988). EBNA3A, EBNA3B and EBNA3C genes 
are arranged in tandem on the EBV genome suggesting that they arose through gene 
duplication (Farrell, 2001). The EBNA3 family are expressed as a single alternately 
spliced transcript from the Cp (Allday et al., 1989). The EBNA3 family of proteins do not 
share much amino acid sequence homology. However, analysis of the EBNA3s amino 
acid sequence revealed a region in the N-terminus of each EBNA3 with increased 
shared homology, called the homology domain (HD), which shared 23% to 28% 
sequence homology (Yenamandra et al., 2009).  However secondary structure 
predictions of the amino acid sequences of the EBNA3 HDs predicted 72% to 78% of 
their folding adopted similar conformations (Yenamandra et al., 2009). However, full 
length EBNA3s overall are predicted to be disordered proteins (West, 2006, 
Yenamandra et al., 2009). EBNA3A and EBNA3C were originally shown to be essential 
to sustain immortalised B cells. However, more recently an EBNA3A negative cell line 
has been established but has significantly attenuated growth (Tomkinson et al., 1993, 
Hertle et al., 2009). As previously discussed EBNA3s share many DNA binding sites with 
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EBNA2 to inhibit EBNA2 transactivation of host and EBV genes (Waltzer et al., 1996, 
McClellan et al., 2013b). However, they are shown to independently bind the host 
factor RBP-Jκ suggesting EBNA2 and EBNA3s compete for RBP-Jκ binding to 
antagonistically control gene expression (McClellan et al., 2013a). RBP-Jκ binding has 
been mapped to each of the EBNA3 homology domains (Robertson et al., 1996b). In 
addition to this, TΦGC and a WΦP motifs in the EBNA3C homology domain have been 
shown to be important for RBP-Jκ interactions (Lee et al., 2009, Calderwood et al., 
2011).  
Analysis of the EBNA3A amino acid sequence showed it contained two negatively 
charged clusters (aa16-60 and aa343-369), a glutamic acid and phenylamine rich 
region (aa271-289), a positively charged cluster (aa376-402) and a large proline rich 
region (aa417-794) which have been hypothesised to play roles in EBNA3A interactions 
with other proteins (Yenamandra et al., 2009)(Figure 1.4A). The EBNA3A homology 
domain is predicted to fold into clusters of α-helices and β-sheets but no structural 
studies have confirmed this (Yenamandra et al., 2009)(Figure 1.4A). EBNA3A has one 
NLS located at residues aa147-157 and another 5 which were predicted by computer 
models and confirmed using immunofluorescent microscopy (Le Roux et al., 1993, 
Buck et al., 2006)(Figure 1.4A). The C-terminal acidic region (841-944) has been shown 
to contain two CtBP-like binding motifs (ALDLS aa857-861 and VLDLS aa889-890) which 
are both necessary to bind to CtBP (Hickabottom et al., 2002, Yenamandra et al., 
2009). Mutation of these motifs to alanine residues impaired the ability of EBNA3A to 
co-operatively immortalise and transform rat embryo fibroblasts with the oncogenic 
Ras protein suggesting EBNA3A-CtBP interactions can mediate repression of host 
genes (Hickabottom et al., 2002). EBNA3A has also been shown to induce the 
40 
 
expression of and associate with Heat shock protein 70 (Hsp70) suggesting it exploits 
Hsp70 to aid its folding and improve its stability during an EBV infection (Young et al., 
2008). The EBNA3A N-terminal domain has been shown to be essential for interactions 
with RBP-Jκ (Robertson et al., 1996b)(Figure 1.4A). In addition to this, when aa170-240 
or aa300-286 were deleted or residues TLGC (aa198-202) were mutated to AAGA, 
EBNA3A was no longer able to silence EBNA2 transactivation of the Cp via RBP-Jκ 
binding in a reporter assay, or maintain the growth of LCLs grown in non-permissive 
conditions (Maruo et al., 2005).  
EBNA3B similarly has been predicted to contain 2 negatively charged regions (aa25-93 
and aa355-378), a proline rich region (aa526-753) and a Sudo-homology domain 
(aa665-889) which have been predicted, but not confirmed, to be involved in protein-
protein interactions (Yenamandra et al., 2009)(Figure 1.4B). Additionally EBNA3B has 
been predicted to fold into α-helices and β-sheets with in its homology domain 
(Yenamandra et al., 2009)(Figure 1.4B). NLS prediction models and confirmation via 
immunofluorescent microscopy identified EBNA3B had 2 functional NLS sequences 
(aa160-166 and aa867-873) (Burgess et al., 2006)(Figure 1.4B). The N-terminal domain 
of EBNA3B (aa1-311) has also been shown to essential for binding RBP-Jκ (Robertson et 
al., 1996b). EBNA3B is not required to maintain immortalised B cells but, despite this 
gene has not been selected against as EBV has evolved to persistently infect humans, 
suggesting that it has a vital role to play during an EBV infection (Chen et al., 2005). 
When mice were infected with EBNA3B knockout EBV this caused highly proliferative B 
cell lymphomas to grow (White et al., 2012). Furthermore, LCLs with EBNA3B deleted 
grow more robustly than LCLs expressing EBNA3B (White et al., 2012). This suggests 
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that EBNA3B may play a role as a virally expressed tumour suppressor during EBV 
latency (White et al., 2012). EBNA3B has been shown to play a role in recruiting T cells 
to EBV infected cells by promoting the expression of intracellular and cell surface 
proteins which has been suggested to prevent lymphoproliferation of B cells during an 
EBV infection (White et al., 2012). However, T cells also aid immortalisation of B cells 
due to T cell binding activating pathways that promote B cell differentiation and 
germinal centre reactions (Nakayama et al., 2002, White et al., 2012). 
Much like EBNA3A and EBNA3B, analysis of EBNA3C amino acid sequence has shown it 
contains a negative charge cluster (aa367-393) and a proline rich domain (Yenamandra 
et al., 2009)(Figure 1.4C). However a glutamine/ proline rich region (aa724-826), which 
had a similar amino acid sequence to the TF Sp1, was able to activate gene expression 
in a CAT reporter assay when conjugated to Gal4 (Marshall and Sample, 1995)(Figure 
1.4B). The EBNA3C homology domain has also been predicted to contain a basic 
leucine zipper (bZIP)(aa244-291) (West et al., 2004). Circular dichroism and ultra-
centrifugation analysis showed this region could fold into an α-helix however they did 
not observe the bZIP folding into homo or hetero dimer coil-coil structures 























Figure 1.4. Domain maps and folding predictions of the EBNA3 family of EBV TFs. A. 
Shows a domain map of EBNA3A. B Shows a domain map for EBNA3B. C. Shows a 
domain map for EBNA3C. The B-zip region is shown in dark blue. The PU.1/ Spi-1 
binding region has been highlighted above the domain map. The PLDLS motif, which 
binds to CtBP1, has also been highlighted. The key for all the domains maps: At the 
top is an amino acid ruler. The domain maps show Negative Charged Clusters(NCC) in 






regions (EF) in light blue, Positively Charged Clusters (PCC) in green, Proline rich 
regions (PP) in purple, Proline and Glutamine rich regions (PQ) in magenta, Sudo 
Homology Domains (SHD) in orange, Acidic regions in navy blue, the Nuclear 
Localisation sequence (NLS) is highlighted in brown and TΦGC motif is highlighted in 
black. Below the domain map is the predicted secondary structure map, the grey bars 
represent unstructured loops, the blue represents alpha helix regions and the pink 
represent regions of Beta-sheets. (Robertson et al., 1996a, Waltzer et al., 1996, Zhao 
et al., 1996, Maruo et al., 2003, West et al., 2004, Maruo et al., 2005, West, 2006, 

















EBNA3C is the most studied of the EBNA3s and has been identified to interact with 
many host proteins. EBNA3C has been shown to bind to C-terminal binding protein 
(CtBP) via PLDLS motif used by Histone deactylases and co-repressors to interact with 
CtBP (Touitou et al., 2001, Kuppuswamy et al., 2008). EBNA3A and EBNA3C have also 
both been shown to epigenetically silence the expression of the cell cycle regulator 
p16 via CtBP (Maruo et al., Skalska et al., 2010b). In addition to this, EBNA3C has been 
shown to bind both isoforms of PU.1 in vitro and can co-activate the expression of 
LMP1 with EBNA2, via a PU.1 consensus site in the LMP1 promotor (Zhao and Sample, 
2000). The aa130-190 region of EBNA3C has been shown to bind to and stabilise the 
transcriptional activator c-Myc, promoting c-Myc recruitment to target genes (Bajaj et 
al., 2008). This same region of EBNA3C is also shown to promote the degradation of 
retinoblastoma (RB) and p27 (Knight and Robertson, 2004, Knight et al., 2005). 
Furthermore, EBNA3C has been shown to interact with and mediate the stability of 
p53, cyclin A and cyclin D1 (Knight and Robertson, 2004, Knight et al., 2004, Yi et al., 
2009, Saha et al., 2011). Together these interactions demonstrate how EBNA3C can 
target multiple control mechanisms of cell cycle via protein-protein interactions to 
promote B cell growth. EBNA3C has also been co-immunoprecipitated with Histone 
deacetylase (HDAC) 1 and 2 and treatment of EBV infected B cells with HDAC inhibitors 
results in expression of EBNA3C repressed genes such as BIM (Radkov et al., 1999, 
Knight et al., 2003, Paschos et al., 2009). This suggests EBNA3C binds HDAC to silence 
Bim expression to promote cell survival during an EBV infection (Paschos et al., 2009). 
EBNA3C homology domain has also been shown be essential to binding RBP-Jκ 
(Robertson et al., 1996b). EBNA3C was originally shown to bind to RBP-Jκ via a TFGC 
motif, deletion of which ablated EBNA3C-RBP-Jκ interactions and EBNA3C inhibition of 
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EBNA2 transactivation (Maruo et al., 2009). In addition to this LCLs expressing EBNA3C 
TFGC-AAAA mutant could not sustain immortalisation (Lee et al., 2009, Maruo et al., 
2009).  
Microarray analysis BL31 cells infected with strains of EBV with each of the EBNA3s 
knocked out revealed significant overlap in their mediation of host expression. 50% of 
the genes identified to have their expression mediated by EBNA3s were shown to be 
regulated by at least 2 of the EBNA3s (White et al., 2010). Additionally out of the 1008 
EBNA3 mediated host genes identified 22 were upregulated by all the EBNA3s and 34 
were down regulated by all the EBNA3s. Whilst 30 novel genes targets were identified 
to be regulated by EBNA3A and EBNA3B the most common combination of EBNA3s 
was EBNA3B and EBNA3C which were shown to influence genes predominantly 
involved with haematopoiesis and B cell activation such as ITGAL and RUNX1 (White et 
al., 2010). All three EBNA3s were shown to be involved in regulating the expression of 
key B cell growth factors such as Notch2 and EBF1. Interestingly EBNA3B was shown to 
disproportionately affect the expression of genes involved with cell migration. 
H3K27me3, indicative of polycomb complex repression, was detected at genes 
repressed by EBNA3s. In EBNA3 knockout cells genes repressed by the EBNA3s were 
shown to not have H3K27me3. This suggested that together the EBNA3s could recruit 
polycomb complex to silence host gene expression involved with apoptosis, cell 
migration and B cell growth and maturation (White et al., 2010). Multiple EBNA3s 
binding at genes was confirmed by ChIP-Seq analysis in Lymphoblastoid cell lines (LCLs) 
and BLs (McClellan et al., 2013b, Wang et al., 2015). Chip-Seq data from LCLs showed 
that 26% of EBNA3A sites were shared with EBNA3C, 21% of EBNA3B sites were shared 
with EBNA3A and 22% of EBNA3B sites were shared with EBNA3C. This confirmed that 
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the EBNA3s could collaborate to mediate host gene expression or mediate the same 
host genes to different degrees to fine tune host gene expression to facilitate B cell 
immortalisation (Wang et al., 2015). 
BCL2L11, also known as BIM, is a key pro-apoptotic factor which is targeted by EBNA3A 
and EBNA3C. Cancers often select for cells which have downregulated BIM expression, 
which permits indefinite cell proliferation (Paulin et al., 1996, Pajic et al., 2001). 
EBNA3A and EBNA3C were shown, using ChiP-Seq and CCC, to interfere with 
interactions between the long range enhancers (1,4 and 6) and the promoter of the 
BCL2L11 locus downregulating its expression. EBNA3A and EBNA3C were shown to 
target the H3K27 methyltransferase (E2H2) to both the BCL2L11 and ACOXL locus 
leading to H3K27me3 and silencing of the BIM locus (Paschos et al., 2009, Skalska et 
al., 2010b, Paschos et al., 2012).  
EBNA3A and EBNA3C have also been shown to repress the expression of the cyclin 
dependent kinase inhibitor p16 INK4a (Touitou et al., 2001, Skalska et al., 2010a, Maruo 
et al., 2011). EBNA3C and EBNA3A bound CtBP was shown using ChIP-Seq to methylate 
the p16INK4a chromatin and silence its expression (Skalska et al., 2010a, Maruo et al., 
2011). EBNA3s may indirectly activate p16INK4a by inhibiting CtBP2 expression 
suggesting the EBNA3s can delicately control p16INK4a induced senescence to promote 
cell growth whilst preventing tumorigenesis and detection by the immune system 
(Skalska et al., 2010a, Maruo et al., 2011). 
EBNA3A and EBNA3C have also been shown to activate the expression of miR-221/222 
to indirectly silence p57 expression. CCC revealed that EBNA3A and EBNA3C 
collaborated to loop long range enhancers to transactivate the expression of miR-
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221/222 (Bazot et al., 2015). Increased expression of miR-221/222 leads to inhibition 
of p57KIP2, a tumour suppressor involved with cell cycle regulation, likely contributing 
to B cell immortalisation during an EBV infection (Visone et al., 2007, Bazot et al., 
2015).  
1.2 : Epstein-Barr Virus associated cancers 
Epstein-Barr virus was the first virus to be associated with causing cancer in humans 
when it was discovered to immortalise Burkitts lymphomas cells in 1964 (Epstein et al., 
1964b). Since then EBV has been shown cause multiple human cancers by hijacking 
host signally pathways to promote cell growth and cell survival leading to cancer 
development (Andersson, 2000).  
1.2.1 : Burkitts lymphoma 
Burkitts lymhphoma (BL) was dicovered by Denis Burkitt in 1958 whilst offering his 
services as a doctor in Uganda (Burkitt, 1962). Denis Burkitt discovered one of the 
three types of BL endemic BL (eBL) (Burkitt, 1962). Cases of eBL are predominantly 
found in Central Africa and in Papa New Guinea, accounting for 30-50% of childhood 
cancers in Central Africa.  In addition to this, over 95% of cases of eBL are shown to be 
EBV positive (Parkin et al., 1988, Hamilton-Dutoit et al., 1993). Sporadic BL (sBl) occurs 
in the US and Europe accounting for 30-50% of childhood lymphomas however, only 
10-15% of cases are EBV positive (Hamilton-Dutoit et al., 1993, Morton et al., 2006). 
40% of Immunodeficiency associated BL (iBL) are EBV positive and coincide with HIV 
infections (Hamilton-Dutoit et al., 1993, Guech-Ongey et al., 2010). All BLs are shown 
to have MYC translocations which position the MYC gene proximal to powerful 
promoters in the Immunoglobin locus deregulating c-MYC expression (Magrath, 1990, 
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Brady et al., 2007). BL are shown to have a latency I programme of latent expression 
(Gregory et al., 1990). In situ hybridisation has confirmed the presence of EBERs which 
have been shown to protect cells from apoptosis and promote tumorigenicity in 
mouse models (Nanbo and Takada, 2002). EBNA1 has also been shown to 
competitively bind to USP7 ubiquitinase in the same pocket that p53 binds (Saridakis 
et al., 2005). Ubiquitination of p53 by USP7 stabilises p53 allowing p53 to promote 
apoptosis (Brooks and Gu, 2011). It is therefore suggested that EBNA1 protects BLs 
with de-regulated MYC expression from apoptosis by destabilising p53 by blocking its 
binding to USP7 (Saridakis et al., 2005).  
1.2.2 : Hodgkin’s lymphoma 
Hodgkin’s lymphomas (HL) produce growths in lymph nodes on the neck, arm or groin 
and are detected through the presence of Hodgkin’s Reed Sternberg cells (Ansell, 
2015). With early detection HL are effectively treated with chemotherapy (Armitage, 
2010). HL develops from B cells after passage through the germinal centre (Kanzler et 
al., 1996, Marafioti et al., 2000). HLs are shown to lack B cell receptor (BCR) which is 
thought to manifest due to DNA damage or epigenetic silencing occurring in the 
immunoglobulin loci (Jox et al., 1999, Ushmorov et al., 2004). Approximately 50% of 
HLs are predicted to be infected with EBV and are shown to have an EBV latency II 
programme of expression (Schmitz et al., 2009, World.Health.Organisation, 2014). EBV 
has been shown to rescue germinal centre B cells from apoptosis that lack functional 
immunoglobin (Bechtel et al., 2005, Mancao et al., 2005). LMP2A has also been shown 
to mimic BCR signalling and microarrays have shown LMP2A alter host gene expression 
to prevent apoptosis and promote B cell growth (Bechtel et al., 2005, Mancao and 
Hammerschmidt, 2007). LMP1 is also shown to mimic CD40 expression activating NFκB 
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expression to promote cell growth and survival (Mosialos et al., 1995, Devergne et al., 
1996, Gires et al., 1997, Uchida et al., 1999). This suggests EBV plays a role in HL 
pathogenesis by protecting HL lacking BCR signalling in the germinal centre from 
apoptosis (Mancao and Hammerschmidt, 2007).  
1.2.3 : Post Transplant Lymphoproliferative Disease  
During EBV primary infection the host immune system plays a key role in regulating 
EBV infection and preventing excessive proliferation of EBV infected B cells (Benninger-
Doring et al., 1999, Nikiforow et al., 2001, Precopio et al., 2003, Lee et al., 2004). 
Cytotoxic T cells are the main effectors of regulating EBV infected cells and do so by 
recognising peptides of EBV proteins present by MHC class II molecules (Maini et al., 
2000, Gudgeon et al., 2005, Hislop et al., 2005, Landais et al., 2005). Transplant 
patients receive immunosuppressants after surgery to prevent graft versus host 
disease. This results in transplant patients having very low T cell counts. In these 
conditions EBV infected cells, sometimes derived from donors, grow uncontrollably 
resulting in Post Transplant Lymphoproliferative Disease (PTLD) (Babcock et al., 1999, 
Rasche et al., 2014). EBV is shown to have a latency III programme of expression in 
PTLD patient samples suggesting the EBNAs and LMPs, without an effective cytotoxic T 
cell response drive excessive growth in B cells (Murray et al., 1992, Tomkinson et al., 
1993, Benninger-Doring et al., 1999, Lee et al., 1999, Portis and Longnecker, 2004, Jha 
et al., 2013). However, EBV-specific T cells grown from patient samples have proven 
effective at treating PTLD (Heslop et al., 2010, Uhlin et al., 2010). In addition to this 
anti-CD20 antibodies (Rituximab) infusions, which tag B cells for degradation, have also 
been shown to be effective at treating PTLD (Stuhler et al., 2006, McIver et al., 2010).  
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1.2.4 : Diffuse large B cell lymphoma 
EBV positive Diffuse Large B Cell Lymphoma (DLBCL) is a cancer that is predominantly 
associated with immunocompetent patients over the age of 50 and is associated with 
worse outcomes when compared to EBV negative DLBCL (Morton et al., 2006, Park et 
al., 2007, Castillo et al., 2011). Caucasians (less than 5% EBV positive) have been shown 
to be the least affected group whilst cases of EBV DLBCL are most prominent in Asia 
(8.9% EBV positive) and South America (14.9% EBV positive) (Park et al., 2007, Beltran 
et al., 2011, Ok et al., 2013). It is suggested that ageing causes the make up of T cell 
population in the immune system to change resulting in reduced Cytotoxic T cell 
activity making patients more susceptible to EBV positive DLBCL (Aw et al., 2007, 
Lefebvre et al., 2012). However, more recent studies have reported similar 
percentages of EBV positive DLBCL cases in people under the age of 50 (Cohen et al., 
2014, Hong et al., 2015). EBV positive DLBCL have been shown to adopt both latency II 
and III programmes of expression (Oyama et al., 2007, Castillo et al., 2011, Nguyen-Van 
et al., 2011). EBV positive DLBCL cells also have been shown to have increased levels of 
NFκB and JAK/STAT implicating a role for LMP proteins in DLBCL pathogenesis (Shair et 
al., 2007, Montes-Moreno et al., 2012, Ok et al., 2014). Additionally, increased CD30 
expression and the expression of the EBERs are used as markers of EBV positive DLBCL 
(Ok et al., 2014).  
1.2.5 : Nasopharyngeal carcinomas  
EBV was detected in Nasopharyngeal carcinoma (NPC) tissues in 1970 (Henle et al., 
1970, zur Hausen et al., 1970). Further analysis revealed that EBV expressed a latency 
II pattern of expression in NPC (Young et al., 1988, Brooks et al., 1992). NPC are most 
prominent in South East Asia and EBV detection in NPCs is shown to increase in specific 
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geographical locations (Wang and He, 2016). Because of this and the large chromatin 
deletion and methylation events detected in NPCs, it is suggested that hereditary 
factors and high carcinogenic diets, such as salted fish, increase susceptibility to EBV 
associated NPC carcinogenesis (Huang et al., 1978, Huang et al., 1989, Waghray et al., 
1992, Lo et al., 1996, Lo et al., 2001, Chan et al., 2002, Yu and Yuan, 2002). LMP2 has 
been detected in the majority of EBV positive NPCs and has been shown to regulate 
STAT and NFκB in NPC cell lines (Brooks et al., 1992, Heussinger et al., 2004, Stewart et 
al., 2004). Additionally, microarray analysis reveals NPCs to have deregulated NFκB 
signalling as a result of up regulation of multiple components of the NFκB signalling 
pathway (Shi et al., 2006). Also, methylation of p16 likely contributes to cell cycle 
deregulation to promote NPC carcinogenesis (Huang et al., 1989, Chan et al., 2002). 
1.14 Gastric Carcinoma 
EBV positive Gastric Carcinoma (GC) accounts for 10% of GC cases worldwide and due 
to GC being the second most prominent cause of death by cancer, EBV positive GC is 
suggested to be the most common EBV associated cancer (Shibata and Weiss, 1992, 
Tokunaga et al., 1993, Boysen and Friborg, 2013). The countries with the highest 
proportion of GC, which are EBV positive GC, are the United States and Germany and 
EBV positive GC occurs more often in males. Much like NPC it has been suggested that 
environmental and genetic factors potentially increase the risk of EBV positive GC 
(Akiba et al., 2008, Camargo et al., 2011). Due to EBV GC being an epithelial carcinoma 
it is debated how EBV infects these tissues. Alternative mechanisms involving EBV 
glycoprotein gHgL interacting with epithelial integrins to enter cells have been 
suggested, but the precise mechanism remains unknown (Chesnokova et al., 2009). 
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EBV carcinomas have been shown to have a latency I programme of expression in cells 
(Oh et al., 2004). The mechanism to how EBV triggers carcinogenesis is not known, 
however EBERs have been suggested to protect EBV positive GC from apoptosis 
(Nanbo et al., 2005).  
1.2.6 : Natural Killer cell and T cell lymphomas 
Detection of EBERs in Natural killer and T cells (NK/T cells) samples from tonsillar tissue 
from IM patients has suggested that during a primary EBV infection EBV is able to 
infect NK/T cells (Anagnostopoulos et al., 1995, Trempat et al., 2002, Hudnall et al., 
2005). The mechanism of EBV infection of NK/T cells is not known, however it is 
suggested that infection occurs when NK/T cells are eliciting a cytotoxic T cell response 
to EBV infected B cells (Tabiasco et al., 2003). Latency II expression programmes have 
been detected in Extra-nodal NK cell lymphomas (ENKL) and EBER in situ hybridisation 
identified the presence of EBV in Nodal Peripheral T cell lymphomas from 
immunocompetent patients (PTCLs) (Kanemitsu et al., 2012, Kato et al., 2012). Despite 
EBV infected cell lines of NK/T lymphomas being established little is understood about 
how EBV latency expression influences NK/T cell lymphomas (Imai et al., 1996, 







1.3 : RBP-Jκ and the Notch signalling pathway 
RBP-Jκ, the effector TF of the notch signalling pathway, was the first host TF shown to 
facilitate EBV TF binding DNA (Waltzer et al., 1994). RBP-Jκ has since been shown to be 
essential for EBNA2 transactivation of expression with 70% of EBNA2 binding sites in 
LCLs being shared with RBP-Jκ. The EBNA3s are suggested to compete for RBP-Jκ 
binding to silence EBNA2 transactivation allowing EBV to control host expression to 
establish a persistent infection (McClellan et al., 2013b, Wang et al., 2015).  
1.3.1 : Introduction of the Notch signalling Pathway 
The Notch signalling pathway is conserved across metazoans and plays key roles in 
development and cell fate determination steps across a plethora of cell types. Delta-
like are cell surface transmembrane ligands, the deletion of which results in early 
embryonic death in mouse models due to their essential role in activating Notch 
signalling pathways during development (Gale et al., 2004, Jung et al., 2011). When the 
delta-like ligand binds to the Notch receptor at the cell membrane an intracellular 
section of Notch (NotchIC) is cleaved by a protease and released into the cytoplasm 
(Santos et al., 2007). NotchIC consists of a chain of Ankyrin (Ank) repeats and a RBP-Jκ 
association molecule (RAM) domain which associate with RBP-Jκ (Nam et al., 2006). 
There is also a C-terminal PEST domain which is ubiquitinated tagging the protein for 
proteosomal degradation ensuring Notch signalling is tightly regulated (Oberg et al., 
2001). Here NotchIC is cleaved by more proteases (ADAM protease and γ-secretase) 
and is then transported to the nucleus (Schroeter et al., 1998, Andersson et al., 2011). 
Whilst in the nucleus NotchIC interacts with two populations of RBP-Jκ, static and 
dynamic RBP-Jκ (Castel et al., 2013). Static RBP-Jκ is permanently associated with the 
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DNA and transcription is silenced by its association with corepressors (CoR) and 
histone-deacetylases (HDACs). CoR and HDACs are displaced from the fixed RBP-Jκ by 
NotchIC which associates with RBP-Jκ via its WΦP motif located in the RAM domain 
(Figure 1.5). Once the WΦP motif has tethered Notch to RBP-Jκ the Ank repeats of 
Notch can bind to RBP-Jκ and provide a platform for TFs like Mastermind (Figure 1.5) 
and Histone acetyltranferase such as p300 to bind to RBP-Jκ and together form the 
Notch complex (Figure 1.5) (Nam et al., 2006). When NotchIC binds to dynamic RBP-Jκ 
in the nucleoplasm NotchIC recruits RBP-Jκ to consensus sites to activate RBP-Jκ 
mediated genes (Castel et al., 2013). Upon Notch binding to the dynamic RBP-Jκ TFs 
and HDACs are recruited to facilitate Notch complex assembly and the activation of 
RBP-Jκ mediated genes (Figure 1.5). The WΦP motif is highly conserved across species 
and mutation of the threonine residue to serine negates Notch-RBP-Jκ binding and 
silences the Notch signalling pathway (Figure 1.5) (Baron, 2003, Johnson et al., 2010). 
Notch signalling is thought to be mediated by the PEST domain in Notch being tagged 
by ubiquitin ligases labelling Notch for proteosomal degradation. Corepressors such as 
SHARP are also known to interfere with Notch signalling by recruiting HDAC to RBP-Jκ 
binding sites to silence Notch induced gene activation (Oswald et al., 2002, Oswald et 
al., 2005). Notch signalling activates the expression of number genes in different cell 
types however the HES-1 family of genes, which expression is involved with 
proliferation, maturation and growth, are targeted by Notch across a plethora of cell 
types (Jarriault et al., 1995, Castel et al., 2013). RBP-Jκ binds to DNA via the RBP-Jκ 
consensus site GTGGGA (HES-1 site) (Friedmann and Kovall, 2010). Notch signalling can 
be deregulated in cancers of the lung, breast, pancreus, central nervous system and in 




Figure 1.5. Model of the Notch signalling pathway. Notch receptor is bound by a Delta 
ligand presented by neighbouring cells. This causes the Intracellular domain of Notch 
(NothchIC) to be cleaved from the receptor where it undergoes further modification in 
the cytoplasm before being allowed to be shipped to the nucleus. When in the nucleus 
Notch interacts with Static RBP-Jκ which is permanently associated with the DNA or 
Dynamic RBP-Jκ which is not bound to DNA. NotchIC displaces Histone deacetylases 
(HDAC) and co-repressors (CoR) off of the Static RBP-Jκ to provide a platform for 
transcription factors such as MAML and Histone acetylates (HAT) to be recruited to 
activate gene expression. Dynamic RBP-Jκ is recruited to genes upon NotchIC binding, 
changing the cells chromatin landscape to promote differentiation or a particular 




1.3.2 : Variation of Notch signalling outcomes 
Despite the Notch signalling pathway having few steps the Notch signalling pathway is 
able to elicit a diverse number of outcomes in a large number of cells types (Baron, 
2003, Bigas et al., 2010, Andersson et al., 2011). The ability of Notch to recruit TFs, 
enhancers and HAT to create cell specific transcriptional landscapes, is thought to be 
the source of the Notch signalling pathways diverse outcomes over different cell types 
(Oswald et al., 2001, Visel et al., 2009). For example, Runt-related-TF (RUNX) enhancer 
has been shown in B cells to be enriched around RBP-Jκ sites and is suggested to open 
the DNA exposing HES-1 sites for Notch complex assembly and gene activation (Ito et 
al., 2015, Gunnell et al., 2016). In contrast Ikaros, a zinc finger protein, has been shown 
to block enhancer binding and Notch1 activation of MYC genes in T-cells (Ong et al., 
2006, Geimer Le Lay et al., 2014). Transcription factors can also indirectly influence 
Notch signalling, for example Notch induced oestrogen receptor (ESR1) expression can 
be silenced by BCL6 preventing MAML recruitment or by recruiting HDAC to 
epigenetically silence expression (Gyory and Minarovits, 2005, Kitagawa, 2016). 
Proteins also directly interact with RBP-Jκ to promote Notch induced gene activation 
such as Ski-interacting protein (SKIP) or interfere with Notch complex assembly such as 
BEN-SOLO protein has been shown to do (Sifang Zhou, 2000, Vasquez-Del Carpio et al., 
2011, Dai et al., 2013). Notch expression levels, post-translational modifications and 
metalloprotease availability have also been shown to influence different Notch 
signalling outcomes in certain cell types (Zolkiewska, 2008, Fortini, 2009).  
1.3.3 : Notch Signalling in B cells 
Notch 1 has been shown to be expressed at different levels throughout B cell 
development, whilst Notch 2 is expressed in late pre-B cells and is essential for 
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marginal zone (MZ) B cell development (Hsieh et al., 1997, He and Pear, 2003b, Kuroda 
et al., 2003, Saito et al., 2003, Santos et al., 2007). Notch signalling is involved in two 
cell fate determining steps during B cell development and maturation. During 
lymphopoiesis Notch 1 signalling has been shown to determine whether B cell 
progenitor cells specialise into B cells or T cells in mice (Ciofani and Zúñiga-Pflücker, 
2005). Notch 1 signalling in mice is activated when delta ligand from a neighbouring B 
cell progenitor cell binds to the notch receptor activating genes to promote the cell to 
specialise into a T cell. It is hypothesised this ensures that an equal number of T cells 
and B cells are produced in the marrow providing balance to the immune system 
(Besseyrias et al., 2007). Hes-1 expression has been shown to be high in immature B 
cells but reduces significantly in mature B cells, which is why it is not thought that EBV 
competes or interacts with Notch during an EBV infection (Bertrand et al., 2000, Saito 
et al., 2003). It must be noted that HES-1 expression is not only activated by the Notch 
pathway, so does not directly correlate to Notch signalling. Although much of the 
research into Notch signalling in B cells has been done in mice, no murine B cell 
malignancies have been shown to result from oncogenic Notch signalling (Zweidler-
McKay et al., 2005). However increased Notch 2 expression has been shown to occur in 
B-cell chronic lymphocytic leukaemia and Notch 1 expression has been shown to be 
higher in malignant B cells from Hodgkin’s lymphoma patients (Hubmann et al., 2002, 
Jundt et al., 2002). Notch signalling and EBV hijacking of host RBP-Jκ are mutually 
exclusive. They lead to different outcomes for B cells in vivo and are not shown to 
compete with each other for RBP-Jκ binding (Zimber-Strobl and Strobl, 2001, Rowe et 
al., 2014). Notch 1 has been shown to mimic the ability of EBNA2 to activate CD21 and 
down regulate Igµ transcription in Burkitts lymphoma cell infected with EBV with 
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EBNA2 knocked out. However, Notch 1 does not mimic EBNA activation of CD23 and 
LMP1 and can only transiently sustain proliferation if LMP1 is artificially activated in 
these cells lines (Strobl et al., 2000, Höfelmayr et al., 2001).  
1.3.4 : Introduction to RBP-Jκ  
The Notch signalling pathway and the transcription factor suppressor of hairless (SuH) 
were discovered in D. melanogaster and is conserved across metazoans (C.elegans 
(Lag-1 or CSL), mouse (CSL) and humans (RBP-Jκ or CBF1)) (Bailey and Posakony, 
1995)(Figure 1.6). Four isoforms of RBP-Jκ are expressed in humans and there is little 
variation between their amino acid sequences with the exception of the N and C 
termini of each isoform. RBP-Jκ variant 1 is the largest isoform with significant 
extensions of the N and C termini and is the second most expressed isoform in B cells 
(Amakawa R, 1992, Kenia G. Krauer, 1999). RBP-Jκ variant 2 is the smallest isoform and 
is the dominantly expressed isoform of RBP-Jκ in B cells. RBP-Jκ variants 3 and 4 are 
not expressed in B cells but have significant roles in Notch signalling in a plethora of 
different cell types (Kenia G. Krauer, 1999). The differences between the N and C 
termini of the different isoforms of RBP-Jκ are thought to contribute to the ability of 
relatively small number of RBP-Jκ and Notch isoforms to produce such a large number 
of developmental and cell signalling out comes (Espinosa, 2012). RBP-Jκ has three 
domains in its structure, the N-terminal domain (NTD), the beta trefoil domain (BTD) 
and the C-terminal domain (CTD) (Choi et al., 2012). The BTD and NTD bind the DNA 
RBP-Jκ consensus site (GTGGGA) but have also been shown to bind to RBP-Jκ sites that 
have some sequence variation with a weak affinity (Friedmann and Kovall, 2010). 
NotchIC RAM domain initially associates via its WΦP motif to the BTD, this causes 
conformational changes to RBP-Jκ that promote the NotchIC Ank binding to RBP-Jκ 
59 
 
CTD. MAML then binds to the Notch ANK repeats and RBP-Jκ NTD to form an active 
Notch transcription complex, which activates RBP-Jκ, mediated genes such as MYC, 
CD21 and Igµ which drive cell proliferation (He and Pear, 2003b, Johnson et al., 2010, 
Vasquez-Del Carpio et al., 2011, Choi et al., 2012). Proteins such as SKIP have also been 
shown to be key in the assembly of an active NotchIC-DNA complex as previously 
described (Sifang Zhou, 2000). There are two populations of RBP-Jκ present in the 
nucleus, dynamic and static, and their ability to bind DNA is influenced by epigenetic 
factors anchoring them into closed chromatin structures or Notch binding recruiting 
them to target genes. Notch has been shown by Chromatin Immunoprecipitation 
Sequencing (ChIP-Seq) to promote unique RBP-Jκ binding profiles in cells with 
constitutively activated Notch signalling when compared to cells with Notch signalling 
turned off. There was also a sub population of RBP-Jκ which DNA binding was not 
affected by Notch signalling status called static RBP-Jκ (Castel et al., 2013).  
1.3.5 : The structure of the human Notch complex 
The structure of the human notch complex was determined in 2012 (Choi et al., 2012) 
(Figure 1.6). The complex contained aa8-435 of RBP-Jκ removing the N and C termini of 
RBP-Jκ and preserving the highly conserved core of RBP-Jκ. Notch was assembled using 
2 different domains, the Ank-repeats and a peptide of the RAM domain. This was 
shown to improve the resolution of the RAM domain (Choi et al., 2012). When the Ank 
and RAM domains of Notch were co-crystallised as one protein, in the structure of 
RBP-Jκ-HES-1-site, the resolution of the RAM domain was poor and  was thought to 
have been compromised by the disordered amino acid chain linker between the Notch 
RAM and Ank domains (Nam et al., 2006). The RAM domain WΦP RBP-Jκ binding motif 
is shown to slot into a hydrophobic pocket on the surface of the BTD (Nam et al., 
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2006). Interestingly, the presence of a proline residue immediately after the WΦP RBP-
Jκ binding motif appears to influence the direction in which the RAM domain binds to 
BTD (Borggrefe and Oswald, 2016). The Lin-12 RAM domain, which has a proline 
residue after the WΦP motif, in the structure of the C.elegans CSL-Lin12-DNA complex 
was shown to bind in a linear fashion to the BTD. However, the structure of the human 
Notch transcription complex shows that the RAM domain, which contains a glycine 
residue after the WΦP motif, is shown to kink after the WΦP motif (Wilson and Kovall, 
2006, Choi et al., 2012)(Figure 1.6). The biological implications of this difference are 
not known and this difference could be an artefact of crystal packing. Furthermore, a 
thermodynamic study of the RAM-CSL interaction showed that these residues play a 
less essential role in RAM-CSL interactions (Johnson et al., 2010). The Notch complex 
has also been shown to dimerise when two opposing RBP-Jκ binding sites within 16bp 
of each other are present on the DNA (Arnett et al., 2010). The structure of the Notch 
complex dimer showed that salt bridges form between Notch complexes, which are 
thought to stabilise the dimer complex (Arnett et al., 2010).  
The cross species conservation of interactions between RBP-Jκ, the RBP-Jκ DNA binding 
site and Notch are demonstrated in a comparison between x-ray crystal structures of 
the mouse, C.elegans and human Notch complex and the Drosophila suppresser of 
Hairless complex (Friedmann et al., 2008, Choi et al., 2012, Yuan et al., 2012)(Figure 
1.6). These structures show that, the overall structure of RBP-Jκ involves interactions 
between domains that are located far away from each other in the amino acid 
sequence. This had made expressing truncations of the different RBP-Jκ domains in 
previous studies challenging, preventing the determination of where RBP-Jκ interacting 
proteins bind to RBP-Jκ (Johnson et al., 2010, Calderwood et al., 2011, Kurth et al., 
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2011). This has also made determining where the EBNA3 TΦGC motif interacts with 





























Figure 1.6. Structures of the human Notch complex and its mouse and worm 
homologues. A. X-ray crystal structure C.elegans CSL (RBP-Jκ homologue)(shown in 
blue) bound to DNA with Lin-12 RAM domain bound (Notch homologue)(shown in 
red)(Friedmann and Kovall, 2010). B. X-ray crystal structure of Mouse RBP-Jκ (shown in 
blue) bound to DNA with Notch signalling inhibitor KyoT2 (shown in yellow) bound 
(Collins et al., 2014). C. X=ray crystal structure of the Human Notch complex. RBP-Jκ, 
MAML, Notch ANK repeats and Notch RAM domain shown in blue, pink, orange and 
green respectively (Choi et al., 2012). D. Table of aligned amino acid sequences of RBP-














1.3.6 : EBNA interactions with RBP-Jκ 
The host transcription factor RBP-Jκ has been implicated in targeting the EBNAs to DNA 
since it was shown to recruit EBNA2 to the LMP1 promoters of the EBV genome (Wang 
et al., 1987, Allday et al., 1993, Zimber-Strobl et al., 1993). RBP-Jκ has been shown to 
bind to EBNA2 and the EBNA3 family HD using pull downs from EBV infected B cells 
(Johannsen et al., 1996, Waltzer et al., 1996, Calderwood et al., 2011). Pull-downs, 
using RBP-Jκ as bait, of truncations of the EBNAs identified EBNA2280-337, EBNA3A172-220, 
EBNA3B1-311 and EBNA3C183-240 as RBP-Jκ binding regions (Waltzer et al., 1996). EBNA3s 
were initially thought to bind RBP-Jκ exclusively via TFGC/TLGC (TΦGC) motif as 
EBNA3CTFGC-AAAA mutants did not pull down RBP-Jκ and were not able to sustain growth 
in EBNA3C negative LCLs (Zhao et al., 1996, Kenia G. Krauer, 1999, Klaus Peter Fuchs1, 
2001, Maruo et al., 2009). Later scanning alanine mutations were used to show how 
EBNA2 bound to RBP-Jκ via WWP motif suggesting EBNA2 mimicked Notch to bind 
RBP-Jκ (Klaus Peter Fuchs, 2001, Zimber-Strobl and Strobl, 2001). However a WTP 
motif was identified 14aa away from the TFGC and was shown to be essential for 
EBNA3CHD-RBP-Jκ interactions when the EBNA3C HD was expressed in E.coli however 
was shown to be dispensable for EBNA3CHD-RBP-Jκ interactions when the EBNA3C HD 
was expressed in mammalian cells (Calderwood et al., 2011). Mutation of RBP-Jκ 
residues L326 and Q333 were shown to knockout EBNA2 binding in a yeast two hybrid 
mutagenesis screen of RBP-Jκ (Klaus Peter Fuchs, 2001). Later an EBNA2 peptide 
containing the WΦP motif was shown to interact with a truncation of the RBP-Jκ BTD 
using ITC (Johnson et al., 2010). This confirmed that EBNA2 bound to the RBP-Jκ BTD 
by mimicking Notch. Mapping where the EBNA3s bind to RBP-Jκ has been more 
challenging. Even though the WΦP motif has been shown to bind the BTD of RBP-Jκ, 
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the binding site of the TΦGC motif has been more challenging to locate (Calderwood et 
al., 2011). Although EBNA3C was pulled down with a truncation of the RBP-Jκ NTD 
there is debate whether the NTD expressed was functional (Calderwood et al., 2011). 
As previously described the NTD relies on β-sheets in the CTD to stabilise the 
hydrophobic core of RBP-Jκ (Choi et al., 2012). Therefore, independently expressing 
NTD has proven challenging for groups studying homologues of RBP-Jκ, leading many 
to question the validity of their own data when they were unable to show proteins of 














1.4 : Aims 
Microarrays of EBNA knockout cell lines have shown that EBNA2 and the EBNA3 family 
hijack the expression of host genes involved with cell survival, apoptosis, cell growth 
and immune evasion to establish a latent EBV infection (Maier et al., 2006, Zhao et al., 
2006, White et al., 2010). Additionally, ChIP-Seq analysis has revealed that the EBNAs 
control host expression predominantly from distal promoters and has identified the 
host transcription factor RBP-Jκ to be an essential adaptor for the EBNAs to interact 
with the host genome (McClellan et al., 2013a, Wang et al., 2015). Chip re-Chip 
experiments have also shown that EBNA2 and the EBNA3s independently occupy 
shared binding sites suggesting they compete for RBP-Jκ binding (McClellan et al., 
2013b). A combination of pull downs, yeast 2-hybrid assays and reporter assays have 
identified the EBNA2 WFP, EBNA3 family TΦGC and the EBNA3C WTP motifs play key 
roles in EBNA-RBP-Jκ interactions (Ling and Hayward, 1995, Lee et al., 2009, 
Calderwood et al., 2011). However, the mechanism to how the EBNAs hijack host 
expression via RBP-Jκ is still not fully understood. Understanding the mechanism to 
how the EBNAs exploit RBP-Jκ to immortalise B cells and establish persistent EBV 
infection could improve our understanding to how cells lose control of essential 
pathways and develop into cancers. Additionally, understanding the mechanism of 
how EBNAs hijack host gene expression could lead to the discovery of potential 
therapeutic targets in order to treat EBV associated cancers.  
Therefore, we aim to use structural biology approaches to obtain three dimensional 
structures of the EBNAs bound to RBP-Jκ to study how the EBNAs interact with RBP-Jκ. 
We also aim to use biophysical techniques to examine the role and contribution of the 
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EBNA RBP-Jκ binding motifs to improve the understanding of the mechanism to how 
EBV TFs hijack RBP-Jκ to promote the establishment of persistent EBV infections and 

















Chapter 2: Methods 
2.1: Molecular biology 
2.1.1 : Restriction Enzyme Digests 
Buffer selection and DNA concentrations were based on manufacturer’s 
recommendations. Digests were incubated at 37oC for 2 hours then stored at 4oC. 
Restriction digests were analysed using a 1% agarose gel and stained with simply red 
stain. Uncut DNA and single restriction digests were run on the agarose gel in parallel 
to double restriction digests where appropriate.  
2.1.2 : Polymerase chain reaction (PCR) 
Buffer selection, polymerase and nucleotides used in the PCRs were based on 
manufacturer’s recommendations. The primers were designed using serial cloner 
software and ordered from Thermofisher. The annealing temperature was calculated 
using the NEB Tm calculator (https://www.neb.com/tools-and-resources/interactive-
tools/tm-calculator). PCRs were carried out using a G-Storm thermal cycler and stored 
at 4oC upon completion. The PCR products were run on a 1% agarose gel and vectors 
with no polymerase were run in parallel with the PCRs as negative controls. PCR 
products that were to be used for cloning were purified using the QUIAGEN QIA-prep 
Gel extraction Miniprep kits. 
2.1.3 : DNA Sequencing 
All DNA sequencing was completed by the Eurofins MWG operon automated 
sequencing service. 1000ng of DNA was added to 20ng of sequencing primer and made 




2.1.4 : Agarose gel electrophoresis 
Agarose powder was melted in boiling ultrapure water, after cooling simply gel red 
was added and then the mixture was poured into a cast. DNA samples were mixed 
with Orange DNA Loading Dye then loaded into wells and ran at 95V for 50 minutes 
(Biorad power pack). 1kb ladder was ran in parallel to estimate the size of the DNA 
products loaded. Bands were analysed on a Licor machine. 
2.1.4 : Small scale plasmid DNA preparation  
1µg of plasmid was used to transform 100µL of competent DH5α E.coli cells. Plasmid 
was mixed with DH5α E.coli cells and incubated on ice for 15 minutes, then heat 
shocked for 45 seconds at 42oC and returned to the ice for 5 minutes. 250µL of LB was 
added to the transformed cells and they were then grown in a 37oC shaking incubator 
at 225rpm for an hour. The cells were plated on agar, containing an appropriate 
selective antibiotic for the vector, then cultured at 37oC overnight. Colonies were then 
picked and grown in LB containing selective antibiotic overnight. Cells were pelleted at 
4000rpm in a Sorvall™ ST 8 Small Benchtop Centrifuge, the medium was removed and 
the plasmid was extracted and purified using QIAGEN QIA-prep Miniprep kits according 
to manufacturers recommendations. 
2.1.5 : Ligation  
Buffer selection, polymerase and nucleotides used in the PCRs were based on 
manufacturer’s recommendations. The amount of insert to add to the ligation reaction 
was calculated using the formula below and takes into account the molar ratio of 
insert to vector, the insert length, the vector length and the mass of the vector.  
𝑰𝒏𝒔𝒆𝒓𝒕 𝒎𝒂𝒔𝒔 (𝒏𝒈) = 𝑴𝒐𝒍𝒂𝒓 𝒓𝒂𝒕𝒊𝒐 ×  [
𝑰𝒏𝒔𝒆𝒓𝒕 𝒍𝒆𝒏𝒈𝒕𝒉 𝒊𝒏 𝒃𝒑
𝑽𝒆𝒄𝒕𝒐𝒓 𝒍𝒆𝒏𝒈𝒕𝒉 𝒊𝒏 𝒃𝒑
]  × 𝑽𝒆𝒄𝒕𝒐𝒓 𝒎𝒂𝒔𝒔 𝒊𝒏 𝒏𝒈 
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Ligation reactions were incubated in ice water overnight. The following day the ligation 
was transformed into competent DH5α E.coli and plated onto agar containing an 
appropriate antibiotic. Colonies were grown in selective LB overnight. Cells were 
pelleted at 4000rpm (Ch 500062PP rotor, VWR microstar 17 centrifuge), the medium 
was removed and the plasmid was extracted and purified using QIAGEN QIA-prep 
Miniprep kits according to manufacturers recommendations. Diagnostic restriction 
digests were carried out and successful ligations were sent off for sequencing.  
2.1.6 : Competent Bacteria 
DH5α or Rosetta pLysS De3 E.coli cells from -80oC stock were streaked onto agar plates 
and incubated at 37oC overnight. chloroquine was added to plates and Lysogeny broth 
(LB) was used to grow Rosetta pLysS De3 E.coli cells. A single colony was picked and 
used to inoculate 10ml of LB which grown up overnight at 37oC in a shaking incubator. 
1ml of the overnight culture was used to inoculate 200ml of LB which was grown to an 
OD of 0.4. The E.coli is rapidly cooled on ice, then pelleted at 4000rpm (J-LITE JLA 
8.1000 Fixed Angle rotor, Avanti J-26XP centrifuge). Pellets were resuspended in 66mls 
of BufferI (Appendix 3), incubated on ice for 15 minutes then pelleted at 4000rpm for 
12 minutes at 4oC (J-LITE JLA 8.1000 Fixed Angle rotor, Avanti J-26XP centrifuge). Next 
the pellet was resuspended in 8mls of BufferII (Appendix 3) and incubated on ice for 20 
minutes. Cell were then aliquoted into sterile Eppendorf tubes, flash frozen in liquid 






2.1.7 : Cloning  
2.1.7.1 : Cloning of pFastBac vectors to express C-terminally His-tagged RBP-Jκ8-435. 
cDNA of C-terminally His-tagged RBP-Jκ8-435 was amplified, using PCR, from the 
pET28B.JK.8-435 vector (Appendix 2) which was produced by a summer student in 
Michelle West’s Group. Forward and reverse primers (‘RBP-Jκ 8-435 Forward SmaI’ and 
‘RBP-Jκ 8-435 Reverse XbaI’)(Appendix 1) were designed to add SmaI and XbaI 
restriction sites respectively to the cDNA of C-terminally His-tagged RBP-Jκ8-435 cDNA of 
C-terminally His-tagged RBP-Jκ8-435 and pFastBac.CP.17.2 vector (Figure 2.1)(Appendix 
2) was digested with SmaI and XbaI restriction enzymes and ligated together with a 1:3 
vector to insert ratio. This strategy simultaneously removed the N-terminal His-tag 
from the p10 multiple cloning site (MCS) whilst inserting the C-terminally His-tagged 
RBP-Jκ8-435 cDNA. Diagnostic restriction digests of the ligation products were carried 
out to determine whether the cDNA of C-terminally His-tagged RBP-Jκ8-435 had been 
correctly inserted into the p10 MCS of the empty pFastBac.CP.17.2 vector. SmaI and 
XbaI single restriction digests of pFastBac.CP.17.2 were run as controls. Successful 
clones were sent for sequencing at Eurofins for verification.  
2.1.7.2 : Cloning of pFastBac co-expression vectors to co-express EBNA2272-333 and RBP-
Jκ8-435 or RBP-Jκ variant 2 
cDNA of the EBNA2272-333 fragment was amplified, using PCR, from the pF.CP17.272 
vector produced by a masters student from Dr Christomous Prodromou group. Primers 
‘EBNA2 fragment Forward NheI, XbaI’ and ‘EBNA2 fragment Reverse BamHI’ were 
designed to add XbaI and BamHI restriction sites to the EBNA2272-333 cDNA (Appendix 
1). EBNA2272-333 cDNA, pF.JK.8-435 vector and pF.JK.V2 vector were cut with XbaI and 
BamHI restriction enzymes and ligated together with a 1:3 vector to insert ratio. 
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Diagnostic restriction digests of the ligation products were run to determine whether 
EBNA2272-333 cDNA had been correctly inserted into the polyhed MCS of the pF.JK.8-
435 vector and pF.JK.V2 vectors. Successful clones were sent for sequencing at 
Eurofins for verification. pF.JK.8-435.272 and pF.JK.V2.272 vectors were made into 
recombinant baculovirus by the processes discussed in chapter 2.2.1. 
2.1.7.3 : Cloning of pFastBac co-expression vectors to co-express full length EBNA2 and 
RBP-Jκ8-435 or RBP-Jκ variant 1 or 2 
EBNA2 cDNA was amplified, using PCR, from the pF.CP17.EB2 vector (appendix 2) 
produced by a masters student from Dr Christomous Prodromou group. Primers 
‘EBNA2FL Reverse SalI’ and ‘EBNA2FL Forward NheI, XbaI’ (appendix 1) were designed 
to add XbaI and SalI restriction sites to the EBNA2 cDNA. EBNA2 cDNA, pF.JK.8-435 
vector, pF.JK.V1 and pF.JK.V2 vector were cut with XbaI and SalI restriction enzymes 
and ligated together with a 1:3 vector to insert ratio. Diagnostic restriction digests of 
the ligation products were run to determine whether EBNA2 cDNA had been correctly 
inserted into the polyhed MCS of the pF.JK.8-435 vector and pF.JK.V2 vectors. 
Successful clones were sent for sequencing at Eurofins for verification. pF.JK.8-435.EB2 
vector was made into recombinant baculovirus by the processes discussed in chapter 
2.2.1. 
2.1.7.4 : Cloning of pFastBac vectors to express His-tagged EBNA3C100-356 or EBNA3C100-
413 
EBNA3C100-356 and EBNA3C100-413 cDNA was amplified, using PCR, from the 
pcDNA.EBNA3C vector provided to us by Dr A Bell from the University of Birmingham 
(appendix 2). Forward and reverse primers (3CHD p10 Forward HindIII, 3CHD.1 p10 
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Reverse NheI and 3CHD.2 p10 Reverse NheI (appendix 1)) were designed to add XbaI 
and SalI restriction sites respectively to the EBNA3C100-356 and EBNA3C100-413 cDNA. 
EBNA3C100-356 cDNA, EBNA3C100-413 cDNA and pFastBac.CP.17.2 vector were cut with 
NheI and HindIII restriction enzymes and ligated together with a 1:3 vector to insert 
ratio. Diagnostic restriction digests of the ligation products were run to determine 
whether the EBNA3C100-356 and EBNA3C100-413 cDNA had been correctly inserted into 
the p10 MCS of the empty pFastBac.CP.17.2 vector. Successful clones were sent for 
sequencing at Eurofins for verification. pF.EB3C.HD1 and pF.EB3C.HD2 vectors were 
made into recombinant baculovirus by the processes discussed in chapter 2.2.1. 
2.1.7.5 : Cloning of pFastBac co-expression vectors to co-express EBNA3C100-356 or 
EBNA3C100-413 with RBP-Jκ8-435 
EBNA3C100-356 and EBNA3C100-413 cDNA was amplified, using PCR, from the 
pcDNA.EBNA3C vector provided to us by Dr A. Bell from the University of Birmingham 
(Appendix 2). Forward and reverse primers (3CHD polyhed Forward XbaI, 3CHD.1 
polyhed Reverse BamHI, 3CHD.2 polyhed Reverse BamHI (Appendix 1)) were designed 
to add XbaI and BamHI restriction sites respectively to the EBNA3C100-356 and 
EBNA3C100-413 cDNA. EBNA3C100-356 cDNA, EBNA3C100-413 cDNA and pF.JK.8-435 vector 
were cut with XbaI and BamHI restriction enzymes and ligated together with a 1:3 
vector to insert ratio. Diagnostic restriction digests of the ligation products were run to 
determine whether EBNA3C100-356 and EBNA3C100-413 cDNA had been correctly inserted 
into the polyhed MCS of the pF.JK.8-435 vector. Successful clones were sent for 
sequencing at Eurofins for verification. pF.JK.8-435. EB3C.HD1 and pF.JK.8-435. 
EB3C.HD2 vectors were made into recombinant baculovirus by the processes discussed 
in chapter 2.2.1. 
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2.1.7.6 : Plasmid Maps 
 
Figure 2.1. pFastBacDual plasmid map from the Invitrogen Bac-to-Bac manual. 
PFCP17.2 has been engineered from a pFastBacDual vector to contain a cleavable N-
terminal 6x His-tag in multiple cloning site (MCS) controlled by the p10 promoter (p10 
MCS) and a N-terminal Cleavable StrepII-Tag in the MCS controlled by the polyhedron 





































2.1.8 : Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples and cell pellets were mixed in a 1:1 ratio with Gel Sample Buffer (GSB) 
and boiled on a heating block for 2 and 10 minutes respectively. Boiled cell lysates 
were spun down at 12500 rpm (Ch 500062PP rotor, VWR microstar 17 centrifuge) to 
prevent cell debris being loaded onto the gel. Samples were loaded onto 10% or 4-12% 
Tris-Bis pre-cast Novex SDS-PAGE gels and run in MOPS buffer for 50 mins at 200V 
using a Biorad volt pack. Seeblue® plus2 pre-stained protein standard was ran 
alongside samples. Gels were stained using Simply blue stain microwaved with the gel 
for 10-20 seconds.  
2.1.9 : Western blotting 
Cell pellets were lysed in GSB buffer, boiled, spun at 13,000 x g (Ch 500062PP rotor, 
VWR microstar 17 centrifuge) for 2 minutes, then ran on a 10% or 4-12% Bis-Tris SDS-
PAGE gel with a SeeBlue™ Plus2 Pre-stained Protein Standard. The protein was 
transferred onto a nitrocellulose membrane at 75V for 90 minutes using a Biorad 
power pack. Ponceu stain was used to verify the transfer had been successful then was 
washed off the membrane with water then PBS buffer. The membrane was then 
blocked in 2% powdered milk dissolved in PBS Tween, washed with PBS, then probed 
with primary anti-body. After the primary antibody was bound the membrane was 
washed in PBS tween and incubated with secondary antibody conjugated to a 
Horseraddish-peroxidase (HRP). After a final wash to remove any unbound secondary 
antibody the membrane was stained with ECL. The chemiluminescence emitted by the 
bands was measured on a Licor machine. Appropriate positive and negative controls 
were ran along side the samples. 
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2.1.10 : Electrophoretic mobility shift assay (EMSA) to test whether the C-terminally 
His-tagged RBP-Jκ8-435 expressed in insect cells was functional 
Single stranded oligonucleotides encompassing the RBP-Jκ consensus site were 
dissolved in ultrapure water at 100mg/ml, mixed together, then denatured in a 95oC 
heating block. They were then slowly annealed by gradually decreasing the 
temperatureby leaving the heat block to cool down overnight. 3.3µM of RBP-Jκ 
consensus site (AAACACGCCGTGGGAAAAAAT) or RBP-Jκ consensus mutant 
(AAACACGCCGTGGCTAAAAAT) was mixed with EMSA stock buffer (5 x Buffer: 50mM 
Tris pH7.5, 5mM MgCl, 2.5mM EDTA, 2.5mM DTT, 250mM NaCl, 0.25µg/µl PolydIdC, 
20% glycerol) then incubated with increasing concentrations of C-terminally His-tagged 
RBP-Jκ8-435 expressed in insect cells for 30 minutes at room temperature. Each sample 
was then loaded onto a 6% Nupage DNA retardation gel in 0.5xTBE buffer and 
separated for 50 minutes at 100V. The gel was stained with Gel Safe Red, then bands 
were visualised on the Licor machine.   
2.1.11 : Site directed mutagenesis of the EBNA3C RBP-Jκ binding motifs. 
The Q5 site directed mutagenesis kit from NEB was used to mutate EBNA3C cDNA, in a 
pSG5 vector, TΦGC RBP-Jκ binding motif to alanines and the tryptophan in the WΦP 
motif to serine. AFGC, TAGC and AAGC mutants were probing how RBP-Jκ-EBNA3C 
interactions were affected when compared to TFGC-AAAA EBNA3C mutants. We also 
intended to see, by probing the western blots with antibodies with specificity to other 
host TFs known to bind EBNA3C, how these mutants affected other EBNA3C-host 
protein interactions. The EBNA3C STP mutant was made to confirm whether it ablates 
EBNA3C-RBP-Jκ interactions (Calderwood et al., 2011). Primers with the desired 
mutated sequences were designed to amplify the entire vector in opposite directions 
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from the sequence that was to be mutated shown in chapter 2.1.7. Q5 fidelity mix 
contained a high fidelity polymerase and buffers designed to aid with the amplification 
of the entire vector. The PCR products were incubated with a kinase, ligase, DpnI mix 
(KLD mix) which simultaneously phosphorylated the ends of the linear PCR products 
and ligated the linear PCR products back into circular vectors whilst the DpnI digested 
the methylated DNA of the original vector. The mutated vectors were transformed into 
NEB DH5α competent E.coli by heat shock at 42oC for 30 seconds, grown up in Super 
Optimal broth with Catabolite repression (SOC) media for 1 hour, then plated onto 
ampicillin agar which were incubated at 37oC overnight. Colonies were picked, grown 
in LB with ampicillin at 37oC then the DNA was extracted using a QIAGEN QIA-prep 
Miniprep kit. Each of the mutant vectors was then sent for sequencing at Eurofins to 
verify whether the DNA had been successfully mutated.  
2.1.12 : Large scale plasmid preparation 
Re-streaked colonies of each of the pSG5 vectors containing wild type EBNA3C and 
EBNA3C with mutated RBP-Jκ binding motifs were picked and grown up in 50ml over a 
day. The 50ml culture were then used to grow 400ml cultures of each vector in LB with 
ampicillin overnight. Each of the cultures were pelleted at 4000rpm (TX-100 rotor, 
Thermo heraeus multifuge x3r centrifuge), resuspended in SolI (Appendix 3), lysed in 
SolII (Appendix 3), then the pH was neutralised with SolIII (Appendix 3) to prevent 
damaging the vector. The cell debris was separated from the solution by spinning the 
mixture down at 4000rpm (TX-100 rotor, Thermo heraeus multifuge x3r centrifuge) 
and filtering it through cheese cloth into fresh falcon tubes. Isopropanol was added to 
solution to precipitate the DNA which was pelleted at 4000rpm (TX-100 rotor, Thermo 
heraeus multifuge x3r centrifuge). The DNA pellet was resuspended in ultrapure water 
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and the RNA was precipitated with 5M NH4 acetate. The RNA was pelleted at 4000rpm 
(TX-100 rotor, Thermo heraeus multifuge x3r centrifuge) and the DNA supernatant was 
pipetted into fresh falcon tubes. 100% ethanol was added to the DNA supernatant and 
samples were incubated at -20oC to precipitate the DNA. The DNA was pelleted at 
4000rpm (TX-100 rotor, Thermo heraeus multifuge x3r centrifuge), resuspended in 4ml 
of water and CsCl2 was dissolved in the DNA solution. Ethidium Bromide was added to 
the CsCl-DNA solution in excess then this mixture was pipetted into Beckmann optiseal 
centrifuge tubes and ultra-centrifuged at 50,000 RPM overnight at room temperature 
(VTi 65.2 Vertical-Tube Rotor, Proteome Lab XL-A/XL-I centrifuge). This produced a 
density gradient which separated the linear chromosomal DNA from the desired 
circular plasmid DNA. The band of plasmid DNA was extracted from the ultracentrifuge 
tube using a syringe. Ethidium bromide was removed by adding the mixture to CsCl 
saturated butanol. The DNA entered the aqueous phase whilst the ethidium bromide 
remained in the organic butanol phase. The DNA was pelleted at 4000rpm (TX-100 
rotor, Thermo heraeus multifuge x3r centrifuge) and left at room temperture to dry. 
The DNA pellet was resuspended in as little ultrapure water as possible to keep the 
DNA concentrated.  
2.1.13.1 : Quantification of C-terminally His-tagged RBP-Jκ8-435 expressed in 100ml of 
E.coli bound to Co2+-beads. 
The talon beads (Co2+ beads) were blocked with 5% BSA dissolved in PBS buffer 
overnight at 4oC. Pellets of 100ml preparations of E.coli expressing C-terminally His-
tagged RBP-Jκ8-435 were thawed, lysed in buffer A (50mM Tris pH8.8, 500mM NaCl, 
0.5mM TCEP, 10mM imidazole) + nuclease + lysozyme and sonicated 10 sec on, 10 sec 
off for 2 minutes at 35% using a Vibra-Cell VC 750 sonicator (Sonics). The cell debris 
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was separated from the lysate by centrifuging the sample at 13,500rpm (Ch 500062PP 
rotor, VWR microstar 17 centrifuge). The lysate was then incubated with blocked talon 
beads for an hour on a rolling shaker. The beads were then washed twice with buffer 
A. Known quantities of Bovine Serum Albumin were boiled in Gel Sample Buffer 
(GSB)(Appendix 3) and 30µL of RBP-Jκ8-435 bound to talon beads boiled in GSB were run 
on a Bis-Tris SDS-PAGE gel alongside a SeeBlue™ Plus2 Pre-stained Protein Standard. 
The gel was run in MOPS buffer for 50 minutes at 200V after which it was stained with 
Coomassie. The band intensities from the Coomassie were measured on the Licor 
machine and it was estimated that there was 0.44μg RBP-Jκ8-435 on the 30µL sample of 
talon beads. The formula below was used to calculate how much RBP-Jκ8-435 bound to 





=  ~30µ𝑀 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑏𝑜𝑢𝑛𝑑 𝑡𝑜 100µ𝐿 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠  
 
2.1.13.2 : Pull down assay using RBP-Jκ8-435.  
The talon beads were blocked with 5% BSA dissolved in PBS buffer overnight at 4oC. 
100ml preps E.coli expressing C-terminally His-tagged RBP-Jκ8-435 were pelleted at 
1100rpm  (TX-100 rotor, Thermo heraeus multifuge x3r centrifuge) and frozen. The 
pellets were thawed, lysed in buffer A + nuclease + lysozyme and sonicated 10 sec on, 
10 sec off for 2 minutes at 35% using a Vibra-Cell VC 750 sonicator (Sonics). The cell 
debris was separated from the lysate by centrifuging the sample at 13,500rpm (Ch 
500062PP rotor, VWR microstar 17 centrifuge). The lysate was then incubated with 
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blocked talon beads for an hour on a rolling shaker. The beads were then washed 
twice with buffer A.  
The DG75 pellets were resuspended in lysis buffer PD (50mM Tris pH7.5, 150mM NaCl, 
20mM MgCl2, 1% NP-40, 0.5% Na Deoxycholate) and sonicated five times 10 seconds 
on 10 seconds off at 35% using a Vibra-Cell VC 750 sonicator (Sonics). The cells were 
spun at 13,500 rpm (Ch 500062PP rotor, VWR microstar 17 centrifuge) to separate the 
cell debris from the lysate. Next, the DG75 cell lysate was incubated with RBP-Jκ8-435 
bound to the cobalt beads (talon beads) at 4oC for 1 hour, then washed with buffer PD 
(Appendix 3) for 10 minutes, then washed with Phosphate Buffer Saline (PBS) for 10 
minutes and then the beads were boiled in GSB for western blot analysis. 
Unfortunately, due to time constraints we were unable to reduce the significant 
amounts of background binding of EBNA3C and the EBNA3C mutants to the talon 
beads. 
2.2: Expression, purification and analysis of postranslational modifications. 
2.2.1: Introduction to insect cell expression system  
Insect cells as an expression system offer protein crystallographers better folding 
machinery than E.coli cells and post translational modifications with fewer of the 
difficulties associated with mammalian cell protein expression systems.  To utilise 
insect cells as an expression system a recombinant baculovirus containing the genes 
encoding for the protein of interest must be produced in order to infect the insect cells 
and express the protein of interest. To produce a RBP-Jκ expressing recombinant 
baculovirus RBP-Jκ cDNA regions were cloned into a pFastBac vector. Competent MAX 
Efficiency DH10Bac™ cells contain helper vectors that facilitate the transposition of 
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genes from the pFastBac vector into the Bacmid. The recombinant bacmids were 
transfected into SF9 insect cells using Cellfectin to produce P1 stocks of RBP-Jκ 
expressing recombinant baculovirus. Passage 1 (P1) stocks were grown up into P2 then 
P3 baculoviral stocks which could be used for large scale infections of insect cells to 
overexpress RBP-Jκ. 
2.2.1.1 : Transposition and Bacmid generation 
Vectors were transformed into a Bacmid in specialised MAX Efficiency DH10Bac™ 
competent E.coli by heatshock. MAX Efficiency DH10Bac™ competent E.coli contain 
helper vectors which express transposition proteins which facilitate the site specific 
transposition of the DNA between the mini Tn7 elements in the pFastBac vector into 
the mini-Tn7att site in the bacmid. The transformed MAX Efficiency DH10Bac™ cells 
were supplemented with 500µL SOC media, grown for 4 hours at 37oC then plated. 
After 48 hours incubating at 37oC in X-gal agar plates with Gentamicin, Tetracyclin and 
Kanamycin, we used blue-white selection of colonies to verify if the pFastBac vectors 
had been successfully transposed into the bacmid. White colonies were re-streaked to 
verify if they were true white colonies and then picked to be grown up in order to 
extract the bacmid from the cells. The bacmids were purified from the cells via ethanol 
precipitation and diagnostic PCRs were ran using pUC/ M13 primers, which amplify 
across the bacmid transposition sites, to see if the vector had been successfully 
transposed. Due to the large size of the co-expression vectors the Phusion polymerase 
did not have the fidelity to extend across the entire transposed region of the 
recombinant bacmids. We therefore amplified across the cDNA and the most proximal 
transposition site to validate whether the transposition of each co-expression vector 
had been successful. 
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2.2.1.2 : Transfection of Sf9 insect cells and generation of Baculovirus P1, P2 and P3 
stocks 
A monolayer of insect cells were transfected with the bacmid containing the desired 
genes to be expressed. 200µl SF900II medium, 8µl Cellfectin and 2µg of bacmid were 
mixed to make the transfection medium. After a 5 hour incubation of the bacmid and 
transfection mixture with the insect cell monolayer the transfection mixture was 
replaced with SF900II media containing 100U/ml penicillin/streptomycin (pen/strep) 
and incubated at 28oC for 5 to 6 days. Successfully transfected insect cells producing 
recombinant baculovirus would appear swollen and the insect cell nuclei would be 
dense and swollen. The media containing the P1 baculovirus was pipetted into 
cryotubes. After the P1 stock was harvested the cells in the well were dissolved in SDS 
buffer and boiled for western blot analysis of protein expression. P2 baculovirus stocks 
were generated by infecting 50ml of SF9 cells in SF900II medium + pen/strep with 1ml 
of the P1 stock. When cell viability dropped to 70% indicating successful infection the 
insect cells were pelleted at 1000xg (TX-100 rotor, Thermo heraeus multifuge x3r 
centrifuge). The baculovirus containing media was mixed with 2% FCS and stored at 
4oC for up to a year. This process was repeated again with P2 stock to make P3 stocks 
with a high enough viral titre for large scale insect cell preps.  
2.2.1.3 : Viral plaque assay used to calculate titre of baculovirus. 
Viral plaque assays were used to determine of the titre of virus in P3 stocks. 3 plates 
containing monolayers of insect cells were prepared and infected with 10-5, 10-6 and  
10-7 serially diluted P3 baculovirus. The insect cell monolayers were covered in agarose 
mixed with SF900II media . These cells were incubated for 4 days at 27oC. As the virus 
replicates, lyses and infects neighbouring cells the plaques of lysed cells created can be 
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visualised with neutral red staining in plaque forming units (pfu). By counting the 
number of plaques, the titre of virus can be calculated using the dilution factor of the 
virus and the volume of inoculum used using the formula below.  
𝑻𝒊𝒕𝒓𝒆 𝒐𝒇 𝑽𝒊𝒓𝒖𝒔 (𝒑𝒇𝒖/𝒎𝒍) =  
𝑻𝒉𝒆 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒑𝒍𝒂𝒒𝒖𝒆𝒔 𝒄𝒐𝒖𝒏𝒕𝒆𝒅 × 𝑫𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓 




2.2.1.4 : Insect Cell infection and Protein expression 
Insect cells at 2 x 107cells/ml were infected with baculovirus overexpressing the 
protein of interest. Insect cells were counted by mixing 10µl cells with at a 1:1 ratio 
with trypan blue, loading them onto Countess® Cell Counting Chamber Slides and using 
the Countess® Automated Cell Counter to count the cells and estimate cell viability. To 
establish the optimal infection time for protein expression a 200ml small scale 
infection of insect cells was initially carried out. In order to calculate the amount of 
baculovirus to use the viral titre, cell density, cell volume and the multiplicity of 
infection (MOI) were taken into account (shown in the formula below). 
𝑽𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒃𝒂𝒄𝒖𝒍𝒐𝒗𝒊𝒓𝒖𝒔 𝒓𝒆𝒒𝒖𝒊𝒓𝒆𝒅 (𝒎𝑳) 
=
𝑴𝑶𝑰 × 𝒄𝒖𝒍𝒕𝒖𝒓𝒆 𝒄𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕 (𝒄𝒆𝒍𝒍𝒔 𝒑𝒆𝒓 𝒎𝒍)  × 𝒄𝒖𝒍𝒕𝒖𝒓𝒆 𝒗𝒐𝒍𝒖𝒎𝒆(𝒎𝑳)
𝒗𝒊𝒓𝒂𝒍 𝒕𝒊𝒕𝒓𝒆
 
We infected the insect cells with a MOI of two which meant for every insect cell there 
would be two virions. Insect cells expressing C-terminally His-tagged RBP-Jκ8-435 and N-
terminally His-tagged EBNA3C100-356 were harvested 2 days after infection as we 
measured a drop in yield by day 3 of the prep.  
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2.2.2 : Insect cell expression and purification of RBP-Jκ  
2.2.2.1 : Analysis of expression of C-terminally His-tagged RBP-Jκ8-435 and N-
terminally His-tagged RBP-Jκ variant in insect cells. 
50ml of Sf9 cells were infected with baculovirus at an MOI of 2 and were incubated at 
27oC for three days. Each day 1ml of cells was taken, spun down at 1000 x g (TX-100 
rotor, Thermo heraeus multifuge x3r centrifuge) for 8 minutes, washed with PBS and 
then frozen. On the third day all the cell pellets were lysed in GSB buffer, boiled for 
analysis on Coomassie gels and western blots. His-tagged ZTA from Prof Allison 
Sinclair’s group was run as a positive control. 
2.2.2.2 : Nickel bead pulldown of C-terminally His-tagged RBP-Jκ8-435 expressed in insect 
cells. 
50ml of Sf9 cells were infected with baculovirus at an MOI of 2 and are incubated at 
27oC for three days. After 3 days the cells were pelleted and lysed in 1ml of lysis buffer 
(50mM Tris pH8.8, 500mM NaCl, 5mM β-mercaptoethanol) with a dounce 
homogeniser (on ice) and spun at 13,000 x g (Ch 500062PP rotor, VWR microstar 17 
centrifuge) for 20 minutes at 4oC. The beads were primed with lysis buffer spun at 
13,000rpm (Ch 500062PP rotor, VWR microstar 17 centrifuge) for 1 minute then the 
lysis buffer was removed. The lysate was incubated with the beads on a windmill 
rotator for 60 minutes at 4oC. The beads were spun down at 5000 x g (Ch 500062PP 
rotor, VWR microstar 17 centrifuge) for 30 seconds. The lysate was removed and 
stored at -20oC for future analysis. Beads were washed twice in buffer (50mM Tris 
pH8.8, 500mM NaCl, 5mM β-mercaptoethanol). After each wash step the beads were 
spun down and the wash buffer was removed. The wash step was repeated twice to 
ensure high purity. Next, elution buffer (50mM Tris pH8.8, 500mM NaCl, 5mM β-
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mercaptoethanol, 200mM imidazole) was added to the beads and mixed for 20 
minutes as described previously. The beads pelleted at 5000 x g (Ch 500062PP rotor, 
VWR microstar 17 centrifuge) for 30seconds and the eluate was removed and stored 
on ice. To determine if any protein remained bound to the beads they were incubated 
in 2 x GSB for 5 minutes at 95oC. The samples taken at each step of the Ni2+ bead pull 
down were mixed with GSB buffer at 1:1 ratio and boiled for SDS-PAGE and western 
blot analysis.  
2.2.2.3 : Quantification of C-terminally His-tagged RBP-Jκ8-435 expressed in 45ml of 
insect cells 
Known quantities of Bovine Serum Albumin (BSA) and 5µL of RBP-Jκ8-435 eluate from 
the Ni2+ bead pull down were boiled in GSB and run on a Bis-Tris SDS-PAGE gel. The 






6000𝑚𝐿 (𝑙𝑎𝑟𝑔𝑒 𝑠𝑐𝑎𝑙𝑒 𝑝𝑟𝑒𝑝)
50𝑚𝐿 (𝑠𝑚𝑎𝑙𝑙 𝑠𝑐𝑎𝑙𝑒 𝑝𝑟𝑒𝑝)
= ~0.6𝑚𝑔 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑦𝑒𝑖𝑙𝑑  
2.2.2.4 : Initial large scale expression of C-terminally His-Tagged RBP-Jκ8-435  in 3L of 
insect cells 
The buffers used were based on the buffers used to purify C-terminally His-tagged 
RBP-Jκ8-435 in the structure of the Notch transripction complex (Wilson and Kovall, 
2006). We substituted the reducing agent β-mercaptoethanol (βME) for Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) as βME is known to oxidise during 
Isothermal titration calorimetry (ITC) binding assays which generates artefacts when 
collecting data. P3 stock (amounts of which varied on baculovirus yield) of 
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recombinant baculovirus expressing C-terminally His-Tagged RBP-Jκ8-435 was used at an 
MOI of 2 to infect 3L of Sf9 insect cells in SF900II media +Pen/Strep. C-terminally His-
Tagged RBP-Jκ8-435 was expressed in Sf9 insect cells for two days then pelleted at 1000 
x g for ten minutes in a Beckman Avanti J-20 High Capacity Centrifuge. The pellet was 
frozen, thawed, then lysed in buffer A (50mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP) 
with a dounce homogeniser (10 plunges). Nuclease was added to digest the DNA 
released and the lysate was filtered through a 50 μm syringe filter to make the lysate 
less viscous. After this the lysate was spun at 20,000 x g for 40 minutes to pellet the 
cell debris in a Beckman Avanti J-20 High Capacity Centrifuge. The lysate was loaded 
onto a His Trap FF column (GE life sciences) and eluted in with a gradient of buffer B 
(50mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP, 1M imidazole). The eluates were 
pooled and passed through a desalt 26/10 column GE life sciences) primed with buffer 
C (20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP) in order reduce the salt 
concentration and remove the imidazole from the buffer. The pooled eluates were 
loaded onto a MonoQ 5/50 (GE life sciences) and eluted with a gradient of high salt 
buffer D (20mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP). The protein was then 
concentrated in a protein concentrator (Millipore 30kDa filter) to 10mg/ml. For 
crystallisation trials the protein was further purified using a S200 10/30 size exclusion 
column primed with buffer C (20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP). Eluates 
from the size exclusion step were concentrated with a Millipore 30kDa filter 
concentrator to ~7mg/ml and flash frozen in liquid nitrogen. At each step 10µL of 
eluates were mixed with 10µL of GSB and boiled for analysis by SDS-PAGE.  
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2.2.2.5 : Optimised large Scale expression of C-terminally His-Tagged RBP-Jκ8-435  in 5L 
of insect cells 
A P3 stock of recombinant baculovirus expressing C-terminally His-Tagged RBP-Jκ8-435  
was used to infect 5L of Sf9 insect cells in SF900II media with Pen/Strep antibiotics. C-
terminally His-Tagged RBP-Jκ8-435 was expressed in Sf9 insect cells for two days then 
spun into a pellet at 1000 x g (JA-20 rotor, Avanti J-26XP centrifuge) for ten minutes. 
The pellet was frozen, thawed, then lysed in buffer A with a dounce homogeniser (15 
to 20 plunges). Nuclease was added to digest the DNA released and the lysate was 
filtered through a 50 μm syringe filter to make the lysate less viscous. The lysate was 
then pelleted at 20,000 x g for 40 minutes (JA-20 rotor, Avanti J-26XP centrifuge). The 
lysate was loaded onto a Co2+ column (5ml Talon column (GE life sciences)) and eluted 
with a gradient of buffer B (50mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP, 1M 
imidazole). We used Co2+ column instead of a Ni2+ columns, as Co2+ columns bind more 
specifically to His-tagged proteins, reducing the amount of impurities which are eluted 
with the protein of interest improving the purity of the sample. The eluates were 
pooled and passed through a desalt 26/10 column (GE life sciences) primed with buffer 
C (20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP) in order to reduce the salt 
concentration and remove the imidazole from the buffer. The sample was then loaded 
onto a MonoQ 5/50 (GE life sciences) and eluted with a gradient of high salt buffer D 
(20mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP). The protein was then concentrated in 
a protein concentrator (Millipore 30kDa filter) at 3500rpm (TX-100 rotor, Thermo 
heraeus multifuge x3r centrifuge) to 10mg/ml. For crystallisation trials the protein was 
incubated with RBP-Jκ consensus site DNA (TTACTGTGGGAAAGA) for 30 mins on ice at 
1:1.2 (RBP-Jκ:DNA) ratio and loaded on to S200 10/30 size exclusion column primed 
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with buffer C (20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP). Eluates from the size 
exclusion step were concentrated with a Millipore 30kDa filter concentrator to ~8-
10mg/ml. At each step 10µL of eluates were mixed with 10µL of GSB and boiled for 
SDS-PAGE analysis.  
2.2.2.6 : Size exclusion column assay to test the effects of DNA and peptide binding to 
the conformation of C-terminally His-Tagged RBP-Jκ8-435 
The RBP-Jκ used in these assays was initially prepared for Isothermal titration 
calorimetry (ITC). C-terminally His-tagged RBP-Jκ was therefore expressed in insect 
cells and purified through to the anion exchange step where it was concentrated to 
~8mg/ml in a protein concentrator (Millipore 30kDa filter) at 3500rpm (TX-100 rotor, 
Thermo heraeus multifuge x3r centrifuge), dialysed into ITC buffer (20mM Tris pH8.8, 
100mM NaCl, 0.5mM TCEP, 0.5mM EDTA) and diluted to 37.8µM. RBP-Jκ8-435 was 
incubated with EBNA2.26aa peptide (see appendix 4) and or RBP-Jκ8-435 consensus site 
DNA (TTACTGTGGGAAAGA) for hour on ice then each assay was passed through S200 
10/30 size exclusion column primed with buffer C (20mM Tris pH8.8, 100mM NaCl, 
0.5mM TCEP). 10µL from each well of each assay was mixed with 10µL of GSB and 
boiled for SDS-PAGE anlysis. The chromatograms from each assay were overlaid using 
unicorn software.  
2.2.3 : Phosphorylation of RBP-Jκ expressd in insect cells.  
2.2.3.1 : λ-phosphatase dephosphorylation assay 
C-terminally His-tagged RBP-Jκ8-435 was expressed in insect cells, purified on a Co2+ 
column and desalted on the desalt 26/10 column. The RBP-Jκ8-435 was concentrated to 
1.4mg/ml giving a concentration of 29µM. 50µL of RBP-Jκ8-435 was incubated for 30 
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minutes on ice with 10mM MgCl2 and 3µL (100 units) of λ-phosphatase (NEB) or buffer 
C (20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP) as a negative control. The RBP-Jκ8-435 
incubated with or without λ-phosphatase was loaded onto a MonoQ 5/50 and eluted 
with a gradient of high salt buffer D (20mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP).  
2.2.3.2 : In-gel trypsin digests of RBP-Jκ8-435 expressed in insect cells. 
During the anion exchange purification process RBP-Jκ8-435 expressed in insect cells 
eluted in 2 peaks (peak 1 and peak 2). To investigate why, 10µL of peak one and peak 
two of the eluates of the anion exchange purification step were mixed with 10µL of 
GSB, boiled then run on a 10% Bis-Tris SDS-PAGE gel in MOPS. The gel was stained with 
Coomassie and the 49kDa bands represent RBP-Jκ8-435 were cut out of the gel with a 
scalpel. The cut-out bands were destained with destain buffer (50% MeCN, 25 mM 
NH4HCO3) , then dehydrated in a speedvac, reduced with DTT, alkylated with 
iodoacetamide solution (50 mM iodoacetamide, 25 mM NH4HCO3) in the dark and 
dehydrated once more before being soaked in a trypsin solution (12.5 ng/ul trypsin, 25 
mM NH4HCO3) overnight. The peptides from each sample were separated from the 
remaining undigested protein using reversed phase separation facilitated by adding 
formic acid. The peptides were stored in 0.1% TFA at -20oC prior to mass spectroscopy 
analysis.  
2.2.3.3 : Collection and of Mass spectroscopy data analysis. 
Peptides were loaded on to the LTQ-Oribitrap XL (University of Sussex) via a nanoLC 
column in order to separate the peptides by size before being ionized. The peptides 
were ionised with an electrospray (2.2-3.0 kV) creating an aerosol of charged peptides. 
These gaseous charged peptides were injected in packets into the orbitrap at a tangent 
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to the inner electrode. The voltage of the inner electrode was ramped up till the 
charged peptides established an orbit around the inner electrode. Once the analyte 
was loaded and orbiting the field was ramped down and became static. This allowed 
the peptides to separate in to different rings of orbit around the inner electrode based 
on their mass to charge ratio. The current generated by the charged peptide oscillating 
around the inner electrode was detected by the outer electrode and sensors attached 
to outer electrode simultaneously calculated the mass of multiple peptides based on 
their different mass to charge ratio dependent oscillations. A BSA standard was 
injected initially to calibrate the LTQ-Oribitrap XL then the peptides from the peak 1 
and peak 2 in-gel digests were injected. The raw mass spectra for each charged 
peptide detected was loaded in to Mascot software which verified both peaks 
contained Human RBP-Jκ. Mascot software was next used to fit amino sequences into 
the masses of the peptides detected in the LTQ-Oribitrap XL. We set the mascot 
software parameters to search for peptide sequences from human RBP-Jκ and set the 
software to search for peptides sequences with phosphorylated residues. Sequence 
coverage and statistics on detected peptides were calculated by the Mascot software. 
2.3.3.4 : Using Cuckoo workshop Group-based prediction software to verify predicted 
phosphorylation sites of RBP-Jκ8-435 expressed in insect cells and identify potential 
kinase candidates.  
We used an online tool to verify whether the peptides corresponding to 
phosophorylated-peptides sizes by mass spectroscopy were indeed predicted to 
contain phosphorylated residues.The cuckoo workshop had developed an online tool 
for predicting phosphorylation. The tool works by comparing the inputted sequence 
with a matrix of known phosphorylation sites and kinome databases then scores the 
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residues likelihood of being phosphorylated (Xue et al., 2008). To reduce false positives 
the tool scans the residues upstream and downstream of the threonine, serine or 
tyrosine residue in the suspected kinase binding motif to determine whether the 
folding of the region is ordered or disordered (Xue et al., 2008). If the protein around 
the motif is disordered they hypothesised that this would reduce the likelihood the 
suspected kinase site would be able to interact with kinases adding another level of 
selection (Xue et al., 2008). The software also predicts the false positive rate for each 
inputted sequence therefore providing a guide for the phosphorylation prediction 
algorithm to how many kinase sites to disregard(Xue et al., 2008). Finally the program 
also organises the kinases in the kinome database by hierarchy therefore making the 
predictions more biologically relevant (Xue et al., 2008).  
2.2.4 : E.coli expression and purification of RBP-Jκ 
2.2.4.1 : Small scale 1L E.coli expression and purification of C-terminally His-tagged 
RBP-Jκ8-435  
Competent Rosetta plys De3 were transformed with pET28B.JK.8-435 by heat shock for 
45 sec at 45oC, and then briefly recovered in Lysogeny broth (LB) with no antibiotics at 
37oC, diluted in LB then plated onto chloroquine/ kanamycin (chl/kan) agar plates and 
incubated over night at 37oC. Colonies were selected, grown in 50ml of LB (chl/kan) 
media grown overnight and used to inoculate 1L of LB (chl/kan) media at an Optimal 
density (O.D) of 0.07. Some of the 50ml inoculant was used to produce glycerol stocks 
which were stored at -80oC. The 1L culture was grown to an O.D of 0.8, then rapidly 
cooled on ice prior to induction with 0.5mM of Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) overnight in a shaking incubator at 18 oC. The cells were then pelleted at 
4000rpm for 20 minutes in a 4000rpm (J-LITE JLA 8.1000 Fixed Angle rotor, Avanti J-
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26XP centrifuge). The cells were then lysed in buffer A (50mM Tris pH8.8, 500mM 
NaCl, 0.5mM TCEP) + DNAase (25 units) + 1ml of lysozyme and sonicated 10s on, 10s 
off for 10min at 30% using a Vibra-Cell VC 750 sonicator (Sonics). The lysate was spun 
at 20,000rpm for 1 hour to separate the cell debris from the lysate (JA-20 rotor, Avanti 
J-26XP centrifuge).  
The lysate was loaded onto a Co2+ column (5ml Talon FF column (GE Life Sciences)), 
washed and eluted with a gradient of imidazole buffer B (50mM Tris pH8.8, 500mM 
NaCl, 0.5mM TCEP, 1M imidazole). We continued using Co2+ columns for the initial 
purification step as Co2+ columns bind to His-tags more specifically than Ni2+ columns 
reducing the number of impurities in the eluates. The eluates from the Co2+ column 
purification step were then loaded onto a desalt 26/10 column (GE Life Sciences) 
calibrated in buffer C (20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP) to reduce the 
[NaCl] to 100mM and remove the imidazole. The desalted sample was loaded onto a 
5ml HitrapQ column (GE Life Sciences) and eluted with an increasing gradient of high 
salt buffer D (20mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP). Finally, the eluates from 
the anion exchange step were concentrated to 250µL, incubated with DNA 
(TTACTGTGGGAAAGA) on ice with a 1:1.5 protein to DNA ratio and loaded on to a S200 
10/30 size exclusion column (GE Life Sciences) equilibrated in buffer C. 10µL samples of 
eluates from each step were mixed with equal amounts of GSB, boiled and run on 10% 
Bis-Tris SDS-PAGE gel in MOPS at 200V for 50 mins then stained with Coomassie for 




2.2.4.2 : Large scale E.coli expression and optimised purification of C-terminally His-
tagged RBP-Jκ8-435  
Glycerol stocks of Rosetta plys De3 transformed with pET28B.JK.8-435 were inoculated 
in 150ml of LB (chl/kan) media overnight which was used to inoculate 4L of LB 
(chl/kan) media at an O.D of 0.07. The 4L culture was grown to an O.D of 0.8, rapidly 
cooled on ice ready for the cells to be induced with 0.5mM of Isopropyl β-D-1-
thiogalactopyranoside (IPTG overnight in a rotating incubator at 18 oC. The cells were 
then pelleted at 4000rpm for 20 minutes (J-LITE JLA 8.1000 Fixed Angle rotor, Avanti J-
26XP centrifuge). The cells were then lysed with buffer A (50mM Tris pH8.8, 500mM 
NaCl, 0.5mM TCEP, 10mM imidazole) + DNAase (50units) + lysozyme and sonicated 60s 
on, 30s off for 15min at 35% using a Vibra-Cell VC 750 sonicator (Sonics). The lysate 
was spun at 20,000rpm for 1 hour to separate the cell debris from the lysate (JA-20 
rotor, Avanti J-26XP centrifuge).  
The lysate was loaded onto a Co2+ Column (5ml Talon FF column (GE Life Sciences)), 
washed and eluted with a gradient of imidazole buffer B. The eluates from the Co2+ 
column purification step were then loaded onto a desalt 26/10 column (GE Life 
Sciences) calibrated in buffer C to reduce the concentration of NaCl to 100mM and 
remove the imidazole. The desalted sample was loaded onto a 5ml HitrapQ column 
(GE Life Sciences) and eluted with an increasing gradient of high salt buffer D. The 
gradient was stopped when [NaCl] 150mM until all the RBP-Jκ8-435 had eluted. Finally, 
the eluates from the anion exchange step were concentrated to 250µL, incubated with 
double stranded oligonucleotide (TTACTGTGGGAAAGA) on ice with a 1:1.5 protein to 
DNA ratio and loaded on to a S200 10/30 size exclusion column (GE Life Sciences) 
equilibrated in buffer C. 10µL samples of eluates from each step were mixed with 
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equal amounts of GSB and boiled or SDS-PAGE analysis. The chromatograms from each 
purification step were produced on unicorn software.  
2.2.5 : Expression of full length EBNA2 and EBNA3C homology domain 
2.2.5.1 : Analysis of small scale infection of recombinant baculovirus expressing full 
length EBNA2 
A P2 stock of recombinant baculovirus expressing full length EBNA2 had been 
produced by a masters student from Dr Christomous Prodromou group but not tested 
for expression. We grew up a P3 stock of the baculovirus and infected 100ml of insect 
cells at an MOI of 2. Insect cells were incubated at 27oC in SF9 medium with pen/strep 
antibiotics. Samples of cells were taken each day after infection, pelleted and lysed in 
GSB buffer for SDS-PAGE and western blot analysis. 
2.2.5.2 : Purification of N-terminally His-tagged EBNA3C100-356 expressed in insect cells. 
A P3 stock of recombinant baculovirus expressing N-terminally His-tagged EBNA3C100-
356 was used to infect 3L if Sf9 insect cells in SF900II media with Pen/Strep antibiotics. 
N-terminally His-tagged EBNA3C100-356 was expressed in Sf9 insect cells for two days 
then spun into a pellet at 1000 x g for ten minutes (J-LITE JLA 8.1000 Fixed Angle rotor, 
Avanti J-26XP centrifuge). The pellet was frozen, thawed, then lysed in buffer A (50mM 
Tris pH8.0, 500mM NaCl, 0.5mM TCEP, 20mM imidazole, 5% glycerol) with a dounce 
homogeniser (15 plunges). Nuclease was added to digest the DNA released and the 
lysate was filtered through a 50 μm syringe filter to make the lysate less viscous. After 
this the lysate was spun at 20,000 x g for 40 minutes (JA-20 rotor, Avanti J-26XP 
centrifuge) to pellet the cell debris. The lysate was loaded onto a 5ml Talon (GE life 
sciences) and eluted with a gradient of buffer B (50mM Tris pH8.0, 500mM NaCl, 
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0.5mM TCEP, 1M imidazole, 5% glycerol). The eluates were then concentrated in a 
protein concentrator (Millipore 10kDa filter) at 3500rpm (TX-100 rotor, Thermo 
heraeus multifuge x3r centrifuge) to 250µL. This concentrated protein was loaded on 
to S200 10/30 size exclusion column primed with buffer C. Eluates from the size 
exclusion step were concentrated with a Millipore 10kDa filter concentrator to 
~0.5mg/ml, flash frozen in liquid nitrogen and stored at -80oC. At each step 10µL of 
eluates were mixed with 10µL of GSB, boiled and run on 4-12% Bis-Tris SDS-PAGE gels 
in MOPS buffer at 200V for 50mins alongside a SeeBlue™ Plus2 Pre-stained Protein 
Standard. These gels were then stained with Coomassie for analysis.  
2.3 : Thermodynamic techniques  
2.3.1 Introduction to Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) is used to measure the enthalpy (ΔH), 
stoichiometry (N) and entropy (ΔS) of the interactions between two biomolecules 
(Freyer and Lewis, 2008). In the reaction cell the ligand is titrated on to the receptor 
which causes a release of heat as the two molecules interact. The change in 
temperature is detected between the reaction cell and the control cell and the 
MicroCal ITC200 heats the control cell till the cells are at equal temperatures. The 
energy the machine uses to correct the temperatures between the two cells is 
registered as a heat peak which is integrated to quantify the energy released by the 
ligand and receptor binding. The ligand is titrated into the reaction cell till the 
receptors are saturated with ligand generating a binding curve. The binding curve is 
fitted to a non-linear regression curve which allows the gradient and the midpoint of 
the curve to calculated. The midpoint of the curve represents the point where the 
[ligand], [receptor] and [complex] is equal therefore the stoichiometry (N) of the 
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interaction can be calculated. The gradient of the curve is used to calculate kassociation 
(ka) which can be used to calculate kdisassociation (kd) which quantifies the affinity of the 
interaction between the ligand and receptor. Enthalpy (ΔH) is calculated from the 
largest heat peak as this represents the maximal energy released from the ligand and 
receptor interacting. As the interaction occurs in water changes in entropy (ΔS), due to 
conformational changes to the proteins caused by the interaction, can be calculated. 
The error is calculated from the sum of the deviations between model fitted curve and 
the integrated heat peak data collected. Finally, the enthalpy (ΔH) and entropy (ΔS) 
can be used to calculate Gibbs free energy (ΔG) which confirms whether the 
interaction occurs spontaneously. When designing ITC experiments there must be 
enough of the ligand and receptor to generate measurable heat peaks. Additionally it 
is imperative that the buffer the ligand and receptor are in are the same buffer as 
differences will generate heat peaks and create artefacts in the ITC data (Freyer and 
Lewis, 2008).  
2.3.2 : Isothermal Titration Calorimetry analysis of RBP-Jκ interacting with peptides.  
RBP-Jκ8-435 was then thawed on ice then dialysed into ITC dialysis buffer (Buffer C + 
1mM EDTA) overnight at 4oC. The peptides (Appendix 4) arrived in powder form, were 
measured on a precision microbalance and dissolved in DMSO. The peptide DMSO 
stock was used to make 600µM solution of peptide in buffer ITC (20mM Tris pH8.8, 
100mM NaCl, 0.5mM TCEP, 0.5mM EDTA, 2% DMSO). DMSO was added to the buffers 
with peptide or RBP-Jκ8-435 dissolved in so they both contained 2% DMSO. Dr 
Chrisostomos Prodromou consulted us about the design of our ITC and recommended 
we used between 30-60µM of RBP-Jκ8-435 to ensure that the heat peaks generated, by 
what we predicted to be a relatively weak interaction, were large enough to be 
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accurately measured. Due to the low predicted yield of a 5L prep of C-terminally His-
tagged RBP-Jκ8-435 expressed in insect cells we calculated that we would only produce 
enough material per preparation to have a maximum of concentration 37.8µM RBP-
Jκ8-435 in each ITC binding assay. 37.8µM of RBP-Jκ8-435 was loaded into the sample cell 
then 30 injections of 600µM of peptide dissolved in buffer ITC were titrated onto RBP-
Jκ8-435. To be able to measure the interactions between the EBNA3A.33aa or 
EBNA3B.33a peptides and RBP-Jκ we reduced the number of injections to 20 whilst 
increasing the volume of peptide we injected to increase the size of the heat peaks in 
order to make the weak binding curves more accurate. Heat peaks were measured 
using MicroCal ITC200 (Malvern analytical) at 30oC. Curves were fitted to the heat 
peaks and the kd, stoichiometry and entropy of each interaction was calculated using 
origin 5.0 Software.  
2.3.3.1 : Fluorescent polarisation binding assay of the RBP-Jκ8-435-EBNA2.28aa.FP 
interaction 
The EBNA2.26aa peptide was ordered from Peptide Synthetics with a fluorescein tag. 
Two glycine residues were added to the N-terminus of the protein to facilitate the 
chemistry required to conjugate the fluorescein tag to the peptide. 28µM of C-
terminally His-tagged RBP-Jκ8-435 (expressed in insect cells) was serially diluted over 12 
wells (in triplicate) containing 100nM EBNA2.28aa.FP-RBP-Jκ8-435 and buffer FP (buffer 
C + 2%DMSO + 0.5%IPEGAL). Samples were incubated at 4oC for 30 minutes then the 
percentage of polarised emissions (i.e the percentage EBNA2.28aa.FP bound to RBP-J) 
was measured using the BMG Lab-tech Polarstar omega. As the EBNA2.28aa.FP binds 
to C-terminally His-tagged RBP-Jκ8-435 (expressed in insect cells) the emissions for the 
fluorescein tag become polarised allowing us to measure the proportion of the 
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EBNA2.28aa.FP in the wells that is bound to RBP-Jκ8-435. When 50% of the emissions 
from the EBNA2.28aa.FP peptide are polarised half of the EBNA2.28aa.FP in the well is 
bound to RBP-Jκ8-435 which means that there is an equilibrium of free EBNA2.28aa.FP 
and EBNA2.28aa.FP bound to RBP-Jκ8-435. Therefore, the kd of the interaction can be 
calculated as the concentration of the receptor. From this we calculated the kd of the 
EBNA2.28aa.FP-RBP-Jκ8-435 interaction. 
2.3.3.2 : Fluorescent polarisation competition binding assays 
10µM of unlabelled competitor peptides were dissolved in buffer FP (Buffer ITC + 
0.05% IPEGAL) then serially diluted across a 96 well plate in triplicate. 1mM RBP-Jκ8-435 
was incubated with 1mM EBNA2.28aa.FP and added to all the wells. These plates were 
left to incubate at 4oC for 30 minutes then the percentage of polarised emissions (i.e 
the percentage EBNA2.28aa.FP still bound to RBP-Jκ8-435) was measured using the BMG 
Lab-tech Polarstar omega. 
2.3.4 : Introduction to a novel Biosensor called SwitchSense  
SwitchSense is a biosensor system which can monitor binding of proteins to DNA, 
protein-protein interactions and measure conformational changes in proteins. 
Switchsense utilises a DNA nanolever bound to a gold chip to tether proteins to the 
chip as opposed to antibodies or gold chips coated in reagents that chemically 
immobilise proteins.  The DNA nanolever is made of two parts, the DNA switch is a 
single stranded piece of DNA covalently bound to the gold chip and has a fluorophore 
attached to the end (Figure 2.4A). The other half of the DNA nanolever can be 
synthesised to contain a consensus site for a transcription factor we wanted to study 
or premade DNA switches capable of binding to His-tags could be ordered. The 
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designed half of the nanolever is annealed to the DNA switch (Figure 2.4A) before 
starting binding assays. Depending on the experiment alternating or direct current was 
passed through the chip and due to the DNA’s negative charge the nanolever is 
attracted or repelled from the gold chip. In order to measure the movement of the 
DNA nanolever an extremely sensitive light sensor measures the fluorescence emitted 
from the fluorophore attached the DNA nanolever. When the DNA nanolever is 
attracted to the gold chip with a positive charge the fluorophores emissions are 
quenched by the gold plate enabling the machine to measure whether the nanolever is 
in an up-right or horizontal position (Figure 2.4B). The rate at which the switch 
recovers from the horizontal position has is termed the dynamic response and this can 
be measure for an individual recovery or multiple recoveries in real time as samples 
are injected and passed over the chip.  
When a protein binds to the consensus site that has been designed into the nanolever 
this causes the dynamic response to slow as the protein increases the hydrodynamic 
friction or drag of the nanolever. This decrease in the dynamic response of the 
nanolever can be measured in real time to generate binding and disassociation curves 
which can be used to calculate kds of protein-DNA interactions. In addition to this the 
dynamic response can also be altered when the conformation of the protein changes 
due to more open conformations increasing the hydrodynamic friction and more 
tightly packed conformations decreasing hydrodynamic friction. Therefore, the 
SwitchSense Biosensors can also measure the effect of drug-binding, peptide binding 
and protein interactions on the conformation of the protein of interest.  
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The Switchsense biosensor is extremely robust and can tolerate a large range of 
buffers and reagents, even cell lysates, that other biophysical machines cannot. The 
most significant benefit of the switchsense biosensor for our project was that the 
machine can measure binding interactions of proteins even when only fM quantities of 
material are available potentially allowing us to study the EBV transcription factors 



























Figure 2.5. Introduction to SwitchSense Bioassay. A. This diagram shows the DNA 
containing the RBP-Jk consensus site (GTGGGA) being annealed to the Switch (in 
black). The fluorescent tag on the switch is shown in orange. B. In this diagram on the 
left the RBP-Jk (shown in blue) has been bound to the switch. There is a negative 
current passing through the chip. On the right hand side a positive current is passing 
through the chip. This attracts the DNA switch to the chip. When the switch is proximal 
to the gold chip the fluorophore on the switch is quenched by the gold chip. This 
allows the machine to detect when switch is up-right or attracted to the chip. The 
machine measures the dynamic response (i.e the DNA recovering from the position in 
the right of the diagram to the position on the left) which changes whether something 
is bound to the chip. These measurements can then be used to calculate the 









2.3.4.1 : SwitchSense assay; Optimising RBP-Jκ binding to RBP-Jκ consensus nanolever 
and control nanolever. 
C-terminally His-tagged RBP-κ8-435 was purified as described in chapter 2.2.2.5 up to the 
anion exchange step and flash frozen. RBP-κ8-435 was thawed on ice and diluted into a 
1µM stock with SwitchSense buffer (20mM Tris pH8.8, 50mM NaCl, 0.5mM TCEP, 
2%DMSO). RBP-Jκ8-435 was diluted with SwitchSense buffer into 100nM and 10nM 
aliquots to test the optimal amount to bind to the RBP-Jκ8-435 consensus nanolever (5’ 
AAA CAC GCC GTG GGA AAA AAT ATC AGC GTT CGA TGC TTC CGA CTA ATC AGC CAT 
ATC AGC TTA CGA CTA 3’) and control nanolever, which was later found to contain a 
RBP-Jκ non-consensus site (5’ GTG TGA ACC CTC CAA CAA AGG TAG CAT TTG CCA GCT 
CTC GTG ATG CAG 3’). RBP-Jκ consensus nanolever and control nanolever were 
annealed to the switches by injecting them onto the switches in triplicate. The 
machine heated the chip to ~80oC then gradually cooled allowing the nanolevers to 
anneal to the switches. 10nM, 100nM and 1µM concentrations of RBP-Jκ8-435 were 
injected onto the RBP-Jκ consensus nanolever and RBP-Jκ non-consensus nanolever in 
triplicated. The Biosensor Switchsense measured the dynamic response in real time. 
The machine automatically combines the data from the three repeats to produce the 
binding and disassociation curves. Due to time constraints of the free trial we were 
unable to wait for RBP-Jκ8-435 to completely disassociate from the nanolever so the koff 
was estimated from the small disassociation curve generated by giving RBP-Jκ8-435 40 
minutes to disassociate. Switchanalysis software was used to produce the curves and 




2.3.4.2 : SwitchSense assay to determine the effects Notch2 and EBNA peptides have on 
RBP-Jκ-DNA binding. 
RBP-κ8-435 was thawed on ice and diluted into a 100nM stock with SwitchSense buffer. 
DMSO stocks of each of the peptides were dissolved in Buffer SwitchSense. 100nM of 
RBP-κ8-435 was incubated with 100nM of each of the peptides for 30 minutes on ice. 
Each of the RBP-κ8-435-peptide complexes were injected in triplicate on to chips with 
RBP-Jκ consensus nanolever or RBP-Jκ non-consensus nanolever bound. The Biosensor 
SwitchSense measured the dynamic response in real time as the RBP-κ8-435-peptide 
complexes bound to the switch and was also able to measure a single movement of 
the nanolever. Switch analysis software was used to produce the curves from this data 
with the help of the technicians from Dynamic Biosensors.  
2.3.4.3 : Switchsense was used to determine the effect of DMSO on the conformation of 
RBP-κ8-435 
RBP-κ8-435 was thawed on ice and diluted into a 100nM stock with Buffer SwitchSense 
with and without 2% DMSO. RBP-κ8-435 with and without 2% DMSO was injected in 
triplicate on to chips with RBP-Jκ consensus nanolevers bound. The Biosensor 
SwitchSense measured the dynamic response in real time as the RBP-κ8-435 bound to 
the nanolevers. The machine automatically combined the data from the three repeats 
to produce the binding and disassociation curves. Switchanalysis software was used to 





2.4 : Cell culture 
2.4.1 : DG75 cell culture 
DG75 cells were chosen to overexpress EBNA3C and the EBNA3C mutants for the pull 
down as they were B cells (i.e the cells EBV immortalises during latency) with an EBV-
negative background (to prevent EBNAs interfering with EBNA3C-RBP-Jκ interactions). 
DG75 cells were grown up in RPMI 1640 Medium with penicillin and streptomycin 
added at 37oC. Cells were split 1 in 10 every three days to sustain the cell line.  
2.4.2 : Cell counting 
DG75 cells were counted by mixing 10µl cells with at a 1:1 ratio with trypan blue, 
loading them onto Countess® Cell Counting Chamber Slides and using the Countess® 
Automated Cell Counter to count the cells and estimate cell viability.  
2.4.3 : Electroporation of plasmids into B cells 
DG75 Cells were diluted 1 in 3 with fresh media the day before electroporation to 
ensure the cells would be in a growth phase for the electroporation. Cells were 
pelleted at 1300 rpm for 10 miuntes (TX-100 rotor, Thermo heraeus multifuge x3r 
centrifuge) and resuspended at 2 x 107 cells/ml in serum-free media and aliquoted into 
1 million cell aliquots into electroporation cuvettes. The cells were then incubated with 
20µg of each of the vectors on ice for ten minutes then electroporated with a BioRad 
Gene Pulser II at 260V and 950 μF. The cells were then left to recover in serum free 
media at 37oC for 30 minutes after which they were transferred to conditioned media 
cell culture flasks and incubated at 37oC for 48 hours. After this the cells were pelleted 
at 1300rpm (Ch 500062PP rotor, VWR microstar 17 centrifuge), washed in PBS and 
then flash frozen in liquid nitrogen for storage at -80oC. Some cells were kept aside for 
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western blot analysis to test whether they expressing the EBNA3C mutants. BL31 cells 
infected with EBV or MutuIII whole cell lysates were ran in parallel as EBNA3C positive 
controls. 
2.5 : Crystallisation trials and structural biology 
2.5.1 : Broad screen crystallisation trials of RBP-Jκ8-435-DNA-EBNA2.26aa or RBP-Jκ8-435-
DNA-EBNA3C.33aa expressed in insect cells 
RBP-Jκ8-435 was expressed in insect cells, purified with a Co2+ column step, an anion 
exchange step, incubated with DNA (TTACTGTGGGAAAGA) and then passed through a 
size exclusion column. The DNA contained a RBP-Jκ consensus site and had a 2bp 
overhang. The RBP-Jκ8-435-DNA complex was then concentrated to ~8mg/ml using 
Vivaspin 20 MWCO 30000 concentrator spun at 4000rpm (TX-100 rotor, Thermo 
heraeus multifuge x3r centrifuge). Concentrated RBP-Jκ8-435-DNA complex was 
incubated with the EBNA2.26aa or EBNA3C.33aa peptide at a 1:1.5 ratio. The complex 
was loaded onto 98 well sitting drop plates at 4oC or at room temperature with broad 
crystal screening conditions JCSG+, PacT, Proplex (molecular dimensions) and Natrix 
(Hampton research) using an Art Robins Phoenix robot. 200nL of complex was mixed 
with 200nL of crystallisation condition in each sitting droplet. The crystallisation plates 
were left at 4oC or 20oC to grow crystals. The plates were scored 7 days after being set 
up and images of crystals were taken using a leica microscope camera system and 
processed in leica imaging software.  
2.5.2 : Resolution of crystal structure  
The crystal produced in Proplex C2 condition was fished then cryoprotected by 
incrementally increasing the percentage of PEG4000 to 30% and then flash freezed in 
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liquid nitrogen. The crystal was exposed to X-rays on the IO2 beamline at the Diamond 
Light Source where a full data set with a resolution of 3.6Å was acquired. Dr Mark Roe 
processed the scatter data. Initially Diamond XIA2 software was used to reduce the 
scatter data (Winter, 2010). Next Phaser software from the CCP4 package was used for 
the molecular replacement (McCoy et al., 2007, Winn et al., 2011). The phase data of 
the RBP-Jκ8-435 and DNA (PDB: 3V79) from Choi et al’s 2012 structure of the Notch 1 
transcription complex was used for molecular replacement (Choi et al., 2012). The 
initial refinements were completed in refmac software and the phenix suite was used 
for completion (Vagin et al., 2004, Adams et al., 2010). The image of the structure was 
taken in Pymol software (The PyMOL Molecular Graphics System, Version 1.2r3pre, 
Schrödinger, LLC, DeLano). Data processing statistics were produced by XIA2 software 
and the refinement statistics were calculated by the phenix suite (Adams et al., 2010, 
Winter, 2010).  
2.5.3 : Modelling the EBNA2 peptide onto the crystal structure of RBP-Jκ8-435 bound to 
RBP-Jκ consensus site. 
Wincoot software was used to mutate each of the residues of the RAM domain in the 
structure of the Notch1 transcription complex (Choi et al., 2012) to residues of EBNA2, 
aligned by the WΦP motif (Emsley et al., 2010). Rotamers of each of the EBNA2 
residues were tested by eye to ensure that there were no steric clashes with the RBP-
Jκ electron density. Our structure of RBP-Jκ8-435 bound to RBP-Jκ consensus site and the 
structure of the Notch1 transcription complex with EBNA2 modelled onto the structure 
were over laid onto each other in pymol. The Notch1, RAM domain, RBP-Jκ, 
Mastermind and DNA from the structure of the Notch 1 complex (Choi et al., 2012) 
were hidden leaving the structure of RBP-Jκ8-435 bound to DNA with the EBNA2 peptide 
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modelled onto it. The same process was repeated to model EBNA2, EBNA3A, EBNA3B 
and EBNA3C onto the structure of the Notch1 transcription complex (Choi et al., 2012) 
and the structure of CSL (Lag-1) bound to DNA with Lin-12 RAM peptide (PDB: 3BRD) 
(Friedmann et al., 2008). The models were edited and imaged in pymol (The PyMOL 
Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC, DeLano). 
2.5.4 : Broad screen crystallisation trials of the RBP-Jκ8-435-DNA-EBNA2.14aa complex 
expressed in E.coli cells 
RBP-Jκ8-435 was expressed in E.coli, purified with a Co2+ column step, an anion exchange 
step, incubated with DNA (TTACTGTGGGAAAGA) and then passed through a size 
exclusion column. The DNA contained a RBP-Jκ consensus site and had a 2bp overhang. 
The RBP-Jκ8-435-DNA complex was then concentrated to ~10mg/ml using Vivaspin 20 
MWCO 30000 concentrator spun at 4000rpm (TX-100 rotor, Thermo heraeus multifuge 
x3r centrifuge). Concentrated RBP-Jκ8-435-DNA complex was incubated with the 
EBNA2.14aa 1:4 protein to peptide ratio. The complex was loaded onto 96 well sitting 
drop plates at room temperature with broad crystal screening conditions JCSG+, PacT, 
Proplex (molecular dimensions) and Natrix (Hampton research) using an Art Robins 
Phoenix robot. 200nL of complex was mixed with 200nL of crystallisation condition in 
each sitting droplet. The crystal trials were left in a 20oC incubator to grow crystals. 
The plates were checked for crystals daily for the first 7 days then weekly after this. 
Images of crystals were taken using a leica microscope camera system and processed 
in leica imaging software.  
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2.5.5 : Production of deepwell blocks of optimisation conditions and set up of 
optimisation plate crystal trials of RBP-Jκ8-435-DNA-EBNA2.14aa complex expressed in 
E.coli cells. 
The crystal conditions designed in optimisation plates 1 and 2, Natrix conditions, 
published conditions and the PEG screens were manually pipetted into 2ml 96 well 
deep well blocks and stored at 4oC. The crystallisation conditions were manually 
pipetted from the deep well blocks into buffer wells in 48 well sitting drop plates then 
Douglas Instruments Oryx8 robot was used to load 200nL of crystallisation buffer and 
200nL of complex onto the sitting drop wells. The plates were sealed and incubated at 
20oC then checked for crystals everyday for the first 7 days then weekly after this. 
Images of crystals were taken using a leica microscope camera system and processed 
in leica imaging software.  
2.5.6 : Production of crystal seed for crystallisation trials 
The Seed Bead kit from Hampton research was used to generate seed stocks of crystals 
grown in optimisation plate 1 C2 and Natrix G10. Crystals were pipetted in to the 
Eppendorf tubes with the seed bead and the crystallisation buffer from the wells and 
was vortexed and put on ice three times. The seed stock was serially diluted with more 
crystallisation buffer then flash frozen in liquid nitrogen. Seeded crystallisation trials 
were set up in 48 well sitting drop plates with the Douglas Instruments Oryx8 robot 
which was used to load 180nL of crystallisation buffer, 200nL of protein complex and 
20nL of seed stock onto the sitting drop wells. The plates were sealed and incubated at 
20oC then checked for crystals everyday for the first 7 days then weekly after this. 
Images of crystals were taken using a leica microscope camera system and processed 
in leica imaging software.  
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2.5.7 : Proplex A8, Proplex A8 PEG400 and PacT E7 additive screens to crystallise RBP-
Jκ8-435-DNA-EBNA2.14aa complex expressed in E.coli cells. 
Proplex A8, Proplex A8 PEG400 or PacT E7 was pipetted into 96 deep well blocks so 
that they could be mixed with molecular dimension additive screen and loaded with 
RBP-Jκ8-435-DNA-EBNA2.14aa complex expressed in E.coli cells into 96 well hanging 
drop plates. 200nL of additive screen mixed with crystallisation buffer was loaded with 
200nL of Jκ8-435-DNA-EBNA2.14aa complex at 2.5mg/ml, 5mg/ml or 20mg/ml using the 
Art Robins Phoenix robot. The plates were sealed and incubated at 20oC then checked 















Chapter 3 : Results chapter 
Chapter 3.1 : Optimisation of the purification of RBP-Jκ expressed in SF9 
insect cells and E.coli 
We intitially attempted to express RBP-Jκ variant 2 as this was the isoform of RBP-Jκ 
predominantly expressed in B-cells and would therefore be the most likely RBP-Jκ 
isoform to interact with EBV transcription factors (Masashi Kawaichi, 1991, Amakawa 
R, 1992, Kenia G. Krauer, 1999). We also used a C-terminally His-tagged RBP-Jκ8-435 as 
this had previously been used to purify and crystallise human RBP-Jκ (Wilson and 
Kovall, 2006). 
EBNA2, EBNA3A, EBNA3B and EBNA3C have been shown to bind to RBP-Jκ and 
interactions between EBNA2, EBNA3A or EBNA3C and RBP-Jκ have been shown to be 
essential to sustaining EBV immortalised cell lines (Waltzer et al., 1996, Zhao et al., 
1996, Zhao et al., 2011). EBNA2 and EBNA3s binding to the human genome is 
facilitated by RBP-Jκ and it is clear that RBP-Jκ plays a key role in enabling EBV TFs to 
manipulate host gene expression (McClellan et al., 2013a, Kalchschmidt et al., 2016, Lu 
et al., 2016).  
EBNA2 has been shown to activate genes through EBNA2 binding and this activation is 
inhibited by EBNA3A, EBNA3B and EBNA3C (Ling and Hayward, 1995, Johannsen et al., 
1996, Robertson et al., 1996a, Waltzer et al., 1996, Calderwood et al., 2011). EBNA2 
and EBNA3s binding to RBP-Jκ is mutually exclusive and they bind competitively to 
human genome sites (McClellan et al., 2013a). However, there is no molecular 
information to explain how EBNA2 and EBNA3C antagonistically hijack and control 
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RBP-Jκ gene expression. We aimed to express and purify RBP-Jκ to study the 
thermodynamics and nature of the EBNA-RBP-Jκ interactions and to attempt obtain 
structural information on the EBNA domain RBP-Jκ complexes.  
3.1.1.1 : Producing recombinant baculovirus to express RBP-Jκ variant 2 and RBP-Jκ8-435 in 
Sf9 insect cells 
We used PCR to amplify C-terminally His-tagged RBP-Jκ8-435 cDNA from a bacterial 
vector (pET28b.JK.8-435) produced by a summer student in Michelle West’s laboratory 
(Figure 3.1A). We digested the RBP-Jκ8-435 PCR product and the the destination 
baculovirus expression vector (pFastBac.CP.17.2) (Figure 3.1B). The pFastBac17.2 
vector was a pFastBac co-expression vector that had been engineered in the laboratory 
by Dr Christomous Prodromou group to contain two multiple cloning sites (MCS), p10 
MCS containing a N-terminal His-tag and polyhed MCS which contained a cleavable N-
terminal Strep-II tag (Figure 2.1). P10 and polyhed referred to the promoters of each of 
the MCS. The restriction sites that were chosen to ligate the C-terminally His-tagged 
RBP-Jκ8-435 cDNA into the pFastBac17.2 vector would remove the N-terminal His tag 
from the p10 MCS so that RBP-Jκ8-435 would only be expressed with a C-terminal His-
tag. Once the C-terminally His-tagged RBP-Jκ8-435 cDNA had been ligated into the 
pFastBac17.2 vector a diagnostic restriction digest was undertaken to identify 
successful plasmid clones (Figure 3.1C). Clones C.1 and C.3 produced products with 
sizes close to the predicted size of the insert (1311bp) (Figure 3.1C). However, 
sequencing showed that only C3 contained the C-terminally His-tagged RBP-Jk8-435 




RBP-Jk variant 2 had already been cloned into pFastBac.CP.17.2 by a Masters student 
from Dr Christomous Prodromou group (pF.JK.V2). However, a different cloning 
strategy to the pF.JK.8-435 vector was used which meant the RBP-Jκ variant 2 would 
be expressed with an N-terminal His-tag. 
The vectors containing N-terminally His-tagged RBP-Jκ variant 2 and C-terminally His-
tagged RBP-Jκ8-435 were transposed into bacmids that would be used to generate 
recombinant baculovirus. The plasmids were initially transformed into MAX efficiency 
DH10BacTm E.coli. These cells not only contained the destination bacmid but also 
helper vectors that facilitated the transposition of the pFastBac vectors into the 
bacmid (Chapter 2.2.1). Successful transpositions were identified by blue-white 
screening as the bacmid contained a gene expressing LacZ peptide. These colonies 
were restreaked and a diagnostic PCR was performed, which amplified the bacmid 
DNA across both the translocation sites (Figure 3.2). All the bacmids tested gave PCR 
products of the correct predicted size, 4099bp and 3965bp for RBP-Jκ variant 2 and 
RBP-Jκ8-435 respectively (with the exception of pF.JK.8-435 C1)(Figure 3.2). 
Next the bacmids containing N-terminally His-tagged RBP-Jκ variant 2 and C-terminally 
His-tagged RBP-Jκ8-435 were transfected into Sf9 insect cells to produce recombinant 
baculovirus. After the transfection the media containing the P1 recombinant 
baculovirus was extracted and the Sf9 insect cells were analysed for RBP-Jκ expression 
by western blot (Figure 3.3). Both N-terminally His-tagged RBP-Jκ variant 2 
(JK.V2)(54kDa) and C-terminally His-tagged RBP-Jκ8-435 (JK.8-435)(49kDa) were 
expressed, however RBP-Jκ variant 2 had much lower levels of expression compared to 





Figure 3.1. Diagnostic Gels for cloning C-terminally His-tagged RBP-Jk8-435 from  a 
pET28b vector into a pFastBac vector. A. 1% Agarose Gel showing PCR of cDNA 
encoding C-terminally His-tagged RBP-Jk8-435 (1311bp expected size) from pET28b.JK.8-
435. The temperatures indicate the temperature used during the annealing step. B. 1% 
agarose gel showing restriction digests of the pFastBac17.2 vector. C. Diagnostic 
restriction digests of different clones following ligation of the RBP-Jk8-435 PCR product 
and pFastBac17.2. Clones 1 and 3 produced products with sizes proximal to the 
predicted size of the insert and were sent for sequencing. Clone 3 was concluded to be 
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Figure 3.2. Diagnostic PCR showing successful translocation of pFastBac vectors 
containing N-terminally His-tagged RBP-Jk variant 2 and C-terminally His-tagged RBP-
Jk8-435 into bacmids. The pFastBac Vectors containing N-terminally His-tagged RBP-Jk 
variant 2 and C-terminally His-tagged RBP-Jk8-435 were transposed into bacmids ready 
to produce recombinant baculovirus. Diagnostic PCRs amplified entire transposed 
region in the bacmid using pUC M13 primers and were run on 1% agarose gel with a 
1Kb ladder. Expected band sizes for transposed RBP-Jk variant 2 and RBP-Jk8-435 were 





















































































































Figure 3.3. Western blot analysis of Sf9 insect cells infected with of N-terminally His-
tagged RBP-Jk variant 2 or C-terminally His-tagged RBP-Jk8-435 P1 baculovirus. 
Bacmids containing pFJK.V2 or pFJK.8-435 were transfected into Sf9 insect cells and 
cell lysates were prepared after 72 hours. Samples were ran on a 10% Tris-SDS gel and 
probed with an anti-His antibody. Purified His-tagged Epstein-Barr virus ZTA protein 
was used as a positive control. Expected band sizes for N-terminally His-tagged RBP-Jk 
















































3.1.1.2 : Ability to pull down RBP-Jκ with nickel beads is dependent on which terminal the 
His-tag is attached to. 
Initially we calculated the optimal time to harvest the insect cells post transfection by 
infecting them with recombinant baculovirus expressing N-terminally His-tagged RBP-
Jκ variant 2 or C-terminally His-tagged RBP-Jκ8-435 and taking samples each day for 
western blot analysis (Figure 3.4). It is important to harvest infected cells before cell 
viability drops below 90% to avoid losing significant amounts of protein yield. C-
terminally His-tagged RBP-Jκ8-435 reached peak expression by day 2 and by day 3 the 
insect cells appear to begin lysing significantly reducing the protein yield (Figure 3.4). 
N-terminally His-tagged RBP-Jκ variant 2 also reached peak yield by day 2 (Figure 3.4).  
We next used nickel beads to attempt to purify N-terminally His-tagged RBP-Jκ variant 
2 and C-terminally His-tagged RBP-Jκ8-435 from a small scale insect cell infection. 
Although, on a stained gel, the RBP-Jκ V2 was visible in cell lysates, it did not bind to 
nickel beads (Figure 3.5). This was evident on western botting with anti-his antibody 
(Figure 3.4).  
In contrast, C-terminally His-tagged RBP-Jκ8-435 successfully bound to the nickel beads 
and could be eluted with imidazole (Figure 3.6). This was confirmed by western 
blotting (Figure 3.4). To estimate the concentration of RBP-Jκ8-435 we ran eluate from 
the nickel bead pull down of C-terminally His-tagged RBP-Jκ8-435 against known 
concentrations of bovine serum albumin (BSA) on an SDS-PAGE gel (Figure 3.7). We 
















Figure 3.4. Western blot analysis of a small scale grow up of Sf9 insect cells infected 
with N-terminally His-tagged RBP-Jk variant 2 or C-terminally His-tagged RBP-Jk8-435 
P3 baculovirus. The sf9 cells were and incubated at 27oC in rotating incubator. Samples 
were taken from the grow up 1, 2 and 3 days after infection, run on a 10% Bis-Tris SDS 
gel then probed with an anti-His antibody. The Sf9 insect cells were lysed after 3 days 
of expression and bound to Ni-beads, washed, then eluted proteins using imidazol and 
ran on a SDS-PAGE gel and probed for with anti-his anti-body. Purified His-tagged 
Epstein-Barr virus ZTA protein was used as a positive control. Expected sizes for N-
terminally His-tagged RBP-Jk variant 2 and C-terminally His-tagged RBP-Jk8-435 were 




























































































































Figure 3.5. Nickel bead pull down of RBP-JK variant 2 expressed in Sf9 insect cells. Sf9 
cells were infected with N-terminally His-tagged RBP-Jk Variant 2 baculovirus (JK.V2) 
and incubated at 27oC in shaking incubator for 3 days. Samples were taken each day, 
then spun down and harvested. Cells were dounce homogenised and the lysate was 
separated from the pellet and incubated on Ni-beads. Ni-beads were washed in buffer 
A then incubated in the elution buffer B. Samples from each step were boiled in GSB 
and run on a 10% Bis-Tris SDS gel then stained using Coomassie Blue. Expected band 








Figure 3.6. Nickel bead pull down of RBP-Jk8-435 expressed in Sf9 insect cells. Sf9 cells 
were infected with C-terminally His-tagged RBP-Jk8-435 baculovirus (JK.8-435) and 
incubated at 27oC in shaking incubator for 3 days. Samples were taken each day, then 
spun down and harvested. Cells were dounce homogenised and the lysate was 
separated from the pellet and incubated on Ni-beads. Ni-beads were washed in buffer 
A then incubated in the elution buffer B. Samples from each step were boiled in GSB 
and run on a 10% Bis-Tris SDS gel then stained using Coomassie Blue. Expected band 


































Figure 3.7. Quantification of RBP-Jk8-435 levels expressed in Sf9 cells. 5µL from 50µL 
eluate of RBP-Jκ8-435 was analysed. BSA standard were loaded to estimate the 
concentration of RBP-Jκ8-435.  Samples were boiled in GSB and run on a 10% Bis-Tris SDS 
gel then stained using Coomassie Blue. Expected band size for C-terminally His-tagged 



















































































3.1.1.3 : Initial Purification of C-terminally His-tagged RBP-Jκ8-435 expressed in Sf9 insect 
cells. 
We scaled up the insect cell culture from a 45ml culture (Figure 3.7) to a 3L culture in 
order to optimise the large scale purification of C-terminally His-tagged RBP-Jκ8-435. 
RBP-Jκ8-435 was purified from the lysate using a 1ml Ni2+ HistrapFF column and was 
eluted using an increasing concentration of imidazole (Figure 3.8A). The chromatogram 
clearly shows the elution peak of C-terminally His-tagged RBP-Jκ8-435 as the 
concentration of imidazole is increased (Figure 3.8B). There were also a large amount 
of impurities shown binding and eluting from the Histrap column (Figure 3.8A). 
The next step in the purification was to pass the eluates from the Ni2+ step through a 
26/10 desalt column to reduce the salt concentration from 500Mm to 100mM. This 
was carried out to ensure that the C-terminally His-tagged RBP-Jκ8-435 had a net 
positive charge and would be able to bind to the MonoQ 5/50 anion exchange column.  
C-terminally His-tagged RBP-Jκ8-435 was eluted from MonoQ 5/50 anion exchange 
column as an increasing concentration of NaCl was passed though the column (Figure 
3.9). A marked reduction in impurities was seen after this step but C-terminally His-
tagged RBP-Jκ8-435 required further purification for crystal trials (Figure 3.9A). The 
chromatogram of the MonoQ purification step showed that C-terminally His-tagged 
RBP-Jκ8-435 was eluted in two peaks (Figure 3.9A and B). This could have been due to 
post translational modifications, such as phosphorylation, that could have occurred 
whilst C-terminally His-tagged RBP-Jκ8-435 was being expressed in the Sf9 insect cells. 
Because we wanted a homogenous population of C-terminally His-tagged RBP-Jκ8-435 
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for our crystallisation trials, we only pooled the eluates from the larger peak for the 
size exclusion step. 
In order increase the purity of C-terminally His-tagged RBP-Jκ8-435 we passed the 
eluates from the anion exchange step through a S200 10/30 size exclusion column 
(Figure 3.10). The broad elution peak produced was quite wide which could indicate 
the presence of multiple conformations of protein. 
To determine whether the purified RBP-Jκ8-435 we produced was functional we carried 
an electrophoretic mobility shift assay (EMSA) to test whether RBP-Jκ8-435 expressed 
could bind specifically to the RBP-Jκ DNA consensus site (Figure 3.11). When increasing 
amounts of C-terminally His-tagged RBP-Jκ8-435 was incubated with an excess of DNA 
containing a RBP-Jκ consensus site a shift indicative of RBP-Jκ binding was observed 
(Figure 3.11). However, when the RBP-Jκ consensus site was mutated from GTGGGA to 
GTGGCT no visible band shift was detectable (Figure 3.11) The C-terminally His-tagged 
RBP-Jκ8-435 produced was therefore able to specifically bind to its cognate site in vitro 
(Figure 3.11). 
At the end of the purification process we had obtained approximately 100µL of 
8mg/ml of relatively pure C-terminally His-tagged RBP-Jκ8-435, a total yield of 
approximately 0.8mg of protein. We therefore sought to increase the yield of RBP-Jκ8-















Figure 3.8. Analysis of Ni2+ column (1ml HisTrap FF) purification step of His tagged 
RBP-Jk8-435 expressed in 3 litres of Sf9 cells. A. Coomassie stained gel showing elution 
fractions from Co2+ column (1ml HisTrap FF) as an increasing concentration of 
imidazole was passed through.  10µL from each 1ml fraction was mixed with 10µl GSB 
buffer and boiled for anlysis. B. Chromatogram from the Histrap step produced in 
Unicorn software. Shown is protein (blue), concentration of buffer B/ [imidazole] 
(green), flow rate (orange) and [salt] (in brown). The jump of flow in the middle was 
due to the column over pressurising and the AKTA pausing. Fractions C5 to D7 were 
pooled for further purification.  
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Figure 3.9. MonoQ column purification of C-terminally His-tagged RBP-Jk8-435. A. 
Coomassie stained gel showing fractions from the MonoQ 10/50 column from GE 
healthcare as an increasing [NaCl] is passed through. 10µL from each 1ml of eluent was 
mixed with 10µl GSB buffer, boiled and loaded onto the 4-12% Bis-Tris SDS page gel 
where it was run MOPS buffer. B. Chromatogram showing eluates from monoQ. 
Shown is protein (blue), concentration of buffer D/ [NaCl] (green), flow rate (orange) 
and [salt] (in brown). Peaks containing RBP-Jκ have been marked with an astrix. 
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Figure 3.10. Size exclusion purification step of C-terminally His-tagged RBP-Jk8-435 
expressed in sf9 cells. A. Chro,atogram of size exclusion step. B. RBP-Jk8-435 was passed 
through a Superdex S200 10/30 from GE healthcare calibrated in Buffer C. Coomassie 
stained gel of samples of each fraction. Bands in B1 to B3 are impurities and bands in 

























































Figure 3.11. Electro mobility shift assay of RBP-Jk8-435 binding to DNA. Double 
stranded oligonucleotides containing RBP-Jk consensus site or a mutant site were 
incubated with increasing amounts of C-terminally His-tagged RBP-Jk8-435 then run on a 
6% DNA retardation gel in 0.5x TBE buffer. Gels were stained using Gel Safe Red and 










3.1.1.4 : Optimisation of the Purification of C-terminally His-tagged RBP-Jκ8-435 expressed 
in Sf9 insect cells. 
By increasing the number of plunges we dounced homogenised the lysate and 
increasing the 3L prep to a 5L prep we increased the yield to approximately 2mgs, 
however we found that the predominant factor dictating protein yield was the quality 
of the recombinant baculovirus used to infect the insect cells. We were however able 
to make some improvements to the purification method to optimise the yield and 
purity.  
To reduce the background binding of impurities in the first purification step we 
switched from a Ni2+ column (1ml Histrap FF) to a Co2+ column (5ml Talon). Not only 
would the larger column potentially bind more C-terminally His-tagged RBP-Jκ8-435 but 
whilst Co2+ beads do not bind His-tagged proteins as tightly, they do bind more 
specifically to His-tagged proteins. Co2+ ions co-ordinate their bonds in the same 
orientation as Ni2+ which allows them to bind to His-tags. However, the net charge of 
the atom is weaker which does mean that Co2+ ions have a weaker interaction with 
His-tags however this also significantly reduces binding to impurities improving the 
purity of the eluates. We also increased the volume of buffer used in the wash step 
from 20ml of buffer to 100ml to help remove the impurities.  
The eluates from the Co2+ column purification step contained significantly less 
background binding of impurities compared to the Ni2+ column purification step 
(Figure 3.12A and 3.8A). We also increased the volume of the wash step in the MonoQ 
purification step from 5ml to 10ml, which allowed us to produce a pure enough sample 
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of C-terminally His-tagged RBP-Jκ8-435 (Figure 3.12B) so that we could pool eluates 
directly from this step for Isothermal titration calorimetry (ITC) analysis.  
To improve the homogeneity of the C-terminally His-tagged RBP-Jκ8-435 for further 
purification we incubated the RBP-Jκ consensus site DNA (TTACTGTGGGAAAGA) before 
the size exclusion step so that any DNA that did not bind to RBP-Jκ8-435 would be 
separated in the column. We also found that by incubating the RBP-Jκ consensus site 
DNA with C-terminally His-tagged RBP-Jκ8-435 the elution peak from the size exclusion 
step was significantly sharpened indicating that DNA binding drove the RBP-Jκ sample 
into a single conformation (Figure 3.12C and 3.13). We also tested the effect of 
incubating a peptide of EBNA2 containing the RBP-Jκ motif (EBNA2.26aa) to see if this 
improved the homogeneity of C-terminally His-tagged RBP-Jκ8-435 (Figure 3.13). The 
peptide had little effect on sharpening the elution peak of C-terminally His-tagged RBP-
Jκ8-435 (Figure 3.13). We therefore decided to incubate C-terminally His-tagged RBP-Jκ8-























Figure 3.12. Results of optimisation of purification of C-terminally his-tagged RBP-Jk8-
435 A. Coomassie stained gel of Co2+ column (TalonFF 5ml) Step. 10µL from each 
fraction was taken as an increasing [imidazole] was passed through the Co2+ column. 
Well C8 to D10 were pooled for ion exchange purification step. B Coomassie stained 
gel of MonoQ 10/50 step as an increasing gradient of [NaCl] was passed through. B6 to 
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Figure 3.13. Size exclusion step when C-terminally His-tagged RBP-Jk8-435 is incubated 
with DNA and/or peptide before passing through the column. RBP-Jκ8-435 was 
incubated with DNA and/or peptide with a ratio of 1:1.5 for 1 hour on ice and 
concentrated in a Viva spin MW30000 then injected into the Superdex 200 10/30 on 
an AKTA purifier. Above is the chromatogram from each run. Below is a Coomassie 
stained of each fraction from each run where 10µL from each fraction was mixed with 
10µl GSB buffer, boiled and loaded onto the 4-12% Tris SDS page gel where it was run 
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3.1.1.5 : Investigation into the post translational modifications of C-terminally His-tagged 
RBP-Jκ8-435 expressed in insect cells.  
As identified by the chromatogram of the MonoQ purification step of C-terminally His-
tagged RBP-Jκ8-435 eluted in two peaks (Figure 3.12B). Therefore, we investigated 
whether these peaks contained C-terminally His-tagged RBP-Jκ8-435 with post 
translational modifications.  Anion exchange columns separate protein by charge 
therefore we predicted that the most likely posttranslational modification that was 
causing RBP-Jκ8-435 to be eluted in two peaks was phosphorylation.  
If RBP-Jκ8-435 was being phosphorylated in the insect cells we predicted that the most 
likely peak to contain phosphorylated RBP-Jκ8-435 would be peak 1 (Figure 3.14) as 
phosphorylated residues have a negative charge which can cause the pI of the protein 
to increase significantly particularly when in buffers with a pH of 7 or more (Zhu et al., 
2005). An increased in pI would cause the electrostatic interaction between the 
protein and the anion exchange media to be weaker than that of the same protein 
with a lower pI. Therefore, a phosphorylated protein would elute off of the anion 
exchange medium at a lower concentration of salt.   
To test this hypothesis we incubated eluates of C-terminally His-tagged RBP-Jκ8-435 
from the Co2+ column purification step, after desalting, with λ-phosphatase (Figure 
3.14). We found that peak 1 disappeared when C-terminally His-tagged RBP-Jκ8-435 was 
incubated with λ-phosphatase consistent with phosphorylated forms of RBP-Jκ being in 
this peak (Figure 3.14).  
To confirm whether C-terminally His-tagged RBP-Jκ8-435 is phosphorylated in peak 1 we 
cut out a bands from a Coomassie stained gel from peak 1 and peak 2 of the MonoQ 
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purification step and performed trypsin digest to enable mass spectrometry to be 
carried out.  
To determine whether the peptides, identified from either peak by mass spectroscopy, 
contained phosphorylated residues we set the Mascot Software to prioritise the 
identification of peptides containing phosphorylated residues (Figure 3.15). This 
revealed that the C-terminally His-tagged RBP-Jκ8-435 in peak 1 was potentially 
phosphorylated on residues Y66, S70, S394 or S405. The mass spectroscopy data for 
peak 2 did not detect phosphorylated peptide (Figure 3.16). Due to the good coverage 
of the data (49% for peak 1 and 31% for peak 2) and the search parameters being 
stringently set (peptide tol ±0.1Da) it is likely that peak 1 contained phosphorylated 
forms of RBP-Jκ8-435.  
To confirm our findings, we ran the peptides predicted by mass spectroscopy to 
contain phosphorylated residues though Cuckoo’s online Post Translation Preditction 
(PTM) tool (Figure 3.17). The PTM tool confirmed that residues Y66, S70, S394 or S405 
were predicted to be phosphosites and suggested potential kinases that could 
phosphorylate these residues (Figure 3.17).  
The RBP-Jκ residues Y66, S70, S394 or S405 that were predicted to be phosphorylated 
were highlighted on the crystal structure of the Notch1 transcription complex (Choi et 
al., 2012) (Figure 3.18). All these residues are on the surface of RBP-Jκ and therefore 
potentially accessible to kinases (Figure 3.18).  
Using the online line tool Phosphosite.org, a database that records published 
phosphorylation sites of proteins, none of these phosphorylation sites have been 
identified before on RBP-Jκ. We therefore decided to pool eluates from peak 2 for 
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further purification even though this lowered our overall yield. This was to ensure our 
C-terminally His-tagged RBP-Jκ8-435 was as homogenous as possible for crystallisation 
trials, as peak 1 was likely to contain mixture of phosphorylated forms of RBP-Jκ8-435. 
However, after concluding a series of experiments using RBP-Jκ8-435 expressed in insect 
cells, it became apparent that low yields and the length of time and resources 
necessary to generate new virus and grow up insect cells was restricting progress on 

























Figure 3.14. A chromatogram showing the effect of λ-phosphatase on C-terminally 
His tagged RBP-Jk8-435 purification properties. Purified RBP-Jk8-435 was incubated with 
λ-phosphatase at 4oC for 2 hours then analysed by running it through a monoQ 5/50 
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44 - 54     597.8451     1193.6757  1193.6768  -0.001    R.GDQTVLILHAK.V      (Ions score 55) 
59 - 64     349.1612     696.3079   696.3078    0.0000   K.SYGNEK.R           (Ions score 10) 
66 - 81     649.2960     1944.8662  1944.8725  -0.0063   R.FFCPPPCVYLMGSGWK.K (Ions score 22) 
66 - 81     1053.4852    2104.9559  2104.8052   0.1507   R.FFCPPPCVYLMGSGWK.K (Ions score 13)  Phospho (ST); Phospho (Y) 
85 - 89     346.6552     691.2959   691.2959   -0.0000   K.EQMER.D            (Ions score 14) 
121 - 126   378.6707     755.3269   755.3272   -0.0003   K.NYCTAK.T           (Ions score 25) 
127 - 135   521.2585     1040.5024  1040.5026  -0.0002   K.TLYISDSDK.R        (Ions score 31) 
138 - 144   431.2359     860.4572   860.4578   -0.0006   K.HFMLSVK.M          (Ions score 16) 
145 - 159   564.9353     1691.7841  1691.7865  -0.0024   K.MFYGNSDDIGVFLSK.R  (Ions score 32) 
163 - 169   379.7419     757.4692   757.4698   -0.0006   K.VISKPSK.K          (Ions score 23) 
176 - 186   575.2819     1148.5492  1148.5496  -0.0004   K.NADLCIASGTK.V      (Ions score 46) 
187 - 192   360.2135     718.4125   718.4126   -0.0001   K.VALFNR.L           (Ions score 39) 
195 - 201   389.7061     777.3977   777.3981   -0.0003   R.SQTVSTR.Y          (Ions score 22) 
239 - 249   640.8167     1279.6189  1279.6197  -0.0008   R.DGYIHYGQTVK.L      (Ions score 30)                                                 
250 - 261   652.3455     1302.6765  1302.6788  -0.0023   K.LVCSVTGMALPR.L     (Ions score 29)                                                    
270 - 285   584.3036     1749.8889  1749.8897  -0.0008   K.QTALLDADDPVSQLHK.C (Ions score 49)                                                
286 - 291   401.2017     800.3888   800.3891   -0.0003   K.CAFYLK.D           (Ions score 32)                                                        
296 - 304   600.2805     1198.5465  1198.5474  -0.0010   R.MYLCLSQER.I        (Ions score 50)                                                        
305 - 315   651.8472     1301.6799  1301.6802  -0.0003   R.IIQFQATPCPK.E      (Ions score 85)                                                 
384 - 396   801.8656     1601.7166  1601.7184  -0.0018   R.VWFGDVEAETMYR.C    (Ions score 57)                                                   
397 - 412   920.9073     1839.8001  1839.8318  -0.0316   R.CGESMLCVVPDISAFR.E (Ions score 46)                                             
397 - 412   960.8503     1919.6861  1919.7981  -0.1120   R.CGESMLCVVPDISAFR.E (Ions score 3)   Phospho (ST)                                    
420 - 430   618.3769     1234.7393  1234.7398  -0.0004   R.QPVQVPVTLVR.N      (Ions score 47)                                                   
                                                    
Figure 3.15. Mass Spectroscopy results of the 1st peak from RBP-Jk8-435 MonoQ 
purification step. Purified RBP-Jk8-435 was passed through a MonoQ 5/50. The two 
peaks were run on a 10% Tris-HCL SDS page where the RBP-Jk8-435 bands were cut out 
using a scalpel for in-gel-digestion with trypsin. Digested JK.8-435 was loaded on to the 
mass spec LTQ-OrbitrapXL where they ran against a BSA standard. A. Table contains 
information and statistics generated by the Mascot Software used to identify RBP-Jk8-
435 showing whether peptides contain phosphorylated residues. B. A table containing a 
summary of the peptides identified from the peak data generated by 1st peak from the 
MonoQ step. Start-end column lists the aa number of the peptide, observed m/z is the 
peptide mass over charge measured, Mr expt mass expected, Mr calc is calculated 
mass of predicted peptide, ΔMr is the difference between these calculations, Sequence 
shows the sequence of the peptide, Ion score links to RAW data and phosphorylation 
column describes peptide phosphorylation. 
 
 
Start–End  Observed m/z   Mr(expt)   Mr(calc)    ΔMr     Sequence              Ion Score links  Phosphorylation? 
 
A 
Nominal mass (Mr): 56343; Calculated pI value: 6.80 
NCBI BLAST search of Q06330|SUH_HUMAN against nr 
Taxonomy: Homo sapiens 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Phospho (ST),Phospho (Y) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 49% 
 
Matched peptides  Bold Red, Phosphorylated peptides  Highlighted in yellow, 
Not in construct Highlighted in grey 
 
     1 MDHTEGSPAE EPPAHAPSPG KFGERPPPKR LTREAMRNYL KERGDQTVLI  
    51 LHAKVAQKSY GNEKRFFCPP PCVYLMGSGW KKKKEQMERD GCSEQESQPC  
   101 AFIGIGNSDQ EMQQLNLEGK NYCTAKTLYI SDSDKRKHFM LSVKMFYGNS  
   151 DDIGVFLSKR IKVISKPSKK KQSLKNADLC IASGTKVALF NRLRSQTVST  
   201 RYLHVEGGNF HASSQQWGAF FIHLLDDDES EGEEFTVRDG YIHYGQTVKL  
   251 VCSVTGMALP RLIIRKVDKQ TALLDADDPV SQLHKCAFYL KDTERMYLCL  
   301 SQERIIQFQA TPCPKEPNKE MINDGASWTI ISTDKAEYTF YEGMGPVLAP  
   351 VTPVPVVESL QLNGGGDVAM LELTGQNFTP NLRVWFGDVE AETMYRCGES  
   401 MLCVVPDISA FREGWRWVRQ PVQVPVTLVR NDGIIYSTSL TFTYTPEPGP  
   451 RPHCSAAGAI LRANSSQVPP NESNTNSEGS YTNASTNSTS VTSSTATVVS  



















Start - End  Observed  Mr(expt)   Mr(calc)   Delta    Miss Sequence 
44 - 54      597.8452    1193.6759  1193.6768  -0.0010    R.GDQTVLILHAK.V      (Ions score 36) 
85 - 89      346.6553    691.2960   691.2959    0.0001    K.EQMER.D            (Ions score 9)                                                        
121 - 126    378.6708    755.3269   755.3272   -0.0003    K.NYCTAK.T           (Ions score 12) 
138 - 144    431.2358    860.4570   860.4578   -0.0008    K.HFMLSVK.M          (Ions score 27)                                                     
145 - 159    846.9002    1691.7859  1691.7865  -0.0006    K.MFYGNSDDIGVFLSK.R  (Ions score 52) 
163 - 169    379.7420    757.4695   757.4698   -0.0003    K.VISKPSK.K          (Ions score 30) 
176 - 186    575.2814    1148.5482  1148.5496  -0.0014    K.NADLCIASGTK.V      (Ions score 42) 
187 - 192    360.2136    718.4127   718.4126    0.0001    K.VALFNR.L           (Ions score 31) 
195 - 201    389.7062    777.3979   777.3981   -0.0002    R.SQTVSTR.Y          (Ions score 21) 
239 - 249    640.8165    1279.6185  1279.6197  -0.0012    R.DGYIHYGQTVK.L      (Ions score 38) 
250 - 261    652.3460    1302.6775  1302.6788  -0.0014    K.LVCSVTGMALPR.L     (Ions score 85) 
270 - 285    584.3038    1749.8895  1749.8897  -0.0002    K.QTALLDADDPVSQLHK.C (Ions score 56) 
296 - 304    600.2806    1198.5467  1198.5474  -0.0007    R.MYLCLSQER.I        (Ions score 60)                                                     
305 - 315    651.8470    1301.6795  1301.6802  -0.0006    R.IIQFQATPCPK.E      (Ions score 89)                                                         
384 - 396    801.8664    1601.7182  1601.7184  -0.0002    R.VWFGDVEAETMYR.C    (Ions score 84) 
420 - 430    618.3771    1234.7396  1234.7398  -0.0002    R.QPVQVPVTLVR.N      (Ions score 38) 
  
Figure 3.16. Mass Spectroscopy results of 2nd peak from RBP-Jk8-435 MonoQ 
purification step. Purified RBP-Jk8-435 was passed through a MonoQ 5/50. The two 
peaks were run on a 10% Tris-HCL SDS page where the RBP-Jk8-435 bands were cut out 
using a scalpel for in-gel-digestion with trypsin. Digested RBP-Jk8-435 was loaded on to 
the mass spec LTQ-OrbitrapXL where they ran against a BSA standard. A. Table 
contains information and statistics generated by the Mascot Software used to identify 
RBP-Jk8-435 showing whether peptides contain phosphorylated residues.  B. A table 
containing a summary of the peptides identified from the peak data generated from 
the 2nd peak in the MonoQ step. Start-end column lists the aa number of the peptide, 
observed m/z is the peptide mass over charge measured, Mr expt mass expected, Mr 
calc is calculated mass of predicted peptide, ΔMr is the difference between these 
calculations, Sequence shows the sequence of the peptide, Ion score links to RAW data 




Start–End Observed m/z  Mr(expt)   Mr(calc)   ΔMr       Sequence              Ion Score links  Phosphorylation? 
 
Nominal mass (Mr): 56343; Calculated pI value: 6.80 
NCBI BLAST search of Q06330|SUH_HUMAN against nr 
Taxonomy: Homo sapiens 
 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Phospho (ST),Phospho (Y) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 31% 
 
Matched peptides  Bold Red, Phosphorylated peptides  Highlighted in yellow, Not in 
construct Highlighted in grey 
 
1 MDHTEGSPAE EPPAHAPSPG KFGERPPPKR LTREAMRNYL KERGDQTVLI 
51 LHAKVAQKSY GNEKRFFCPP PCVYLMGSGW KKKKEQMERD GCSEQESQPC 
101 AFIGIGNSDQ EMQQLNLEGK NYCTAKTLYI SDSDKRKHFM LSVKMFYGNS 
151 DDIGVFLSKR IKVISKPSKK KQSLKNADLC IASGTKVALF NRLRSQTVST 
201 RYLHVEGGNF HASSQQWGAF FIHLLDDDES EGEEFTVRDG YIHYGQTVKL 
251 VCSVTGMALP RLIIRKVDKQ TALLDADDPV SQLHKCAFYL KDTERMYLCL 
301 SQERIIQFQA TPCPKEPNKE MINDGASWTI ISTDKAEYTF YEGMGPVLAP 
351 VTPVPVVESL QLNGGGDVAM LELTGQNFTP NLRVWFGDVE AETMYRCGES 
401 MLCVVPDISA FREGWRWVRQ PVQVPVTLVR NDGIIYSTSL TFTYTPEPGP 











Figure 3.17. Verification of phosphorylation sites using The Cuckoo workshop Group-
based prediction software. The peptides that were predicted to be phosphorylated by 
the Mascot software were inputted into the Cuckoo Post Translation Prediction (PTM) 
software (http://gps.biocuckoo.org/online.php). Both peptides were predicted to 
contain phosphorylatable residues by the software. It also identified that these 























Figure 3.18. Potential phosphorylation sites highlighted on the structure of RBP-Jκ to 
visualise kinase accessibility. Peptides sequences were aligned to the  structure of 
Notch1 transcription complex (3V79) in pymol (RBP-Jκ in blue, RAM molecule in green 
and WTP Notch binding motif is highlighted in pink)(Choi et al., 2012). Entire peptide 
sequence identified in the mass spectrometry was highlighted in yellow whilst the 
residues predicted to phosphorylated were highlighted in red. Zoomed in view shows 









3.1.2.1 : Initial Purification of C-terminally His-tagged RBP-Jκ8-435 expressed in 1L Rosetta 
E.coli cells.  
We transformed a pET28b.JK.8-435, produced by a summer student in Michelle West’s 
group, containing cDNA to express C-terminally His-tagged RBP-Jκ8-435 into E.coli 
Rosetta pLys cells. Cells were harvested and sonicated in buffer A (Appendix 3), then 
the lysate was loaded onto a Co2+ column (5ml Talon FF) and RBP-Jκ8-435 was eluted 
with an increasing concentration of imidazole (Appendix 3) (Figure 3.19A). We chose to 
continue using Co2+ column (5ml Talon FF) for the initial purification step of C-
terminally His-tagged RBP-Jκ8-435 as the Co2+ binds to His-tagged proteins more 
specifically which reduces background binding. Initially, we found that RBP-Jκ was 
eluted with many impurities (Figure 3.19A). The eluates from the Co2+ column 
purification step were desalted in a 26/10 desalt column to lower the concentration of 
sodium chloride from 500mM to 100mM to ensure that the C-terminally His-tagged 
RBP-Jκ8-435 would bind to the anion exchange column. 
We changed the anion exchange column from a MonoQ 5/50 column to a 5ml HitrapQ 
FF column. This was because the Hitrap Q FF column media (45-165µm bead size) is 
less tightly packed compared to MonoQ 5/50 columns (10 µm bead size) which meant 
we could use faster flow rates and complete this purification step faster. Also, it was 
recommended in the MonoQ 5/50 manual not to load more than 10ml of sample per 
purification, which meant after the desalt step we often had to concentrate the 
sample to ensure we could load all the sample at once which added a significant 
amount of time to the purification process. Conversely the HitrapQ FF columns did not 
have a limit to how much sample could be loaded onto the column. C-terminally His-
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tagged RBP-Jκ8-435 was eluted from the HitrapQ column with a salt gradient, however 
there was still a significant amount of impurities present (Figure 3.20A).  
The eluates were pooled, concentrated to 250µL, incubated with RBP-Jκ consensus site 
DNA (TTACTGTGGGAAAGA) and loaded onto an S200 10/300 size exclusion column 
(Figure 3.21). C-terminally His-tagged RBP-Jκ8-435 was eluted from the column with 
fewer impurities, however require further purification (Figure 3.21). The overall yield 
of C-terminally His-tagged RBP-Jκ8-435 expressed in 1L of Rosetta E.coli cells was 
approximately 100µL of RBP-Jκ8-435 at 8mg/ml for a yield of ~0.8mg. This was a 
significant increase in yield per litre of cells used compared to insect cells which 
required approximately 3L of media to produce a similar quantity of C-terminally His-
































Figure 3.19. Analysis of Co2+ column (Talon) purification step of His tagged RBP-Jκ8-435 
expressed in 1 litre of E.coli Rosetta cells. A. Coomassie stained showing pellet, lysate 
and elution fractions from Co2+ column (5ml Talon FF) as an increasing concentration 
of imidazole was passed through. 10µL from each fraction was mixed with 10µl GSB 
buffer, boiled and loaded onto the 10% Tris SDS page gel where it was run in MOPS 
buffer. B. Chromatogram from the Talon step produced in Unicorn software. Shown is 
protein (blue), concentration of buffer B/ [imidazole] (green), flow rate (orange) and 





 HisTrap1ml ecoli jk2 32 lysate rerun001:10_UV  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Cond  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Cond%
 HisTrap1ml ecoli jk2 32 lysate rerun001:10_Conc  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Flow  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Temp
 HisTrap1ml ecoli jk2 32 lysate rerun001:10_Fractions  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Inject  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Logbook







0.0 20.0 40.0 60.0 80.0 ml
X1 X2 1A1 1A4 1A7 1A10 1B12 1B9 1B6 1B3 1C1
 HisTrap1ml coli jk2 32 lysate rerun001:10_UV  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Cond  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Cond%
 HisTrap1ml ecoli jk2 32 lysate rerun001:10_Conc  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Flow  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Temp
 HisTrap1ml ecoli jk2 32 lysate rerun001:10_Fractions  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Inject  HisTrap1ml ecoli jk2 32 lysate rerun001:10_Logbook
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Figure 3.20. Analysis of HitrapQ purification step of C-terminally His-tagged RBP-Jκ8-
435 expressed in 1 litre of E.coli cells. A. Coomassie stained gel showing fractions from 
the 5ml HitrapQ FF column from GE healthcare as an increasing [NaCl] is passed 
through. Each fraction was mixed with GSB buffer, boiled and loaded onto the 10% Tris 
SDS page gel where it was run in MOPS buffer. B. Chromatogram showing HitrapQ 
purification step. Shown is [protein (blue), concentration of buffer D/ [NaCl] (green), 










 Hi trap Q FF 5ml jk3 ecoli 150216:10_UV  Hi trap Q FF 5ml jk3 ecoli 150216:10_Cond  Hi trap Q FF 5ml jk3 ecoli 150216:10_Cond%
 Hi trap Q FF 5ml jk3 ecoli 150216:10_Conc  Hi trap Q FF 5ml jk3 ecoli 150216:10_Flow  Hi trap Q FF 5ml jk3 ecoli 150216:10_Temp











0.0 10.0 20.0 30.0 40.0 50.0 ml
X1 1A1 1A3 1A5 1A7 1A9 1A11 1B12 1B10 1B8 1B6 1B4 1B2 1C1 1C3 1C5 1C7 1C9 1C11 1D12 1D10 1D8
 Hi trap Q FF 5ml jk3 ecoli 150216:10_UV  Hi trap Q FF 5ml jk3 ecoli 150216:10_Cond  Hi trap Q FF 5ml jk3 ecoli 150216:10_Cond%
 Hi trap Q FF 5ml jk3 ecoli 150216:10_Conc  Hi trap Q FF 5ml jk3 ecoli 150216:10_Flow  Hi trap Q FF 5ml jk3 ecoli 150216:10_Temp
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Figure 3.21. Analysis of Size exclusion step for C-terminally His-tagged RBP-Jκ8-435 
expressed in 1 litre of E.coli cells. Fractions were pooled, concentrated, incubated with 
DNA and injected into a size exclusion column primed in low salt Buffer C. Shown is the 
input and different fractions taken as RBP-Jκ8-435 passed through the S200 10/300 size 
exclusion column. Samples were mixed with GSB, boiled and run on a 10% Tris-HCL 
SDS-PAGE gel in MOPS buffer. Wells A12 to B9 were pooled and used for crystallisation 
screens. Chromatogram not shown as air bubbles in the system made the 













      A11  A12  B12   B11  B10   B9    B8  
145 
 
3.1.2.2 : Optimisation of the Purification of C-terminally His-tagged RBP-Jκ8-435 expressed 
in Rosetta E.coli cells. 
To reduce the amount of contaminant binding to the Co2+ column during the first step 
in the purification process we introduced 10mM of imidazole. To increase the yield of 
C-terminally His-tagged RBP-Jκ8-435 we also increased the grow up from 1L to 4L. To 
ensure the E.coli cells were lysed properly we increased the time we sonicated the cell 
pellet. These changes improved to the amount to C-terminally His-tagged RBP-Jκ8-435 
that bound to the Co2+ column and reduced contaminant binding (Figure 3.22A). 
However, some C-terminally His-tagged RBP-Jκ8-435 was lost during the wash step 
(Figure 3.22A). Based on the chromatogram of the first HitrapQFF purification step 
performed, shown (Figure 3.20B) we calculated that C-terminally His-tagged RBP-Jκ8-435 
eluted at approximately 150mM NaCl. We therefore programmed the AKTA to 
increase the salt gradient until 150mM NaCl was running through the column then 
paused the gradient until the elution peak returned to zero. This ensured that 
impurities that eluted at higher or lower salt concentrations to C-terminally His-tagged 
RBP-Jκ8-435 were not eluted with RBP-Jκ8-435 further increasing the purity of the sample 
shown in (Figure 3.22B). 
Finally the eluates from the HistrapQ FF step were pooled, concentrated to 250µL, 
incubated with RBP-Jκ consensus site DNA (TTACTGTGGGAAAGA) and loaded onto an 
S200 10/300 size exclusion column. The eluates from the size exclusion step were pure 
enough for crystallisation trials and with these optimisations we had greatly improved 
the purity and the overall yield from 0.8mg to 4mg of C-terminally His-tagged RBP-Jκ8-
435 (Figure 3.22C). We could produce this yield consistently, which enabled us to 
146 
 
conduct more crystallisation trials with fresh material than we could with the C-






























Figure 3.22. Analysis of optimised steps of the purification of C-terminally His-tagged 
RBP-Jκ8-435 expressed in E.coli.  A. Coomassie stained gel showing pellet, lysate and 
elution fractions from Co2+ column (5ml Talon FF) as an increasing concentration of 
imidazole was passed through. Wells A3 to A10 were pooled for anion exchange. B. 
Coomassie stained gel showing fractions from the 5ml HitrapQ FF column as an 
increasing [NaCl] is passed through. Wells C8 to D6 were pooled for size exclusion. C. 
Shown are fractions taken as RBP-Jk8-435 passed through the S200 10/300 size exclusion 
column. The chromatogram has been aligned to the Coomassie stained gel. The black 
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L   C4   C6  C8  C10  C12 D10 D8  D6  D2 
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3.1.3.1 : Expression and purification of RBP-Jκ conclusion. 
We initially expressed RBP-Jκ in insect cells as a PhD student from Munich had shown 
that the EBNA-RBP-Jκ interactions could be impacted by whether a eukaryotic or 
prokaryotic expression host had been used to produce RBP-Jκ (Robertson et al., 1996a, 
Calderwood et al., 2011). We produced a recombinant baculovirus that expressed C-
terminally His-tagged RBP-Jκ8-435 well in insect cells, which bound efficiently to Ni2+ 
beads (Figures 3.1 to 3.6). We showed that RBP-Jκ8-435 expressed in insect cells bound 
specifically to DNA containing RBP-Jκ consensus site using EMSA, which confirmed 
RBP-Jκ8-435 functionality (Figure 3.7). We also produced a recombinant baculovirus that 
expressed N-terminally His-tagged RBP-Jκ variant 2 (V2) that did not express as well as 
C-terminally His-tagged RBP-Jκ8-435 and did not bind to Ni2+ beads (Figures 3.1 to 3.6). 
We therefore did not continue to optimise expression and purification of RBP-Jκ V2. 
We developed a purification process for RBP-Jκ8-435 expressed in insect cells (Figure 3.8 
to 3.10). RBP-Jκ8-435 eluted off the size exclusion column in a broad peak suggesting it 
was adopting multiple confirmations (Figure 3.10). Binding RBP-Jκ8-435 to DNA, 
containing a RBP-Jκ consensus site, before the size exclusion step sharpened the 
elution peak suggesting DNA binding drove conformational changes to RBP-Jκ8-435, 
which homogenised RBP-Jκ8-435 folding in the sample (Figure 3.13). The same effect 
was not observed when RBP-Jκ8-435 was pre-incubated with EBNA2 peptide before the 
size exclusion step (Figure 3.13). We also observed that RBP-Jκ8-435 underwent post-
translational modification during expression in insect cells. Incubating RBP-Jκ8-435 with 
λ-phosphatase prior to the monoQ purification step identified one of the monoQ 
elution peaks contained phosphorylated RBP-Jκ8-435 (Figure 3.14). Mass spectroscopy 
analysis of this peak identified that residues Y66, S70, S394 or S405 of RBP-Jκ8-435 were 
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phosphorylated (Figure 3.15 and 3.16). Additionally, we verified these residues were 
accessible to kinases (Figure 3.18) and phosphorylatable using Cuckoo workshop 
Group-based prediction software (Figure 3.17).  
After scaling up the preparation of RBP-Jκ8-435 to 5L we increased the yield of protein 
from ~0.8mg to ~2mg and optimising the purification of process we produced RBP-Jκ8-
435 that was pure enough for crystallisation trials (Figures 3.8 to 3.12). From a 5L 
preparation we could even produce up to 4mg of RBP-Jκ8-435 however, this was highly 
dependent on the quality of the P3 recombinant baculovirus produced, which 
fluctuated considerably.    
Due to inconsistent yields of RBP-Jκ8-435 in insect cells and the time consuming process 
affecting progress we switched production of RBP-Jκ8-435 to E.coli. We transformed 
Rosetta E.coli with a bacterial expression vector (pET28b.JK.8-435) to produce C-
terminally His-tagged RBP-Jκ8-435 (Figure 3.19). Initially we encountered lower yields 
(0.8 mg/L of culture) and impurities in the purified RBP-Jκ8-435 (Figures 3.19 to 3.21). By 
improving the lysis step, adding 10mM imidazole to the lysis buffer, increasing the 
length of washes during purification and scaling up the culture to 4L we consistently 
produced yields 4mg of RBP-Jκ8-435 (Figure 3.22). As we were able to consistently 
produce high purity RBP-Jκ8-435 we were able to complete larger numbers of 




Chapter 3.2 : Thermodynamic studies into the interactions between 
Epstein-Barr Viral transcription factors and RBP-Jκ 
After successfully expressing and purifying C-terminally His-tagged RBP-Jκ8-435, in insect 
cells and E.coli, we had the material we needed to start investigating how EBNA2 and 
the EBNA3 family of transcription factors hijack RBP-Jκ mediated viral and cellular 
transcription. Previous work in our laboratory and others (unpublished observations) 
had found that expression of full length EBNA2 and EBNA3s is problematic due to 
issues with instability and insolubility of recombinant proteins. Instability in vitro was 
likely due to EBNA2 and the EBNA3 family being predicted to be predominantly 
disordered (Yenamandra et al., 2009, Friberg et al., 2015). EBNA2 and the EBNA3 
family also rely on multiple host transcription factors for their activity which may 
confer stability in vivo (Maruo et al., 2005, Young et al., 2008, Lee et al., 2009, Chabot 
et al., 2014). Therefore, we decided to initially investigate interactions between 
peptides of EBNA2 and the EBNA3 family, which contained the WΦP and TΦGC RBP-Jκ 
binding motifs, with RBP-Jκ (Ling and Hayward, 1995, Calderwood et al., 2011). EBNA2 
mimics the Notch RAM domain WΦP motif to interact with RBP-Jκ and mutation of this 
motif has been shown to silence EBNA2 activation of host genes (Ling and Hayward, 
1995, Johnson et al., 2010). It has been suggested that the EBNA3 family TΦGC RBP-Jκ 
binding motif, located in the N-terminal homology domain of the EBNA3s, binds to the 
NTD of RBP-Jκ. Mutation of the EBNA3 TΦGC motif to alanines ablates RBP-Jκ binding 
and decreases EBNA3C mediation of host gene expression (Maruo et al 2009, 
Calderwood et al 2011). 
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3.2.1.1 : Isothermal titration calorimetry (ITC) binding assays to study the interactions 
between RBP-Jκ and the EBNAs  
Initially we used ITC to measure the interaction between C-terminally His-tagged RBP-
Jκ8-435 expressed in insect cells and a 14 amino acid peptide of EBNA2314-327 which 
contained the WΦP RBP-Jκ binding motif (EBNA2.14aa) which was provided by Dr 
Chrisostomos Prodromou’s group. Initially C-terminally His-tagged RBP-Jκ8-435 
expressed in insect cells was pooled from the MonoQ purification step, concentrated 
to ~8mg/ml then dialysed in buffer C + 1mM Ethylenediaminetetraacetic acid (EDTA) 
overnight. 1mM EDTA was added to protect the protein from degradation during 
dialysis. Based on previously published affinity of the binding between EBNA2 and RBP-
Jκ (kD = 4.6µM)(Johnson et al., 2010) we calculate that 30µM to 60µM RBP-Jκ would be 
optimal for ITC experiments. Due to low yields of RBP-Jκ being predicted to be 
produced by insect cells (Figure 3.7) we calculated we could use a maximum 37.8µM of 
RBP-Jκ for each ITC experiment. 
The EBNA2 and EBNA3C peptides ordered contained predominantly hydrophobic 
residues, therefore we predicted that they would likely have low solubility in the ITC 
buffer. Consequently, we decided to initially dissolve the EBNA2.14aa peptide powder 
directly into dimethyl sulfoxide (DMSO) and then diluted it into ITC buffer (Appendix 
3). For each injection to produce a measurable heat peak we needed to use at least 10 
times the amount of ligand (peptide) to substrate (RBP-Jκ). But we needed to keep the 
overall concentration of DMSO in the buffer below 0.5% as any more would likely 
disrupt RBP-Jκ8-435 folding. We calculated that the maximum amount of ligand we 
could dissolve in injection solution, before the final percentage of DMSO was greater 
than 0.5%, was 600µM of peptide.  
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0.5% DMSO was added to RBP-Jκ8-435 solution to ensure that both the substrate and 
ligand buffers were the same to prevent heat peaks being generated during the 
binding assay, that would overwhelm the heat peaks generated by the RBP-Jκ8-435-
EBNA2.14aa interaction. We chose to titrate the peptide with 28 injections to ensure 
that the binding curve contained sufficient data points for reliable curve fitting.  
The ITC analysis of the RBP-Jκ8-435-EBNA2.14aa interaction measured a kd of 1.35 ± 0.07 
µM revealing that the interaction was relatively weak as predicted (Figure 3.23). The 
stoichiometry of the interaction was calculated to be 1:1 which confirmed that the 
WΦP RBP-Jκ binding motif was directing EBNA2.14aa peptide interactions with the 



























Figure 3.23. Isothermal Titration Calorimetry analysis of the interaction between C-
terminally His-tagged RBP-Jκ8-435 expressed in Sf9 insect cells and an EBNA2 peptide 
containing Notch binding motif. Heat peaks and integrated fitted heat peaks are 
shown for the interaction between RBP-Jκ8-435 and EBNA2.14aa peptide in low salt 
buffer C + 1mM EDTA + 0.5% DMSO. The Kd is shown next to the integrated fitted heat 
peaks. The WΦP Notch binding motif is highlighted in pink in the amino acid sequence 








3.2.1.2 : EBNA2-RBP-Jκ8-435 interactions are weaker then Notch 2-RBP-Jκ8-435 Interactions.           
We next determined the binding affinity of Notch with RBP-Jκ to compare to binding 
affinity of EBNA2. Notch 2 has been shown to be expressed in mice mature B cells and 
promote Marginal Zone B cell lineage development so we used a peptide of human 
Notch 2 for our analysis (Saito et al, 2003).  The Notch 21700-1725 peptide (Notch2.26aa) 
was designed so that the WΦP RBP-Jκ binding motif (Figure 3.24) was in the centre of 
the peptide and to include residues of the RAM domain previously identified as 
important to the Notch-RBP-Jκ interactions (Johnson et al., 2010)(Appendix 4). A new 
EBNA2312-337 peptide of the same length (EBNA2.26aa) peptide was designed 
containing a central WΦP RBP-Jκ binding motif was used to enable a better 
comparison of binding of the Notch2.26aa peptide (Figure 3.24)(Appendix 4)(Johnson 
et al., 2010).  
We found that the Notch2.26aa peptide bound to RBP-Jκ8-435 with a kd of 0.16µM 
whereas the EBNA2.26aa peptide bound to RBP-Jκ8-435 an order of magnitude weaker 
with a kd of 3.9µM (Figure 3.24). Although both peptides contained the WΦP RBP-Jκ 
binding motif, the presence of a leucine instead of a tryptophan in the Φ position or 


















Figure 3.24. Isothermal Titration Calorimetry analysis of the interaction between C-
terminally His-tagged RBP-Jκ8-435 expressed in insect cells and Notch peptide 
(Notch.26aa) or EBNA2 peptide (EBNA2.26aa) containing WΦP Notch binding motif. 
Heat peaks and integrated fitted heat peaks are shown for the interaction between 
RBP-Jk8-435 and Notch.22aa or EBNA2.14aa. The Kd is shown next to the integrated 
fitted heat peaks. The WΦP Notch binding motif is highlighted in pink in the amino acid 







Notch2.26aa:   MAKRKRKHGSLWLPEGFTLRRDASNH 






3.2.1.3 : Peptides of EBNA3A, EBNA3B and EBNA3C containing the TΦGC RBP-Jκ binding 
motif do not bind to RBP-Jκ8-435 in vitro. 
The TΦGC RBP-Jκ binding motif in EBNA3 proteins is found in the conserved homology 
domain of EBNA3A, EBNA3B and EBNA3C and its been shown that when this motif is 
mutated to four alanine residues EBNA3s no longer binds to RBP-Jκ (Robertson et al., 
1996a, Zhao et al., 1996, Calderwood et al., 2011).  
14 amino acid peptides of EBNA3A194-207, EBNA3B201-214 and EBNA3C204-217 were 
designed to contain the TΦGC RBP-Jκ binding motif at the centre of the peptide 
(EBNA3A.14aa, EBNA3B.14aa and EBNA3C.14aa respectively)(Appendix 4). However, 
we found that none of the EBNA3 family peptides with the TΦGC RBP-Jκ binding motif 
bound to RBP-Jκ8-435 (Figure 3.25). It therefore appears that this motif is not able to 
direct RBP-Jκ in the context of a peptide sequence in vitro. This is in contrast to the 























































































































































































3.2.1.4 : EBNA3C peptides bind RBP-Jκ through the WΦP RBP-Jκ binding motif 
Previous studies identified an additional potential RBP-Jκ binding motif in EBNA3C that 
also resembles the WΦP RBP-Jκ binding motif (WTP)(Calderwood et al., 2011). We 
sought to confirm this interaction using ITC. The WTP motif is located 15 amino acids c-
terminal to the TFGC motif. We therefore investigated their binding affinities using a 
longer 33 amino acid EBNA3C207-239 peptide (EBNA3C.33aa) containing both motifs and 
measured the impact of mutating either motif in this context. To do this we designed 
three 33 amino acid peptides of EBNA3C207-239 that contained wild type EBNA3C 
(EBNA3C.33aa), the TΦGC RBP-Jκ binding motif mutated to alanines 
(EBNA3C.mTFGC.33aa) or the WΦP RBP-Jκ binding motif mutated to alanines 
(EBNA3C.mWTP.33aa) (Appendix 4).  
The wild type EBNA3C peptide (EBNA3C.33aa) bound to RBP-Jκ8-435 with a kd of 1.05µM 
(Figure 3.26) which was slightly stronger than the EBNA2.26aa-RBP-Jκ8-435 interaction 
(kd of 3.9µM)(Figure 3.26) but similar to the EBNA2.14aa peptide affinity (Figure 3.23). 
Reapeats of these experiments confirmed these differences were small and may not 
be significant (Figure 3.30).  
When the TΦGC RBP-Jκ binding motif was mutated to alanines there was no effect on 
the affinity of binding (kd of 1.57µM)(Figure 3.26) consistent with our previous 
observation that the TΦGC motif does not contribute to RBP-Jκ binding in vitro. These 
data indicate that RBP-Jκ binding of EBNA3C peptide is directed by the WTP motif. To 
confirm this, we mutated the WTP motif to alanines which abolished EBNA3C peptide 

















































































































































































































3.2.1.5 : Testing the binding of RBP-Jκ8-435 expressed in E.coli  
Due to time constraints and the unpredictable yields of RBP-Jκ8-435 expressed in insect 
cells we we moved to RBP-Jκ8-435 expressed in E.coli. In order to test whether the E.coli 
generated RBP-Jκ8-435 bound effectively to EBNA peptides we undertook an ITC binding 
assay using the EBNA2.14aa peptide (Figure 3.27). We found that RBP-Jκ8-435 expressed 
in E.coli bound to EBNA2.14aa with a kd of 1.67µM which was comparable to affinity 
between EBNA2.14aa peptide and RBP-Jκ8-435 expressed in insect cells (Figure 3.27 and 
3.30).  
3.2.1.6 : Phosphorylating the threonine residue in the TΦGC RBP-Jκ binding motif does 
not affect RBP-Jκ binding 
EBNA3C has been shown to be phosphorylated in EBV infected cell lines although 
which residues are phosphorylated and how this impacts EBNA3C function is unknown 
(Sample and Parker, 1994, West, 2006). We therefore tested whether phosphorylating 
the threonine in the TΦGC RBP-Jκ binding motif led to detectable RBP-Jκ binding. ITC 
was carried out using a 14 amino acid peptide of EBNA3C204-217 with the threonine of 
the TΦGC RBP-Jκ binding motif phosphorylated (EBNA3C.P.14aa)(Figure 
3.28)(Appendix 4). We detected no binding between RBP-Jκ8-435 (expressed in E.coli) 
and the EBNA3C.P.14aa indicting that phosphorylation of this motif does not affect its 

















Figure 3.27. Isothermal Titration Calorimetry of the interaction between C-terminally 
His-tagged RBP-Jk8-435 expressed in Sf9 insect cells or Rosetta cells with a 14aa 
peptide of EBNA2 containing the WΦP Notch binding motif. Heat peaks, the 
integrated fitted heat peaks and the Kds are shown for the interactions between RBP-
Jk8-435 expressed in Sf9 or Rosetta cells with the EBNA2.14aa peptide in low salt buffer 






























Figure 3.28. Isothermal Titration Calorimetry analysis of the interaction between C-
terminally His-tagged RBP-Jk8-435 expressed in E.coli cells and 14aa peptide of  
EBNA3C containing a phosphorylated TΦGC motif WΦP Notch binding motif. Heat 
peaks and the integrated fitted heat peaks are shown for the interaction between RBP-
Jk8-435 and the EBNA3C.14aa.phos peptide in low salt buffer C + 1mM EDTA + 0.5% 










3.2.1.7 : Do residues in EBNA3A and EBNA3B that mimic the physiochemical properties of 
the WΦP RBP-Jκ binding motif facilitate binding to RBP-Jκ. 
Although EBNA3A and EBNA3B do not contain a WΦP RBP-Jκ binding motif they do 
have residues with similar chemistry to WΦP RBP-Jκ binding motif that align with the 
WΦP RBP-Jκ binding motif of EBNA3C. The tryptophan in the WΦP RBP-Jκ binding 
motif has a large hydrophobic aromatic side chain like the phenylamine residue found 
in the same position on EBNA3A and is hydrophobic like the valine in the same position 
on EBNA3B. The middle residue in the WΦP RBP-Jκ binding motif is not highly 
conserved in Notch and thermodynamically contributes the least to RBP-Jκ binding 
(Johnson et al., 2010) which may allow substitution of the lysine and glutamine 
residues that EBNA3A and EBNA3B have in this position respectively. Neither EBNA3A 
or EBNA3B have a proline in the third position of the EBNA3C WΦP RBP-Jκ binding 
motif they do have similarly hydrophobic residues leucine (EBNA3A) and isoleucine 
(EBNA3B) in the same position. We therefore tested whether 33 amino acid peptides 
of EBNA3A197-239 and EBNA3B205-237 that aligned to the EBNA3C.33aa peptide displayed 
any detectable RBP-Jκ binding by ITC (Appendix 4).  
We found that the EBNA3A.33aa peptide produced a very weak binding curve when 
titrated onto RBP-Jκ8-435 (expressed in E.coli)(Figure 3.29). The calculated kd of the RBP-
Jκ-EBNA3A.33aa interaction was 329 µM (Figure 3.29). In order to measure the weak 
RBP-Jκ8-435- EBNA3A.33aa interaction we had to reduce the number of injections and 
increase the volume of peptide titrated each time in order increase the size of the 
binding peaks to produce a binding curve. EBNA3B.33aa did not have any significant 
RBP-Jκ8-435 (expressed in E.coli) binding (Figure 3.29). Whether this weak binding is 













Figure 3.29. Isothermal Titration Calorimetry analysis of the interaction between C-
terminally His-tagged RBP-Jκ8-435 expressed in E.coli cells and 33aa peptides of the 
EBNA3A and EBNA3B family containing the TΦGC motif. Heat peaks, the integrated 
fitted heat peaks and the Kd are shown for the interaction between RBP-Jk8-435 and 
each of the 33aa EBNA3. The TΦGC RBP-Jκ binding motif and the WΦP Notch binding 
motif have been highlighted in green and pink respectively. Hydrophobic residues that 













EBNA3A.33aa:   QATLGCTGGRRCHVTFSAGTFKLPRCTPGDRQW  
EBNA3B.33aa:   TATLGCDEGTRHATTYSAGIVQIPRISDQNQKI 















Figure 3.30. Table containing summary of all interactions studied with Isothermal 
Titration Calorimetry. The motifs that peptides contained is indicated by ticks. In italics 




















 0.16 ± 0.01 0.83 -1.63 -9.9± 0.05 -9.42 ± 0.06 
Notch2.26aa (R) 
 
 0.27 ± 0.02 0.71 -16.1 -14± 0.11 -9.12 ± 0.07 
EBNA2.14aa (Insect) 
 
 1.35 ± 0.07 1.02 -13.2 -12.1 ± 0.07 -8.09 ± 0.04 
EBNA2.14aa (E.coli) 
 
 1.67 ± 0.06 1.02 -7.66 -10.33 ± 0.06 -8.00 ± 0.05 
EBNA2.26aa 
 
 3.9 ± 0.11 1.06 -1.46 -7.9 ± 0.06 -7.50 ± 0.07 
EBNA2.26aa (R) 
 
 4.7 ± 0.2 0.96 -4.02 -8.6  ± 0.09 -7.38 ± 0.08 
EBNA3A.14aa    
 
- - - - - 
EBNA3B.14aa    
 
- - - - - 
EBNA3C.14aa    
 
- - - - - 
EBNA3C.Phos.14aa    
 
- - - - - 
EBNA3A.33aa  ~ 
 
329 ± 17.8 1.00 -21.5 -11.3 ± 0.45 -0.63 ± 0.02 
EBNA3A.33aa (R)   
 
251 ± 23.2 1.00 -3.69 -6.1 ± 0.39 -4.9 ± 0.3  
EBNA3B.33aa  
 
- - - - - 
EBNA3C.33aa 
  
1.05 ± 0.09 1.19 -9.85 -11.2 ± 0.1 -8.29 ± 0.08 
EBNA3C.33aa (R) 
  
1.23 ± 0.05 1.21 -9.00 -10.9 ± 0.06 -8.17 ± 0.04 
EBNA3C.33aa.mTFGC 
 
 1.57 ± 0.05 1.50 -2.70 -8.7 ± 0.03 -8.05 ± 0.15 
EBNA3C.33aa.mWTP  
 
- - - - - 
EBNA3C.33aa.mTFGC.mWTP   - - - - - 
EBNA3C.33aa (DNA) 
  
0.72 ± 0.02 1.01 -7.10 -10.6 ± 0.03 -10.38 ± 0.19 
Notch consensus 24aa 
 
 0.072 ± 0.004 - −10.1 −19.8 ± 0.5 -9.93 ± 0.02 
EBNA2 27aa 
 
 4.6 ± 1.3 - −2.80 −10.2 ± 3.1 -7.33 ± 0.18 
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3.2.2.1 : Fluorescent polarisation competition assay to measure whether EBNA3C WΦP 
RBP-Jκ binding motif can compete with EBNA2 for RBP-Jκ binding. 
We next wanted to determine whether the WΦP RBP-Jκ binding motifs on EBNA2 
EBNA3C competed for RBP-Jκ binding. To do this we designed a 28 amino acid 
fluorescein tagged EBNA2 peptide containing the WΦP RBP-Jκ binding motif 
(EBNA2.28aa.FP)(Appendix 4). Two Glycine residues were added to the EBNA2.26aa 
peptide sequence in order to facilitate the chemistry needed to covalently bind the 
fluorescein tag to the EBNA2.28aa.FP peptide.  
Initial experiments tested the binding of the EBNA2.28aa.FP peptide to RBP-Jκ8-435 
(expressed in insect cells) using FP. EBNA2.28aa.FP peptide was added to wells 
containing serially diluted  RBP-Jκ8-435 to measure the EBNA2.28aa.FP-RBP-Jκ8-435 
interaction. We found that the peptide bound efficiently with a kd of 0.39µM (Figure 
3.31). Although this was lower than the kd measured by ITC for the EBNA2.26aa-RBP-


















Figure 3.31. Fluorescent polarisation end point assay of N-terminally Fluorescein-
tagged EBNA2 peptide vs C-terminally His-tagged RBP-Jκ8-435 expressed in insect cells. 
An excess of EBNA2.26aa.FP was added to wells containing serially diluted RBP-Jκ8-435 
and the amount of EBNA2.26aa.FP bound to RBP-Jκ8-435 was measured in each well in 
order to estimate the Kd of the interaction. This Kd could then be used to calculate the 









EBNA2.14aa.FP vs RBP-Jκ8-435 
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3.2.2.2 : The EBNA3C WΦP RBP-Jκ binding motif and not the TΦGC motif competes with 
EBNA2 for RBP-Jκ binding.  
We serially diluted 10µM of competitor peptide based on the kds calculated from our 
ITC data. Unlabelled EBNA2.26aa peptide was serially diluted over EBNA2.28aa.FP-
RBP-Jκ8-435 complex and competed off EBNA2.28aa.FP peptide from RBP-Jκ (Figure 
3.32). The EBNA2.26aa only competed off 50% of the EBNA2.28aa.FP peptide from the 
EBNA2.28aa.FP-RBP-Jκ8-435 complex as they likely established an equilibrium due to 
having similar affinities for RBP-Jκ. This served as a control for competitive binding of 
unlabelled peptides. 
We also investigated the ability of the Notch2.26aa peptide to compete off the 
EBNA2.28aa.FP peptide from the EBNA2.28aa.FP-RBP-Jκ8-435 complex (Figure 3.32). 
Consistent with the higher affinity of Notch2 peptide binding to RBP-Jκ, this peptide 
was able to compete off all the EBNA2.28aa.FP peptide from the EBNA2.28aa.FP-RBP-
Jκ8-435 complex (Figure 3.32).  
We next tested if the EBNA3C 33aa peptide were able to compete off the EBNA2 
peptide (EBNA2.28aa.FP) from RBP-Jκ8-435. We found that both the wild type EBNA3C 
(EBNA3C.33aa) and EBNA3C with the TΦGC RBP-Jκ binding motif mutated to alanines 
(EBNA3C.mTFGC.33aa) were able to compete for EBNA2.28aa.FP binding to a similar 
extent as the unlabelled EBNA2.26aa peptide (Figure 3.33). 
We next tested whether EBNA3C with the WΦP RBP-Jκ binding motif 
(EBNA3C.33aa.mWTP) or both the RBP-Jκ binding motifs mutated to alanines 
(EBNA3C.33a.mTFGC.mWTP) were able to compete EBNA2.28aa.FP off of RBP-Jκ8-435. 
We showed that when the WΦP RBP-Jκ binding motif is mutated to alanines the ability 
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of the EBNA3C peptides to disrupt the interactions between EBNA2.28aa.FP-RBP-Jκ8-435 
was abolished (Figure 3.34). We obtained similar results for the double mutant 
EBNA3C peptide EBNA3C.33a.mTFGC.mWTP (Figure 3.34). 
The competition binding assay had shown that the TΦGC RBP-Jκ binding motif does 
not contribute to EBNA3Cs ability to compete with EBNA2 for RBP-Jκ binding, in the 
context of the peptide, contrary to a previous yeast-2-hybrid screen (Zhao et al., 
1996)(Figure 3.33 and 3.34). Instead they showed that the WΦP RBP-Jκ binding motif 
was essential for EBNA3C to compete with EBNA2 for RBP-Jκ binding in the context of 
the peptides. To validate the roles of WΦP and TΦGC RBP-Jκ binding motifs in EBV 
hijacking of RBP-Jκ mediated genes shown in our ITC data in vivo cell assays needed to 
















Figure 3.32. Fluorescent polarisation competition binding assay between 
EBNA2.26aa.FP-RBP-J8-435 complex expressed in insect cells and EBNA2.26aa or 
Notch.26aa peptides. EBNA2.26aa.FP-RBP-J8-435 complex was added to wells 
containing serially diluted competitor peptide. A control competition assay was run in 
parallel using an EBNA2.26aa peptide which did not have a fluoroscein tag. The 
flourescein tag and the WΦP RBP-Jk binding motif are highlighted in orange and pink 
respectively in the peptide sequences below. The bars show the standard deviation for 









































EBNA2.26aa:        QQLHHLPSGPPWWPPICDPPQPSKTQ 







Figure 3.33. Fluorescent polarisation competition binding assay between 
EBNA2.26aa.FP-RBP-J8-435 complex expressed in insect cells and EBNA2.26aa, 
EBNA3C.33.aa or EBNA3C.33aa.mTFGC peptides. EBNA2.26aa.FP-RBP-J8-435 complex 
was added to wells containing serially diluted competitor peptide. A control 
competition assay was run in parallel using an EBNA2.26aa peptide which did not have 
a fluoroscein tag. The flourescein tag, the WΦP RBP-Jk binding motif and the TΦFC 
motif are highlighted in orange, pink and green respectively in the peptide sequences 
below. The bars show the standard deviation for each concentration of competitor 











































EBNA2.26aa.FP            FP-GGQQLHHLPSGPPWWPPICDPPQPSKTQ 
EBNA2.26aa:                   QQLHHLPSGPPWWPPICDPPQPSKTQ 
EBNA3C.33aa:         TATFGCQNAARTLNTFSATVWTPPHAGPREQER 





Figure 3.34. Fluorescent polarisation competition binding assay between 
EBNA2.26aa.FP-RBP-J8-435 complex expressed in insect cells and EBNA2.26aa or 
EBNA3C peptides with the WΦP motif mutated to alanines. EBNA2.26aa.FP-RBP-J8-435 
complex was added to wells containing serially diluted competitor peptide. A control 
competition assay was run in parallel using an EBNA2.26aa peptide which did not have 
a fluoroscein tag. The flourescein tag, the WΦP RBP-Jk binding motif and the TΦFC 
motif are highlighted in orange, pink and green respectively in the peptide sequences 
below. The bars show the standard deviation for each concentration of competitor 


















































EBNA2.26aa.FP              FP-GGQQLHHLPSGPPWWPPICDPPQPSKTQ 
EBNA2.26aa:                     QQLHHLPSGPPWWPPICDPPQPSKTQ 







3.2.3.1 : Design of the RBP-Jκ consensus site nanolever and measuring RBP-Jκ-DNA 
interactions using the SwitchSense Biosensor 
We wanted to study whether EBNA peptide binding caused conformational changes in 
RBP-Jκ similar to the effects of Notch binding (Friedmann et al., 2008) or had any effect 
on RBP-Jκ DNA binding so we used SwitchSense to explore this. We first needed to 
design a DNA nanolever that contained the RBP-Jκ DNA site. RBP-Jκ consensus site 
nanolever was designed by Dynamic Biosensors to ensure the DNA nanolever would 
not fold into secondary structures which would interfere with measurements (Figure 
3.35). The negative control nanolever was provided from a bank of negative controls 
developed by Dynamic Biosensors which are also designed not to fold into secondary 
structures (Figure 3.35).  
C-terminally His-tagged RBP-Jκ8-435 expressed in insect cells was incubated with 
Switchsense chips with RBP-Jκ DNA consensus site and control nanolever bound to 
different electrodes. RBP-Jκ8-435 was added to the Switchsense chip at different 
concentrations (10nM, 100Nm and 1µM) to determine which concentration was 
optimal for producing smooth binding and disassociation curves. The dynamic 
response is shown to slow, producing binding curves, as RBP-Jκ8-435 binds to both the 
RBP-Jκ consensus site and to the control nanolever. It was discovered that the 
nanolever chosen from Biosensor bank of negative controls contained a RBP-Jκ non-
consensus site shown to bind RBP-Jκ (Figure 3.35 and 3.36)(Friedmann and Kovall, 
2010). This unfortunately meant we had to proceed with the SwitchSense assays with 
no negative control. We found that 1µM of RBP-Jκ8-435 saturated the chip too quickly 
and generated a noisy signal, which was difficult to measure, and 10nM of RBP-Jκ8-435 
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did not result in detectable binding (Figure 3.36). 100nM of RBP-Jκ8-435  gave suitable a 
signal and this concentration of RBP-Jκ was used for future experiments (Figure 3.36).  
The SwitchSense software calculated kon from the binding curves generated from 
measuring the dynamic response in real time (Figure 3.36). The koff was measured by 
washing the unbound RBP-Jκ8-435 from the chip and allowing the RBP-Jκ8-435 to 
disassociate from the DNA overnight, although due to how tightly the RBP-Jκ8-435 
bound to the DNA we were not able to gather the data for a complete disassociation 
curve. From the kon and the koff we used the SwitchSense software to calculate the 
approximate kds of the interactions between RBP-Jκ8-435 and the RBP-Jκ DNA consensus 
site (Figure 3.36). As expected the RBP-Jκ8-435 bound to consensus site nanolever (kd = 
~20nM) tighter than non-consensus nanolever (kd = ~70nM). The kd calculated for RBP-
Jκ binding to DNA was in line with previously published data from ITC studies (70nM) 




















Figure 3.35. DNA Sequences of the RBP-Jκ consensus and control Switchsense 
nanolevers. Shown are the DNA sequences of the double stranded designed 
sequences. The RBP-Jκ consensus and non-consensus sites have been coloured in 
green and red respectively. The end of the DNA nanolever that is exposed to buffer are 
labelled surface. The single stranded sequence used to anneal the nanolever to the 









Sequence of RBP-Jκ consensus nanolever (69 bp): 
 
5’ AAA CAC GCC GTG GGA AAA AAT ATC AGC GTT CGA TGC  
3’ TTT GTG CGG CAC CCT TTT TTA TAG TCG CAA GCT ACG  
 
 
TTC CGA CTA ATC AGC CAT ATC AGC TTA CGA CTA 3’ 






Sequence of control nanolever (48 bp control): 
 
5’ CTG CAT CAC GAG AGC TGG CAA ATG CTA CCT TTG TTG GAG  
3’ GAC GTA GTG CTC TCG ACC GTT TAC GAT GGA AAC AAC CTC  
 
 
GGT TCA CAC 3’ 











3.2.3.2 : EBNA2 peptide and the Notch 2 peptide potentially induce conformational 
changes in RBP-Jκ8-435 
We next investigated whether EBNA peptides binding affected RBP-Jκ8-435-DNA 
interactions. We preincubated C-terminally His-tagged RBP-Jκ8-435 expressed in insect 
cells with each of the EBNA peptides (EBNA2.26aa, EBNA3C.33aa and 
EBNA3C.mTFGC.mWTP.33aa, as negative control) and the Notch2.26aa peptide and 
then injected the complexes over the chip with RBP-Jκ DNA consensus site nanolevers 
bound (Figure 3.37). The dynamic response of the RBP-Jκ consensus nanolevers slowed 
as each of the peptide-RBP-Jκ8-435 complexes bound to the nanolevers generating 
association curves (Figure 3.37). The EBNA3C.33a peptide did not affect the ability of 
RBP-Jκ8-435 to bind to DNA (Figure 3.37A). However, the RBP-Jκ8-435 bound to Notch 2 
peptide appeared to have a faster dynamic response than just RBP-Jκ8-435 bound to the 
RBP-Jκ DNA consensus nanolever, which was which could indicate the induction of 
conformational changes reducing the hydrodynamic friction of the RBP-Jκ8-435. This is 
consistent with previous reports demonstrating Notch RAM domain peptide induced 
conformational changes in CSL, which were essential to Notch complex assembly 
(Friedmann et al., 2008).  
Interestingly, when the EBNA2.26aa peptide bound to RBP-Jκ8-435, it appeared to 
induce conformational changes in RBP-Jκ8-435 that reduced the hydrodynamic friction 
and these appeared to be greater than the effects of the Notch2.26aa peptide (Figure 
3.37A). This can be seen more clearly when a single recovery of the nanolever is 















Figure 3.37. SwitchSense assay showing C-terminally his-tagged RBP-Jκ8-435 expressed 
in insect cells complexed with peptides of Notch or EBNAs binding to DNA RBP-Jk 
consensus. A. RBP-Jk was incubated with different peptides and passed over the 
switchsense chip with nanolevers containing a RBP-Jk consensus site bound to the 
switches. As RBP-Jk bound this slows the dynamic response creating a binding curve. B. 
A trace of a single motion of the switch during the previously described assays. Empty 
switches are shown in black. Changes in RBP-Jκ were measured when Notch or EBNA2 
peptide was complexed with RBP-Jκ. Hwever no changes in conformation were 











3.2.3.3 : DMSO does not significantly affect RBP-Jκ8-435 DNA binding. 
Due to the SwitchSense biosensor having the sensitivity required to measure 
conformational changes of RBP-Jκ8-435 we wanted to test whether the DMSO we had 
added to the ITC binding assay to solubilise the larger peptides had had a negative 
effect on RBP-Jκ8-435. To do this, we incubated C-terminally His-tagged RBP-Jκ8-435 
expressed in insect cells in buffer with and without 2% DMSO and then injected it onto 
chips with RBP-Jκ consensus site nanolevers bound. In the association and 
disassociation curves there is no evidence to show RBP-Jκ8-435-DNA interactions were 
affected by the DMSO (Figure 3.38 A and B). The RBP-Jκ8-435 incubated in DMSO did 
have a marginally slower dynamic response compared to the RBP-Jκ8-435 not incubated 
in DMSO suggesting that it may have a more open conformation. However we were 
assured by the technicians from Dynamic Biosensors that the difference shown was 
insignificant and that DMSO was not inducing conformational changes that would be 




















Figure 3.38. SwitchSense assay in buffer with or without DMSO showing C-terminally 
his-tagged RBP-Jk8-435 expressed in insect cells binding to DNA containing a RBP-Jk 
consensus site. A. Binding curve of C-terminally his-tagged RBP-Jk8-435 expressed in 
insect cells in buffer with and without 2% DMSO. B.  A disassociation curve of C-


















3.2.4.1 : Design and optimisation of pull-down assay to study the EBNA3C RBP-Jκ binding 
motifs. 
Previous data had indicated that mutation of the TFGC motif in EBNA3C to AAAA 
disrupted RBP-Jκ binding (Zhao et al., 1996, Calderwood et al., 2011). However, we 
found no binding of the TFGC motif in vitro. We therefore hypothesised that the TFGC-
AAAA mutation may have disrupted the folding of EBNA3C. We set out to mutate 
residues of EBNA3C to study the effects on binding of full length EBNA3C. We 
introduced mutations in full length EBNA3C to generate mammalian expression vector 
encoding EBNA3CT209A (pSG53C.TA), EBNA3CF210A (pSG53C.FA) and EBNA3CTF209AA 
(pSG53C.TFAA) mutants of the EBNA3C TΦGC RBP-Jκ binding motif (Figure 39). We did 
not mutate the glycine and cysteine residues of the TΦGC RBP-Jκ binding motif as we 
hypothesised they may play key roles in folding. We also generated an EBNA3CW227S 
(pSG53C.STP) mutant of the WΦP RBP-Jκ binding motif and a EBNA3CTFGC209AAAA.W227S 
double mutant of both the RBP-Jκ binding motifs (EBNA3C.JK.STP) (Figure 3.39).  
These vectors were then transfected into EBV negative Burkitts lymphoma cell line 
(DG75) alongside a previously generated EBNA3CTFGC209AAAA mutant and cells were 
harvested 48 hours post transfection (Figure 3.40 and 3.41).  
C-terminally His-tagged RBP-Jκ8-435 was expressed in E.coli and bound to talon beads to 
be used as bait for the pulldown. We ran a sample of the beads against BSA standards 
in order to quantify how much RBP-Jκ8-435 bound to the talon beads (Figure 3.42).  
However, when we carried out the pulldown western blot analysis showed that the 
EBNA3C was pulled down even when RBP-Jκ was not incubated with the Co2+ beads 
(Figure 3.43). This demonstrated the EBNA3C construct was binding non-specifically to 
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the Co2+ beads. Due to time constraints we were unable to optimise the pulldown 































Figure 3.39. Mutagenesis of full length EBNA3C RBP-Jk binding motifs TFGC and WTP. 
Agarose gel showing PCR products after site directed mutagenesis reactions. The 
plasmid product predicted band size was 7055bp. All successful mutagenesis reactions 
were transformed in to competent E.coli, colonies were picked and DNA was extracted 







   
   
   
   
   
   
   
   
   
   
   
   
   
   














   
   
   










   
   
   
   
   
   
   
   










   
   
   
   
   
   
   
   
























   




















10      
8       
6       
4     
2.5     
2 


















Figure 3.40. Western blot analysis following transfection of plasmids expressing wild 
type EBNA3C and EBNA3C mutants. Cells were transfected with pSG5 vector, pSG5 
wild type full length EBNA3C (pSG5.3C) or pSG5 vector with EBNA3C TFGC-AAAA 
mutant. Whole cell and lysate samples were analysed by SDS-PAGE. The gel was 
probed with an anti-EBNA3C antibody and BL31 EBV positive cell line was used as a 










   
   








   
   
   
   
   
   
   
   

























   
   
   
   
   
   






























Figure 3.41. Western blot analysis following transfection of plasmids expressing wild 
type EBNA3C and EBNA3C mutants. Cells were transfected with PSG5 vector, pSG5 
vector with full length EBNA3C with TFGC mutated to AFGC, TAGC or AAGC or a pSG5 
vector with full length EBNA3C WTP mutated to STP. Whole cell and lysate samples 
were analysed by SDS-PAGE. The gel was probed with an anti-EBNA3C antibody and 
BL31 EBV positive cell line and MutuIII cell line was used as a positive control. The 






   
   
   
   
   
   
   
   
   
   
   
   
   








   
   
   
   
   
   
   
   






   
   
   
   
   
   








   
   
   
   
   
   
   
   










   
   
   
   
   
   
   




















   
   
   
   
   
   












































Figure 3.42. Quantification of C-terminally His-tagged RBP-Jk8-435 expressed in 100ml 
E.coli bound to 100µL of Co2+ beads (Talon) . A. Coomassie stained gel beads sampled 
from each step and 30µL of beads was analysed for the final quantification. Comparing 
to the BSA standards it was estimated there was approximately 30µM represented in 
the. Shown in yellow were the numbers used to calculate the concentration of RBP-Jk8-
435 on the beads. B. Graph of concentrations of BSA standards plotted against 









   






















































































































Figure 3.43. Western blot analysis of pull down of EBNA3C wild type and EBNA3C 
mutants using C-terminally His-tagged RBP-Jk8-435 expressed in E.coli bound to Co2+-
beads as the bait. C-terminally His-tagged RBP-Jk8-435 bound to Co2+-beads was 
incubated with cell lysates from transfected cells overnight. After washing 30µL of the 
beads were boiled in GSB and analysed by SDS-PAGE and western blotting probed with 








   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   






   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
















   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   






















   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   















   
   
   
   
   
   
   
   
   
   

















   
   
   
   
   
   
   
   
   
   
   
























   
   
   





















   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   





























3.2.5.1 : Conclusions of the thermodynamic studies into the interactions between 
Epstein-Barr Virus transcription factors and RBP-Jκ 
Initially we optimised an Isothermal titration calorimetry (ITC) binding assay using a 14 
amino acid peptide of EBNA2, containing the WΦP RBP-Jκ binding motif, and RBP-Jκ8-
435, expressed in insect cells, to measure the affinities of the interactions between RBP-
Jκ and the EBNA RBP-Jκ binding motifs (Figure 3.23).  
ITC analysis showed a peptide of the Notch 2 RAM domain (Notch2.26aa) bound to 
RBP-Jκ an order of magnitude tighter than EBNA2 peptide (EBNA2.26aa) 
demonstrating that the residues surrounding the EBNA2 WΦP motif had a much 
weaker affinity for RBP-Jκ compared to residues surrounding the Notch 2 WΦP motif 
(Figure 3.24). This was confirmed by our FP competition assay in which the Notch 2 
peptide to competed off all the fluorescein tagged EBNA2 peptide from RBP-Jκ (Figure 
3.32).  
Our ITC analysis also showed that the EBNA3s TΦGC motif in the context of a peptide 
did not contribute to RBP-Jκ interactions in vitro and that phosphorylating the 
threonine in the EBNA3C TFGC motif did not enable RBP-Jκ binding (Figure 3.25, 3.26 
and 3.29). Additionally we showed, using FP competition assays, that the EBNA3C 
TΦGC motif in the context of a peptide did not compete with unlabelled EBNA2 
peptide for RBP-Jκ binding (Figure 3.33 and 3.34). However, our ITC analysis did show 
that the EBNA3C WTP motif in the context of a peptide was essential for RBP-Jκ 
binding in vitro, which agreed with previously published data (Calderwood et al., 
2011)(Figure 3.26). In addition to this FP competition assays showed that the EBNA3C 
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WTP motif was needed to compete with EBNA2 peptide for RBP-Jκ binding (Figure 3.33 
and 3.34).  
In order to complete our thermodynamic studies we switched from producing RBP-Jκ 
in insect cells to E.coli. We confirmed, using ITC analysis, that this did not affect 
interactions between RBP-Jκ and EBNA peptides (Figure 3.27). Interestingly we 
measured weak binding between a 33 amino acid peptide of EBNA3A (EBNA3A.33aa) 
and RBP-Jκ (Figure 3.28). We had previously shown that a peptide of the EBNA3A TLGC 
motif did not have affinity for RBP-Jκ suggesting residues that aligned with the EBNA3C 
WTP motif, with similar hydrophobicity to the WΦP motif, facilitated this weak 
interaction (Figure 3.25 and 3.28). We were confident in the reliability of our ITC as we 
were able to show little difference between repeats (Figure 3.30). 
We also utilised SwitchSense to measure the effects EBNA peptide binding had on RBP-
Jκ-DNA interactions and on the conformation of RBP-Jκ (Figure 3.37). There were no 
measurable differences made to the Kon of RBP-Jκ-DNA interactions when EBNA 
peptides were bound to RBP-Jκ (Figure 3.37). However, SwitchSense analysis showed 
that the Notch 2 peptide confers conformational changes to RBP-Jκ agreeing with 
previously published data (Friedmann et al., 2008). Interestingly SwitchSense 
measured more severe conformational changes to RBP-Jκ when EBNA2 peptide was 
bound (Figure 3.37). However, the physiological connotations of this remain to be 
tested. We attempted to optimise pull downs of full length EBNA3C with mutated 
TFGC and WTP motifs expressed in mammalian cells to confirm the findings of our ITC 
and FP data. However, we encountered significant EBNA3CTFGC-AAAA background binding 
to the Co2+ beads and, due to time constraints, were unable to optimise the assay. 
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Chapter 3.3 : X-ray crystallography studies  
The key aim of this chapter was to solve structure the EBNAs bound to RBP-Jκ in order 
study the interactions between them to regulate host transcription elucidate the 
mechanism of how the EBNAs hijack RBP-Jκ mediated genes. No structures of full 
length EBNA2 and EBNA3 proteins have been solved to date which is most likely due to 
their folding, which is predicted to be predominantly disordered (Yenamandra et al., 
2009). Additionally, few structures of truncations of EBNA2 and EBNA3 proteins exist 
due to them proving difficult to express in large quantities. NMR structures of 
dimerised EBNA2 N-terminal END domains and the EBNA2 N-terminal TAD domain 
bound to the Tfb1/p62 subunit of TFIIH have been solved (Chabot et al., 2014, Friberg 
et al., 2015)(Figure 1.3). These structures enabled study into how EBNA2 dimerises, 
which residues were involved dimerization and EBNA2-TFIIH interactions and the role 
of EBNA2 dimerisation and TFIIH binding in EBNA2 activation of host genes (Chabot et 
al., 2014, Friberg et al., 2015). This atomic resolution detail would not have been 
achievable with biomolecular techniques. In addition to this crystal structures of RBP-
Jκ, CSL and Su(H) have proven essential to identifying how notch signalling is regulated 
in multiple species as traditional techniques, such as pulldowns of truncations RBP-Jκ, 
have not been reliable as RBP-Jκ relies on distal parts of its amino acid sequence to 
fold into its 3D structure (Arnett et al., 2010, Kurth et al., 2011, Choi et al., 2012). 
Therefore, we initially attempted to co-crystallise RBP-Jκ8-435 expressed in insect cells 
bound to DNA with peptides of the EBNAs which contained the TΦGC and WΦP RBP-Jκ 
binding motifs. We also attempt to co-express the EBNAs with RBP-Jκ as we 




3.3.1.1 : Results from the 4oC crystal trials of RBP-Jκ8-435-DNA-EBNA2.26aa expressed in 
insect cells.  
RBP-Jκ8-435 was expressed in insect cells, purified with a Co2+ column step, an anion 
exchange step, incubated with DNA containing the RBP-Jκ consensus site 
(TTACTGTGGGAAAGA) and then passed through a size exclusion column. We designed 
the DNA to contain the RBP-Jκ consensus and have a 2bp overhang which we hoped 
would encourage crystal contact points to form to aid crystallisation. The RBP-Jκ8-435-
DNA complex was then concentrated to ~8mg/ml and incubated with the EBNA2.26aa 
peptide at a 1:1.5 ratio. The sample (~5mg/ml) was loaded onto 98 well sitting drop 
plates with broad crystal screening conditions (JCSG+, PacT, Proplex and Natrix). 
Condition screens JCSG+ and PacT were chosen for the broad screen as they offer a 
large range of PEGs and salts that have previously been used to produce crystal 
structures. Proplex was chosen as the conditions are designed for the crystallisation of 
protein complexes. Natrix was chosen as the conditions are designed to aid the 
crystallisation of protein-DNA complexes. The plates were then examined for crystals 
and crystalline precipitation. The plates were examined after seven days and the 
number of conditions that produced crystalline precipitation were counted (Figure 
3.44). The optimal condition predicted from these trials was 0.1M Tris buffer pH6.5 
with PEG3350 as the precipitant. Due to the long length of time it took these crystal 
trials took to produce only precipitant we decided not continue crystal trials at 4oC, 
however we kept the plates at 4oC to see if they would produce any crystals given 
more time.  
After approximately 19 months we found these plates had produced prism shaped 
crystals (Figure 3.44), in Natrix conditions D2 (0.2M Ammonium acetate, 0.15M 
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Magnesium acetate tetrahydrate, 0.05M HEPES Sodium pH7.0, 5% w/v Polyethylene 
glycol 4000) and F7 (0.08M Sodium chloride, 0.04M Sodium cacodylate trihydrate 
pH6.0, 45% v/v (+/-)-2-Methyl-2,4-pentanediol, 0.012M Spermine tetrahydrochloride). 
The prism shaped crystal from Natrix D2 was fished and cryo-protected by increasing 
the PEG4000 in the buffer incrementally to 30% (Figure 3.45A). The crystals from 
Natrix F7 were also fished and frozen directly into liquid nitrogen due to the fact they 
were already in 45% (+/-)-2-Methyl-2,4-pentanediol (MPD)(Figure 3.45B). 
Unfortunately, the dewar leaked in transit and the crystals had dissolved by the time 

























Figure 3.44. Graphs showing the number of the number of wells containing 
precipitant produced during EBNA2.26aa-DNA-RBP-Jk8-435 complex expressed in 
insect cells crystallisation trials at 4oC. EBNA2.26aa, DNA and RBP-Jk8-435 were 
incubated on ice 1.5:1:1 respectively and plated into 98 well sitting drop crystallisation 
plates containing PacT, JCSG+, Proplex and Natrix crystallisation conditions in a 4oC 
cold room. After 7 days wells containing precipitant were noted, the conditions were 


































































































Figure 3.45. Crystals containing EBNA2.26aa-DNA-RBP-Jk8-435 complex expressed in 
insect cells produced at 4oC over 19 months. A. Shows prism shaped crystals 
containing EBNA2.26aa-DNA-RBP-Jk8-435 complex in a Natrix crystallisation condition 
described below the photo. Also seen are spherulites. B. Shows prism shaped crystals 
of EBNA2.26aa-DNA-RBP-Jk8-435 complex emerging from phase separation and 





Natrix D2 0.2M Ammonium acetate 0.15M Magnesium acetate 
tetrahydrate 0.05M HEPES Sodium pH7.0 5% w/v Polyethylene 
glycol 4000 
Natrix F7 0.08M Sodium chloride 0.04M Sodium cacodylate trihydrate pH6.0 45% 





3.3.1.2 : Results from the room temperature crystal trials of RBP-Jκ8-435-DNA-EBNA2.26aa 
complex expressed in insect cells.  
The RBP-Jκ8-435-DNA-EBNA2.26aa complex was expressed, purified and assembled as 
described in chapter 3.3.1.1 and the same screens were set up at room temperature 
(22oC). After three days rhombus shaped crystals had grown in proplex C2 condition 
(0.1 M sodium citrate pH4.5, 20 % w/v PEG 4000) (Figure 3.46A). After 7 days the 
rhombus shaped crystals had also grown in proplex B8 conditions (0.1 M MgCl2, 0.1 M 
sodium citrate pH5.0, 15 % w/v PEG 4000) (Figure 3.46B). These conditions were very 
similar to each other only varying slightly in the percentage of PEG4000 and pH.  
As the crystals had grown out of phase separation we recorded the number of 
conditions that produced phase separation instead of precipitation with the aim of 
optimising conditions that would produce more rhomboid shaped crystals (Figure 
3.47). As observed in the 4oC trials 0.1M Tris buffer pH6.5 was most commonly seen to 
produce phase separation, however PEG6000 was the most common precipitant.  
We also noticed a significant number of the wells had produced spherulites and 
recorded these conditions with the aim to optimise a condition that could prevent the 
nucleation that had caused the crystals to grow into spherulites (Figure 3.48). A Tris 
based buffer most commonly produced this condition, but the most common pH was 
pH7.5 and the most common precipitant was PEG3350 (Figure 3.48).  
Due to the low levels of RBP-Jκ8-435 being produced in insect cells and the crystals 
grown in conditions Proplex C2 and B8 proving difficult to replicate only a small 
number of trials were completed based on phase separation and spherulite 






















Figure 3.46. Crystals containing EBNA2.26aa-DNA-RBP-Jk8-435 complex expressed in 
insect cells produced at 22oC. A. Shows rhomboid shaped crystals containing 
EBNA2.26aa-DNA-RBP-Jk8-435 complex in a Proplex crystallisation condition described 
below the photo. B. Shows jagged cluster of crystals and small rhomboid crystal of 
EBNA2.26aa-DNA-RBP-Jk8-435 complex emerging from phase separation and precipitant 















Figure 3.47. Graphs showing the number of the number of wells containing phase 
separation produced during EBNA2.26aa-DNA-RBP-Jk8-435 complex expressed in 
insect cells crystallisation trials at 22oC/room temperature . EBNA2.26aa peptide, 
DNA and RBP-Jk8-435 were incubated on ice 1.5:1:1 respectively and plated into 98 well 
sitting drop crystallisation plates containing PacT, JCSG+, Proplex or Natrix 
crystallisation conditions in at room temperature. After 7 days wells containing phase 
separation were noted, the conditions were counted and these graphs were produced 


































































































Figure 3.48. Graphs showing the number of the number of wells containing 
Spherulites produced during EBNA2.26aa-DNA-RBP-Jk8-435 complex expressed in 
insect cells crystallisation trials at 22oC/room temperature . EBNA2.26aa peptide, 
DNA and RBP-Jk8-435 were incubated on ice 1.5:1:1 respectively and plated into 98 well 
sitting drop crystallisation plates containing PacT, JCSG+, Proplex or Natrix 
crystallisation conditions at room temperature. After 7 days wells containing 
spherulites were noted, the conditions were counted and these graphs were produced 





















































































3.3.1.3 : RBP-Jκ8-435 bound to RBP-Jκ consensus site crystal structure produced from 
Proplex C2 condition 
The crystal produced in Proplex C2 condition (Figure 3.46A) was fished then 
cryoprotected and flash frozen in liquid nitrogen. The crystal was exposed to X-rays on 
the IO2 beamline at the diamond light source where a full data set with a resolution of 
3.6Å was acquired.  
Due to the crystal consisting of two rhomboid plates overlapping each other, the 
scatter data produced contained shadow spots which made the asymmetric unit and 
space group determination of the crystal lattice difficult to calculate. Dr Mark Roe 
(University of Sussex crystallography facilities manager) processed the scatter data for 
us. Initially Diamonds XIA2 software was used to reduce the scatter data (Winter, 
2010). Next Phaser software from the CCP4 package was used for the molecular 
replacement. The phase data of the RBP-Jκ8-435 and DNA from the structure of the 
Notch 1 transcription complex was used for molecular replacement (Choi et al., 2012) 
(McCoy et al., 2007, Winn et al., 2011). The initial refinements were completed in 
refmac software and the phenix suite was used for completion (Vagin et al., 2004, 
Adams et al., 2010). We were confident in the quality of the model produced (Figure 
49) as the Rfree and Rwork values were below the PDB cut off of 0.5 (Figure 3.50) despite 
the reasonably high Wilson b factor (Figure 3.50).  
The crystal structure (Figure 3.49) only contained RBP-Jκ8-435 expressed in insect cells 
bound to DNA (TTACTGTGGGAAAGA) and no EBNA2 peptide. The asymmetric unit of 
the crystal contained two complexes RBP-Jκ8-435 bound to DNA that were slightly offset 
which were arranged into a P.21.21.2 lattice. Due to the low resolution of the crystal 
200 
 
structure we were unable to clearly distinguish any electron density over the beta 
trefoil domain that could have been produced by the EBNA2.26aa peptide being bound 
to RBP-Jκ8-435.  
We modelled an EBNA2 peptide onto the structure using wincoot to mutate the 
residues of the NotchRAM peptide in the previous structure of the Notch 1 
transcription complex to EBNA2 residues (aligned to the WΦP RBP-Jκ binding motif) 
then aligned the two structures (Figure 3.51) (Choi et al., 2012). It Is clear from this 
model that the electron density from the Notch peptide sterically clashes with the  
opposing RBP-Jκ8-435-DNA complex. As expected this is also the case when the EBNA2 
peptide is also modelled in place of the NotchRAM peptide (Figure 3.51). This may 
explain why the EBNA2 peptide was not present in the crystal and was likely forced out 
of the complex by crystal packing forces during crystallisation. It was unlikely that the 
EBNA2 peptide was not bound to RBP-Jκ before the adding it to the crystallisation 
conditions as the buffers that the complex was assembled in was similar to the buffer 
used during our ITC assays. Because of the arrangement of the RBP-Jκ molecules in the 









Figure 3.49. X-ray crystal structure produced from Proplex C2 crystallisation 
condition. The structure contains C-terminally His tagged RBP-Jk8-435 expressed in 
insect cells bound to DNA containing the RBP-Jk consensus sight.  The asymmetric 
unit contains two complexes of C-terminally His-tagged RBP-Jk8-435 bound to DNA 
shown as cartoons one in blue and the other in green. The structure was resolved to 
3.63Å, with no detectable electron density visable in the electron density map on the 








Figure 3.50. Table of Data processing and Refinement Statistics for X-ray crystal 
structure of C-terminally His-tagged RBP-Jk8-435 expressed in insect cells bound to 
RBP-Jk consensus site DNA. The data processing and refinement statistics are poor for 
the model of C-terminally His-tagged RBP-Jk8-435 expressed in insect cells bound to 
RBP-Jk consensus site DNA as shadow spots in the scatter data made the data 







Data Processing statistics 
Space group P 21 21 2 
Resolution Range (Å) 3.73-3.63 
Molecules in asymmetric unit 2 
Cell parameters a, b, c (Å) 171.48, 68.52, 107.89 
Cell parameters α, β, γ ()  90, 90, 90 
X-ray source IO2 beamline at Diamond 
Mosaicity (o) 0.515 
Number of unique reflections 14751 
Multiplicity 6.5 (4.7) 
Completeness (%) 98.8 (93.2) 
Rmerge  0.041 (1.336) 
I/σ(I) 0.825  
Refinement statistics 
Rwork/Rfree 0.40/0.47  
Number of reflections 14459 
Number of atoms 7549 
Complexes/ asymmetric unit 2 
Wilson B score (Å2) 132.87 
RMSD bond length (Å) 0.003 
RMSD bond angles (o) 0.713 








Notch2.26aa:   MAKRKRKHGSLWLPEGFTLRRDASNH 
EBNA2.26aa:    QQLHHLPSGPPWWPPICDPPQPSKTQ 
Figure 3.51. X-ray crystal structure, of C-terminally His tagged RBP-Jk8-435 expressed in 
insect cells bound to DNA containing the RBP-Jk consensus sight, with surface shown 
to reveal potential steric clashes between the EBNA2.26aa peptide and the second 
RBP-Jk8-435 in the asymmetric unit of the crystal. A. X-ray crystal structure of C-
terminally His tagged RBP-Jk8-435 expressed in insect cells bound to DNA containing the 
RBP-Jk consensus sight with a transparent molecular surface of the second RBP-Jk8-435 
(in green). An EBNA2 peptide (in yellow) has been modelled on to the structure by 
substituting the Notch-RAM residues in the 3V79 structure for EBNA2 residues using 
the WΦP RBP-Jk binding motif (in pink) to align the two peptides. B. The structure 
described in figure 47.A has been zoomed in to highlight the likely steric clashes 
between the N terminus of the EBNA.26aa peptide and the second RBP-Jk8-435 in the 
asymmetric unit (shown in green). C. Notch26.aa and EBNA2.26aa peptide amino acid 
sequences have been aligned. The RBP-Jk Notch WΦP binding motif is highlighted in 
pink and highly conserved residues identified by S.E Johnson et al 2009 to contribute 







3.3.1.3 : Results of the room temperature crystal trials of RBP-Jκ8-435-DNA-EBNA3C.33aa 
expressed in insect cells.  
The RBP-Jκ8-435-DNA complex was purified as previously described and was then 
incubated with EBNA3C.33aa peptide in a 1:1.5 ratio. Approximately 7mg/ml of 
complex was loaded onto 96 well hanging drop plates with JGSC+, PacT and Proplex 
crystallisation screens. There was little activity in these crystallisation trials which may 
have been due to the RBP-Jκ8-435 being stored at -80oC before the crystal trials. No 
crystals were produced but after 7 days we recorded the conditions that phase 
separation had taken place (Figure 3.52). There was not a distinct pH that scored 
highly, however Tris buffer and the precipitants 20% PEG3350 and 20% PEG6000 gave 
phase separation. We chose not to continue to optimise crystallisation conditions for 
RBP-Jκ8-435-DNA-EBNA3C.33aa due to poor yields of RBP-Jκ8-435 being expressed in 
insect cells and no conditions producing crystals or promising crystalline precipitate. 
We were also concerned that the TΦGC motif in the EBNA3C.33a peptide was shown 
not to bind RBP-Jκ8-435 in our ITC binding assays and that there would be a significant 












Figure 3.52. Graphs showing the number of the number of wells containing phase 
separation produced during EBNA3C.33aa-DNA-RBP-Jk8-435 complex expressed in 
insect cells crystallisation trials at 22oC/room temperature. EBNA3C.33aa peptide, 
DNA and RBP-Jk8-435 were incubated on ice 1.5:1:1 respectively and plated into 98 well 
sitting drop crystallisation plates containing PacT, JCSG+, Proplex or Natrix 
crystallisation conditions at room temperature. After 7 days wells containing phase 
separation were noted, the conditions were counted and these graphs were produced 































































































3.3.2.1 : Switching the production of RBP-Jκ8-435 from insect cells to E.coli increased the 
number of crystallisation strategies we could attempt. 
The main factor that prevented us from creating an efficient production line to 
attempt to crystallise C-terminally His-tagged RBP-Jκ8-435 with EBNA peptides was due 
to low and inconsistent yields of RBP-Jκ8-435 expressed in insect cells. It prevented us 
from increasing the concentration of protein used to 10 to 15mg/ml. Our ITC analysis 
had shown that interactions between the EBNA2.26aa peptide and RBP-Jκ8-435 were 
not significantly impacted by which expression host was used to produce RBP-Jκ8-435 
(Figure 3.27). Therefore we decided to switch the production of RBP-Jκ8-435 to E.coli. 
With larger and more consistent yields we could expand the number of crystallisation 
trials from the strategies shown in blue (Figure 3.53) to the strategies shown in yellow 
in (Figure 3.53). Furthermore as RBP-Jκ8-435 took a shorter amount of time to express 
and purify in E.coli. 
We had concerns that a significant number of residues of the EBNA2.26aa peptide may 
not be binding to RBP-Jκ8-435 and floating freely in solution. We knew from the 
structure of Notch ternary complex that this could compromise the resolution of 
peptides bound to the BTD of RBP-Jκ8-435 and impact crystal formation (Wilson and 
Kovall, 2006, Choi et al., 2012). We therefore decided to use the smaller EBNA2.14aa 
peptide in crystal trials to address these concerns. 
RBP-Jκ8-435-DNA complex was purified as previously described in chapter 3.1.2.2, 
concentrated to approximately 10mg/ml, then incubated with EBNA2.14aa peptide at 
a 1:4 ratio to increase the amount of peptide present. We loaded the RBP-Jκ8-435-DNA-
EBNA2.14aa sample at 10mg/ml onto 96 well sitting drops plates with JCSG+, Proplex, 
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PacT and Natrix crystallisation condition screens. Crystals large enough to take to the 
synchrotron were produced in Proplex A8, E7 and B7 and Natrix G9, E2, C3 and D7 
conditions. Due to issues loading the crystals into pucks some of the samples were lost. 
The crystals produced in Natrix conditions C3 and D7 were identified to be salt crystals 
when exposed to the x-ray source. The rest of the crystals were too small to produce 
scatter data.  
We therefore designed a deep well block of crystallisation conditions to optimise the 
conditions producing small crystals (Figure 3.54). We also included the crystal 
condition Proplex C2 which produced the crystal structure (Figure 3.49). We made a 
gradient of the PEG in these conditions to discourage the crystals entering a nucleation 
phase and producing smaller crystals. Reducing the PEG did reduce the number of 
crystals in the Proplex A8 however these crystals were still too small to expose to an X-
ray source. The Proplex A8 condition predominantly produced crystal showers 
however after approximately 2 weeks a larger crystal grew out of this shower (Figure 
3.55) which was fished but unfortunately was lost during loading and was not exposed 
to an X-ray source. Surprisingly the Proplex C2 condition caused the RBP-Jκ8-435-DNA-
EBNA2.14aa to crash out of solution which was unexpected. We also set up a plate 
where pH was varied, however this had little effect of the crystal growth and most of 
the conditions continued to produce crystal showers (Figure 3.56).  
We next decided to seed the optimisation 2 plate with crystals from the Proplex A8 
condition, from optimisation plate 1 well C2, to determine whether this encouraged 
larger crystals to grow (Figure 3.55). However seeding did not have the desired affect 
and simply generated more crystal showers (Figure 3.57A and B). We also added 5% 
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glycerol to the optimisation 2 crystallisation conditions to prevent the crystals entering 
a nucleation phase and slow the crystallisation process in order to grow fewer larger 
crystals instead of showers of small crystals. This had some success as we managed to 
reduce the number of nucleation points and grow fewer crystals, however the crystals 
were still as small as they were before the addition of glycerol (Figure 3.57D). A larger 
crystal did grow out of the crystal shower (Figure 3.57C), which was fished. However, 
















Figure 3.53. A flow chart showing the process of optimising crystals for structure 
resolution. In light pink are the preparatory steps to assemble the complex for 
crystallisation. Highlighted in light blue are optimisation steps that the RBP-Jk8-435 
complex produced in insect cells were restricted to due to a lack of material being 
produced. Highlighted in yellow are extra optimisation steps that could be achieved 
when expressing RBP-Jk8-435 in E.coli due increased protein production. In green are the 
synchrotron data processing steps and dark red boxes explains why conditions would 
be rejected.  
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Optimisation plate 1 1 2 3 4 5 6 
A 
Proplex C2        
0.1M Na Citrate pH4.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG4000 7% 9% 12% 15% 17% 20% 
0.1M MgCl2 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
B 
Proplex B8       
0.1M Na Citrate pH5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG4000 7% 9% 12% 15% 17% 20% 
0.1M MgCl2 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
C 
Proplex A8       
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG2000 MME 4% 6% 8% 10% 12% 15% 
D 
PacT B6 pH9       
0.1M MEB buffer pH9 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG1500 15% 18% 21% 25% 27% 30% 
E 
PacT B6 pH10       
0.1M MEB buffer pH10 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG1500 15% 18% 21% 25% 27% 30% 
F 
PacT E4        
0.2M K Thiocyanate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
PEG3350 8% 10% 12% 15% 17% 20% 
G 
PacT E4  
0.1M K Thiocyanate 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3350 8% 10% 12% 15% 17% 20% 
 
Figure 3.54. Table showing conditions used to optimise the crystallisation of the 
EBNA2.14aa peptide, C-terminally His-tagged RBP-Jk8-435 (expressed in E.coli) and 
RBP-Jk consensus site DNA complex. Conditions were chosen from conditions that 
produced crystals in the broad screens (JSCG+, PacT, Proplex and Natrix 98-well 












Figure 3.55. Crystal of EBNA2.14aa-RBP-Jk8-435(expressed in E.coli)-DNA complex 
grown in Optimisation plate 1 well C2. A cuboid shaped crystal has grown out of the 
crystal shower surrounding it. The crystal was difficult to fish due to it being stuck to 









Opt1 plate C2 : 0.2M Ammonium Sulphate, 0.1M Na 




Optimisation plate 2 1 2 3 4 5 6 
A 
Proplex B8       
0.1M Na Citrate pH5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG4000 7% 9% 12% 15% 17% 20% 
0.1M MgCl2 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
B 
Proplex A8       
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG2000 MME 4% 6% 8% 10% 12% 15% 
C 
PacT B6 pH9       
0.1M MEB buffer pH9 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG1500 15% 18% 21% 25% 27% 30% 
D 
PacT B6 pH10       
0.1M MEB buffer pH10 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG1500 15% 18% 21% 25% 27% 30% 
E 
PacT E4 0.1M       
0.2M K Thiocyanate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
PEG3350 8% 10% 12% 15% 17% 20% 
F 
PacT E4 0.2M       
0.1M K Thiocyanate 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3350 8% 10% 12% 15% 17% 20% 
G 
PacT E7 pH6.0 
0.1M Na Phosphate pH6.0 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG8000 8% 10% 12% 15% 17% 20% 
H 
PacT E7 pH6.5 
0.1M Na Phosphate pH6.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG8000 8% 10% 12% 15% 17% 20% 
 
Figure 3.56. Table showing conditions used to optimise the crystallisation of the 
EBNA2.14aa peptide, C-terminally His-tagged RBP-Jk8-435 (expressed in E.coli) and 
RBP-Jk consensus site DNA complex. These conditions were derived from new 
crystallisation conditions from the broad screen that produced crystals of the 
EBNA2.14aa peptide-RBP-Jk8-435-DNA complex and those that produced crystals in 









     
         
 
 





Figure 3.57. Pictures of crystals of EBNA2.14aa peptide, C-terminally His-tagged RBP-
Jk8-435 (expressed in E.coli) and RBP-Jk consensus site DNA complex summarising the 
effects of adding 5% glycerol or seed, from optimisation plate 1 well C2, to 
crystallisation conditions. A. A shower of thin crystals needles of EBNA2.14aa peptide-
RBP-Jk8-435-DNA complex produced in optimisation plate 2 well E1. B. A shower of 
EBNA2.14aa peptide-RBP-Jk8-435-DNA complex crystals appear to be larger but still too 
small to expose to an x-ray source. C. A rhomboid shaped crystal has grown out of the 
crystal shower surrounding it. D. The addition of seed from opt1 C2 has reduced the 
number of nuclearisation points but has not produced crystals large enough to expose 





Opt 2 B5 : 0.2M Ammonium Sulphate, 0.1M 
Na Acetate pH5.5, 12% PEG2000 MME 
 
Opt 2 5% glycerol B5 : 0.2M Ammonium 
Sulphate, 0.1M Na Acetate pH5.5, 12% 
PEG2000 MME 
 
Opt 2 E1 : 0.2M K Thiocyanate, 8% PEG3350 
 
 







3.3.2.2 : Optimisation of crystallisation of RBP-Jκ8-435-DNA-EBNA2.14aa  complex 
expressed in E.coli  in Natrix and Published conditions  
Natrix conditions G9 and G10 produced small cuboid crystals and G11 produced small 
pyramid crystals (Figure 3.58A, B and C). Each of the Natrix conditions contained 
0.04M Lithium chloride, 0.08 M Strontium chloride hexahydrate, 0.04 M Sodium 
cacodylate trihydrate pH 7.0, 30% (+/-)-2-Methyl-2,4-pentanediol, 0.012 M Spermine 
tetrahydrochloride whilst G10 and G11 also contained 0.02 M Magnesium chloride 
hexahydrate and 0.012 M Potassium chloride respectively. This was likely the reason 
why the crystals had a similar morphology. 
We generated (+/-)-2-Methyl-2,4-pentanediol (MPD) screens for each of these Natrix 
conditions to attempt to reduce the number of nucleation points to grow fewer larger 
crystals (Figure 3.59). In the second half of this crystal screen we reproduced published 
crystal conditions that had been used to produce crystals of CSL-RAM-DNA complex 
(Figure 3.59)(Friedmann et al., 2008).  
We were unable to reproduce the cuboid crystals had previously seen (Figure 3.58). 
We obtained predominantly crystal showers. Unfortunately, the conditions based on 
the previously published structure of CSL-RAM-DNA caused the protein to come out of 
solution. However, a hybrid of published conditions and Proplex A8 condition did 
produce small rhomboid crystals (Figure 3.60 A and C).  
We had also made a seed stock from the crystals grown in the Natrix G10 condition 
(Figure 3.58B) and seeded the Natrix and published optimisation plate with this stock. 
Unfortunately, the seed produced small edgeless crystals that were not suitable for 
collecting scatter data (Figure 3.60 B and D).  
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Figure 3.58. Pictures of crystals of EBNA2.14aa peptide, C-terminally His-tagged RBP-
Jk8-435 (expressed in E.coli) and RBP-Jk consensus site DNA complex grown in Natrix 
HT 96 well sitting drop crystallisation conditions. A. A small cuboid crystal of 
EBNA2.14aa peptide-RBP-Jk8-435-DNA complex. Unfortunately, the crystal was too small 
to fish. B. Small cuboid crystals of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex which 
were fished and sent to the diamond light source. C. A small Hexagonal flat-topped 
pyramid shaped crystal of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex. 





Natrix G9 : 0.04 M Lithium chloride, 0.08 M 
Strontium chloride hexahydrate, 0.04 M Sodium 
cacodylate trihydrate pH 7.0, 30% (+/-)-2-
Methyl-2,4-pentanediol, 0.012 M Spermine 
tetrahydrochloride  
 
Natrix G10 : 0.04 M Lithium chloride, 0.08 M 
Strontium chloride hexahydrate, 0.04 M Sodium 
cacodylate trihydrate pH 7.0, 30% (+/-)-2-Methyl-2,4-
pentanediol, 0.02 M Magnesium chloride 
hexahydrate, 0.012 M Spermine tetrahydrochloride  
 
Natrix G11 : 0.04 M Lithium chloride, 0.08 M Strontium chloride 
hexahydrate, 0.04 M Sodium cacodylate trihydrate pH 7.0, 30% (+/-)-
2-Methyl-2,4-pentanediol, 0.02 M Magnesium chloride hexahydrate, 






Optimisation plate: Natrix and 
published conditions 
1 2 3 4 5 6 
A 
Natrix G9 
0.04 M Lithium chloride 0.04M 0.04M 0.04M 0.04M 0.04M  0.04M 
0.08 M Strontium chloride hexahydrate 0.08M 0.08M 0.08M 0.08M 0.08M 0.08M 
0.04 M Sodium cacodylate trihydrate pH 7.0 0.04M 0.04M 0.04M 0.04M 0.04M  0.04M 
(+/-)-2-Methyl-2,4-pentanediol 25% 27% 30% 33% 35% 38% 
0.012 M Spermine tetrahydrochloride  12mM 12mM 12mM 12mM 12mM 12mM 
B 
Natrix G10 
0.04 M Lithium chloride 0.04M 0.04M 0.04M 0.04M 0.04M  0.04M 
0.08 M Strontium chloride hexahydrate 0.08M 0.08M 0.08M 0.08M 0.08M 0.08M 
0.04 M Sodium cacodylate trihydrate pH 7.0 0.04M 0.04M 0.04M 0.04M 0.04M  0.04M 
(+/-)-2-Methyl-2,4-pentanediol 25% 27% 30% 33% 35% 38% 
0.012 M Spermine tetrahydrochloride  12mM 12mM 12mM 12mM 12mM 12mM 
0.02 M Magnesium chloride hexahydrate 0.02M 0.02M 0.02M 0.02M 0.02M 0.02M 
C 
Natrix G11 
0.04 M Sodium chloride 0.04M 0.04M 0.04M 0.04M 0.04M  0.04M 
0.08 M Strontium chloride hexahydrate 0.08M 0.08M 0.08M 0.08M 0.08M 0.08M 
0.04 M Sodium cacodylate trihydrate pH 7.0 0.04M 0.04M 0.04M 0.04M 0.04M  0.04M 
(+/-)-2-Methyl-2,4-pentanediol 30% 33% 35% 38% 40% 43% 
0.012 M Spermine tetrahydrochloride  12mM 12mM 12mM 12mM 12mM 12mM 
0.02 M Magnesium chloride hexahydrate 0.02M 0.02M 0.02M 0.02M 0.02M 0.02M 
0.012 M Potassium chloride 12mM 12mM 12mM 12mM 12mM 12mM 
D 
Proplex C2       
0.1M Na Citrate pH5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3550 4% 6% 8% 10% 12% 15% 
E 
 3BRD Friedmann et al 2008 Worm CSL-RAM-DNA complex 
0.1M bis-tris pH6 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3350 22% 24% 26% 28% 30% 32% 
0.2M MgCl2 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
F 
 3BRF Friedmann et al 2008 Worm CSL-RAM-DNA complex 
0.1M HEPES pH7.2 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3350 17% 19% 21% 23% 25% 27% 
0.2 M ammonium acetate  0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
G 
 3BRG Friedmann et al 2008 Mouse CSL-RAM-DNA complex 
0.1M bis-tris pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3350 22% 24% 26% 28% 30% 32% 
H 
Proplex A8 PEG 3350   
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3550 4% 6% 8% 10% 12% 15% 
Figure 3.59. Table showing conditions used to optimise the crystallisation of the 
EBNA2.14aa peptide-RBP-Jk8-435-DNA complex. These conditions were derived from a 
Natrix screen that produced crystals of the EBNA2.14aa peptide-RBP-Jk8-435-DNA 




Figure 3.60. Pictures of crystals of EBNA2.14aa peptide, C-terminally His-tagged RBP-
Jk8-435 (expressed in E.coli) and RBP-Jk consensus site DNA complex grown in Natrix 
and published condition optimisation plate. A. Small crystals of EBNA2.14aa peptide-
RBP-Jk8-435-DNA complex. Unfortunately, these crystals were too small to fish. B. Small 
crystalline precipitate of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex which were too 
small to be fished. C. Small crystals of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex. 
Unfortunately, these crystals were too small to fish. D. Small crystalline precipitate of 






Opt 3 H2: 0.2M Ammonium Sulphate, 0.1M Na 
Acetate pH5.5, 6% PEG3550 
 
Opt3 Natrix G10 seed H2: 0.2M Ammonium 
Sulphate, 0.1M Na Acetate pH5.5, 6% PEG3550 
 
Opt 3 H3: 0.2M Ammonium Sulphate, 0.1M Na 
Acetate pH5.5, 8% PEG3550 
 
Opt3 Natrix G10 seed H3: 0.2M Ammonium 







3.3.2.3 : Optimisation of Proplex A8 condition 
The Proplex A8 conditions had consistently produced crystal showers, even from 
different preparations of RBP-Jκ8-435-DNA-EBNA2.14aa complex. However, when we 
substituted PEG2000 MME for PEG3350 in the Natrix and published conditions (Figure 
3.59) it produced distinctly different crystals to what we had seen in previous screens. 
We therefore decided to make a Proplex A8 PEG screen to see if a different PEG would 
grow crystals we could collect scatter data from (Figure 3.61).  
The heavier PEG caused the protein to crash out of solution and the lighter PEGs still 
produced crystal showers. However, the PEG400 condition resulted in distinct rod 
shaped crystals (Figure 3.62) and lower concentrations of PEG400 produced larger rod 
crystals (Figure 3.62A and C). However, these crystals were unfortunately too thin to 
collect data from. We also reduced the concentration of protein added to the wells 
from 10mg/ml to 5 mg/ml to attempt to reduce the number of nucleation points which 
would lead to fewer but larger crystals growing. Reducing the concentration of 
complex to 5mg/ml did reduce the number of crystals that grew but did not increase 









Proplex A8 PEG 
Screen 
1 2 3 4 5 6 
A 
Proplex A8 PEG3550       
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3550 4% 6% 8% 10% 12% 15% 
B 
Proplex A8 PEG4000       
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG4000 4% 6% 8% 10% 12% 15% 
C 
Proplex A8 PEG8000       
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG8000 4% 6% 8% 10% 12% 15% 
D 
Proplex A8 6%PEG (salt)       
0.2M Ammonium Sulphate 75mM 0.1M 0.125M 0.15M 0.175M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3550 6% 6% 6% 6% 6% 6% 6% 
E 
Proplex A8 8%PEG (salt)       
0.2M Ammonium Sulphate 75mM 0.1M 0.125M 0.15M 0.175M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG3550 8% 8% 8% 8% 8% 8% 8% 
F 
Proplex A8 PEG550 MME       
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
 PEG550 MME 6% 10% 15% 20% 25% 30% 
G 
Proplex A8 PEG550    
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG550 6% 10% 15% 20% 25% 30% 
H 
Proplex A8 PEG400    
0.2M Ammonium Sulphate 0.2M 0.2M 0.2M 0.2M 0.2M 0.2M 
0.1M Na Acetate pH5.5 0.1M 0.1M 0.1M 0.1M 0.1M 0.1M 
PEG400 6% 10% 15% 20% 25% 30% 
 
Figure 3.61. Table showing conditions used to optimise the crystallisation of the 
EBNA2.14aa peptide-RBP-Jk8-435-DNA complex. Different polymers of polyethylene 
glycol (PEG) were combined with proplex A8 crystallisation condition to attempt to 














Figure 3.62. Pictures of crystals of EBNA2.14aa peptide, C-terminally His-tagged RBP-
Jk8-435 (expressed in E.coli) and RBP-Jk consensus site DNA complex grown in Proplex 
A8 PEG optimisation plate at different concentrations. A. A small rod-shaped crystal 
of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex. The complex did not grow crystal 
showers however these crystals were too thin to expose to an x-ray source. B. A small 
rod-shaped crystal of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex growing out of 
crystalline precipitate can be seen. These crystals were too thin to expose to an x-ray 
source. C. Small rod-shaped crystals of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex 
are shown growing out of crystalline precipitate. These crystals were too small to be 
fished. D. A small rod-shaped crystal of EBNA2.14aa peptide-RBP-Jk8-435-DNA complex. 
Although the crystals did not grow crystal showers these crystals were too thin to 




Proplex A8 opt 5mg/ml H4: 0.2M Ammonium 
Sulphate, 0.1M Na Acetate pH5.5, 20% PEG400 
 
Proplex A8 opt 5mg/ml H5: 0.2M Ammonium 
Sulphate, 0.1M Na Acetate pH5.5, 25% PEG400 
 
Proplex A8 opt 5mg/ml Hand pipetted: 0.2M NH4 
Sulphate, 0.1M Na Acetate pH5.5, 20% PEG400 
 
Proplex A8 opt 10mg/ml H4: 0.2M Ammonium 








3.3.3.1 : Expression of a conserved region of EBNA2 to co-crystallise with RBP-Jκ8-435-DNA 
complex 
As we were unable to optimise a crystallisation condition for the RBP-Jκ8-435-DNA-
EBNA2.14aa complex we decided to express and purify larger RBP-Jκ binding region of 
EBNA2 (EBNA2272-333) in insect cells to try and increase the likelihood of obtaining a 
structure of a RBP-Jκ-DNA-EBNA2 complex.  
A Masters student from Dr Chrisostomos Prodromou group had produced a pFastBac 
vector that contained cDNA to express N-terminally His-tagged EBNA2272-333 but had 
found the construct expressed the EBNA2 produced poorly and was not stable in 
solution. We therefore decided to co-express EBNA2272-333 with RBP-Jκ8-435 and 
anticipated that RBP-Jκ8-435 would stabilise EBNA2272-333 during expression and 
purification. We also decided to switch the His-tag on the EBNA2272-333 to a StrepII tag 
to aid its stability during purification by inserting the EBNA2272-333 cDNA into the 
polyhed MCS of the pFastBacCP17.2 vector. 
The cDNA coding for EBNA2272-333 was successfully amplified from the vector produced 
by Dr Chrisostomos Prodromou masters student (Figure 63A). The EBNA2272-333 DNA 
fragment was ligated into a polyhed MCS of the a pFastBac co-expression vector 
containing either RBP-Jκ8-435 or RBP-Jκ variant 2 cloned into the p10 MCS (pF.JK.8-435) 
(Figure 3.63B) . These co-expression vectors were transposed into bacmids to produce 
recombinant baculovirus that would co-express N-terminally His-tagged RBP-Jκ variant 
2 or C-terminally His-tagged RBP-Jκ8-435 with N-terminally StrepII-tagged EBNA2272-333, 
(Figure 3.63 C and D).  
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We tested the expression of insect cells infected with the p1 recombinant baculovirus. 
N-terminally His-tagged RBP-Jκ variant 2 and C-terminally His-tagged RBP-Jκ8-435 were 
shown to be expressed (Figure 3.64A). Western blot analysis also showed that the 
EBNA2272-333 was being co-expressed in both the recombinant baculovirus (Figure 
3.64B). Unfortunately, due to time constraints we were unable to optimise large scale 


















Figure 3.63. Production of pFastBac plasmids co-expression EBNA2 aa272-333 and C-
terminally His-tagged RBP-Jk8-435 or N-terminally His-tagged RBP-Jk variant 2 and the 
transposition of these vectors into a bacmids. A. PCR products of cDNA encoding a 
fragment of EBNA2 aa272-333. The expected band size is 187bp. B. Diagnostic 
restriction digests of different clones following ligation of cDNA of EBNA2.272-333 into 
a pFastBac vector containing C-terminally His-tagged RBP-Jk8-435. Clones 1 to 3 
produced products approximately the predicted size and were sent for sequencing. All 
clones contained the correct product. C, D. The pFastBac Vectors containing 
EBNA2.272-333 and either N-terminally His-tagged RBP-Jk variant 2 or C-terminally His-
tagged RBP-Jk8-435 were transposed into bacmids to produce recombinant baculovirus. 
Diagnostic PCRs amplified entire transposed region in the bacmid. Expected band sizes 














Figure 3.64. Western blot analysis of insect cells co-expressing N-terminally Strep-
tagged EBNA2272-333 with N-terminally His-tagged RBP-Jk variant 2 or C-terminally 
His-tagged RBP-Jk8-435. A. Bacmids containing pFJK.V2.272 or pFJK.8-435.272 were 
transfected into Sf9 insect cells and cell lysates were prepared after 72 hours. Samples 
were run on a 10% Tris-SDS gel and probed with an anti-His antibody. Purified His-
tagged Epstein-Barr virus ZTA protein was used as a positive control. Expected band 
sizes for N-terminally His-tagged RBP-Jk variant 2 and C-terminally His-tagged RBP-Jk8-
435 were 54kDa and 49kDa respectively. B. The same samples were run on a 10% Tris-
SDS gel and probed with an anti-strep-tag antibody. Expected band size for the 
EBNA2272-333 fragment was 11.2kDa. C. Coomassie stained gels of the transfection 
reactions. 
  
A B C 
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3.3.3.2 : Expression of full length EBNA2 and the EBNA3C homology domain to co-
crystallise with RBP-Jκ8-435-DNA complex.  
Due to the RBP-Jκ8-435-DNA-EBNA2.26aa complex proving challenging to crystallise we 
also attempted to co-crystallise the RBP-Jκ8-435-DNA complex with full length EBNA2 
and constructs of the EBNA3C homology domain containing RBP-Jκ binding motifs.  
The same Masters student from Dr Chrisostomos Prodromou group had produced a 
recombinant P2 baculovirus that expressed N-terminally His-tagged full length EBNA2. 
We tested whether it expressed EBNA2 with a small scale insect cell infection. EBNA2 
was poorly expressed as we could detect EBNA2 by western blot analysis (Figure 3.65) 
but no clearly distinguishable bands were shown in the stained gel of the same cell 
pellet (Figure 3.65). EBNA2 also appears to partially degraded (Figure 3.65). We 
therefore decided to co-express full length EBNA2 with C-terminally His-tagged RBP-
Jκ8-435 in insect cells to attempt to improve stability. 
Full length EBNA2 cDNA was successfully amplified from a vector produced by Dr 
Chrisostomos Prodromou Masters student (Figure 3.66A) and cloned into the pFastBac 
expression vectors with N-terminally His-tagged RBP-Jκ variant 1 or 2, or C-terminally 
His-tagged RBP-Jκ8-435 (Figure 3.66B and C). Full length EBNA2 cDNA was successfully 
ligated into the polyhed MCS of the pFastBac expression vectors, which had a N-
terminal StrepII-tag, with N-terminally His-tagged RBP-Jκ variant 1 or 2, or C-terminally 
His-tagged RBP-Jκ8-435 cloned into the p10 MCS (Figure 3.66D).  
Full length EBNA3C had previously been expressed in insect cells by Michelle West’s 
group but was insoluble and partially degraded. The Homology domain (HD) of the 
EBNA3 family is predicted to contain secondary structure so we decided to focus on 
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expressing the EBNA3C HD (Zhao et al., 1996, Yenamandra et al., 2009). EBNA3C100-356 
(3CHD.1) was based on an EBNA3C construct previously used to study EBNA3C-RBP-Jκ 
interactions (Calderwood et al., 2011). Based on alignments of the EBNA3 family we 
designed an additional construct, EBNA3C100-431 (3CHD.2), to include a hydrophobic 
region which we predicted maybe be important for folding. 
We made pFastBac vectors to express N-terminally His-tagged EBNA3C100-356 or 
EBNA3C100-431 and co-express C-terminally His-tagged RBP-Jκ8-435 with N-terminally 
StrepII-tagged EBNA3C100-356 or EBNA3C100-431. We initially amplified cDNA to generate 
EBNA3C100-356 or EBNA3C100-431 destined for the p10 (N-terminal His-tag) or the polyhed 
(StrepII-tag) MCS of the pFastBac vector (Figure 3.67A). We successfully inserted cDNA 
to express EBNA3C100-356 or EBNA3C100-431 into empty pFastBac vector and pF.JK.8-435 
respectively (Figure 3.67B-E).  
We next transposed pF.JK.8-435.EB2, pF.EB3CHD.1, pF.EB3CHD.2, pF.JK.8-435.3CHD.1 
and pF.JK.8-435.3CHD.1 into bacmids to generate recombinant baculovirus. Due to the 
large size of the DNA transposed into the bacmid we were unable amplify the entire 
transposed region to check for successful transposition as the polymerase was unable 
to extend such a large piece of DNA. We determined whether the vectors had been 
successfully transposed by amplifying the bacmid with the forward primers used to 
amplify each of the inserts and the M13 primer most proximal to the insert (Figure 
3.68A).  
Unfortunately, only the bacmid containing pF.EB3CHD.1 expressing N-terminally His-
tagged EBNA3C100-356 was successfully transfected (Figure 3.69). The insect cells should 
appear swollen if the cells have successfully been transfected as this is indicative of 
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baculovirus production. However, after this transfection it was mot clear whether the 
insect cells were swollen. As there was no way to quantify this swelling we were 
unable to show this data.  Due to the cloning strategy being similar to the strategy 
used to produce pF.JK3.272 co-expression vector it was unlikely that there were 
transcriptional issues with EBNA2 and EBNA3C HD constructs. Additionally, RBP-Jκ8-435 
and EBNA2272-333 had been successfully expressed using the same expression system 
(Figure 3.64) which would suggest EBNA3C HD and EBNA2 should have been also 
expressed if the transfection had been successful. Therefore, it was most likely that the 
transfection had been unsuccessful but due to time constraints we were unable to 
repeat the unsuccessful transfections. However, we were able to do one large scale 
insect cell expression of N-terminally His-tagged EBNA3C100-356.  
A Co2+ column (Talon 5ml) was used for the first purification step (Figure 3.70A). 
EBNA3C100-356 was poorly expressed as the expected 29.5kDa bands were faint and not 
the dominant band on the gel (Figure 3.70A). We pooled eluates from the Co2+ column 
purification for size exclusion (S200 10/300 column) to separate the EBNA3C100-356 
from the impurities. Some loss of impurities was observed but it was unclear which 
protein was EBNA3C100-356 so performed a western blot of the size exclusion step 
fractions (Figure 3.70 B and C). The overall yield of EBNA3C100-356 was approximately 
0.4mg which was poor for a 3L prep. This was not enough EBNA3C100-356 to set up 
crystal trials or ITC binding assays. The Coomassie stained gel and the western blot 
showed that there were still significant amounts of impurities in the sample so more 
purification steps would have likely been needed to improve the quality of the 




Figure 3.65. Western blot and SDS-PAGE of analysis of baculovirus expression of N-
terminally His-tagged full length EBNA2. 100ml Sf9 insect cells were infected with 
baculovirus that expressed for N-terminally His-tagged full length EBNA2. Samples 
were taken every day, boiled in GSB and run on a 10% Bis-Tris SDS PAGE. The western 
was probed with an anti-EBNA2 antibody using a lysate from GM12878 cells line as a 
positive control. At higher exposure the positive control is visible. The Coomassie was 
stained in SimplyBlue gel stain. Although the expected mass of EBNA2 is 49kDa EBNA2 




Figure 3.66. Cloning of gene expressing Full length EBNA2 into a pFastBac co-
expression vector containing C-terminally His-tagged RBP-Jk8-435 or N-terminally His-
tagged RBP-Jk variant 1 or variant 2. A. PCR products of cDNA encoding full length 
EBNA2 (1464bp expected size) from pUC19.EB2. B. Restriction digests of pF.JK.V1, 
pF.JK.V2 and pF.JK.8-435. C. Restriction digest of full length EBNA2 cDNA. D. Diagnostic 
restriction digests of different clones following ligation of full length EBNA2 cDNA into 














Figure 3.67. Cloning of genes expressing EBNA3C100-356 (3CHD.1) or EBNA3C100-413 
(3CHD.2) into a pFastBac17.2 vector or a pFastBac co-expression vector containing C-
terminally His-tagged RBP-Jk8-435. A. PCR of cDNA encoding EBNA3C100-356 (3CHD.1) or 
EBNA3C100-413 (3CHD.2) from pUC19.EB3C. p10 (N-terminally his-tagged) and polyXS (N-
terminally strep-tagged) denote the multiple cloning site (MCS) in the pFastBac vector 
the cDNA will be inserted to. B. Restriction digest of inserts and destination vectors 
previously described. C. Diagnostic restriction digests of ligation of cDNA of EBNA3C100-
356 (3CHD.1) or EBNA3C100-413 (3CHD.2) into a pFastBac17.2 vector p10 MCS. D. 
Diagnostic restriction digests of ligation of cDNA containing EBNA3C100-356 (3CHD.1) or 
EBNA3C100-413 (3CHD.2) into a pF.JK.8-435 vector into the polyhed MCS. E. Diagnostic 
restriction digests of ligation of cDNA containing EBNA3C100-356 (3CHD.1) into a pF.JK.8-













Figure 3.68. Diagnostic PCRs of pFastBac vectors, with EBNAs cDNA or cDNA to co-
express EBNAs with C-terminally His-tagged RBP-Jk8-435, transposed into bacmids. A. 
Diagnostic PCRs of vectors pF.JK.8-435.EB2, pF.EB3C.HD1, pF.EB3C.HD2, pF.JK.8-
435.EB3C.HD1 and pF.JK.8-435.EB3C.HD1 transposed into bacmids. Shown are the 
combination of primers used in each of the diagnostic PCRs (M13 forward (M13F), 
M13 reverse (M13R) with the forward primer of each insert). B. A schematic of the 











































Figure 3.69. Western blot analysis of Sf9 insect cells infected with P1 baculovirus 
expressing EBNAs or co-expressing EBNAs with C-terminally His-tagged RBP-Jk8-435. A. 
Bacmids containing pF.JK.8-435.EB2, pF.EB3C.HD1, pF.EB3C.HD2, pF.JK.8-
435.EB3C.HD1 and pF.JK.8-435.EB3C.HD1 were transfected into Sf9 insect cells and cell 
lysates were prepared after 72 hours. Samples were ran on a 10% Tris-SDS gel and 
probed with an anti-His antibody. Purified His-tagged RBP-Jk8-435 was used as a positive 
control. Expected band sizes for C-terminally His-tagged RBP-Jk8-435, N-terminally His-
tagged EBNA3C100-356 (3CHD.1) and N-terminally His-tagged EBNA3C100-413 (3CHD.2) 
were 49kDa, 32kDa and 38.2kDa respectively. B. The same samples previously 
described were run on a 10% Tris-SDS gel and probed with an anti-Strep antibody. 
Expected band sizes N-terminally strep-tagged EBNA3C100-356 (3CHD.1) and N-
terminally strep-tagged EBNA3C100-413 (3CHD.2) were 33.7kDa and 39.9kDa 
respectively. Although the expected mass of EBNA2 is 49kDa EBNA2 runs at 
















Figure 3.70. Analysis of Co2+ column (Talon) and size exclusion purification steps of N-
terminally His tagged EBNA3C100-356 expressed in 5 litres of insect cells. A. Coomassie 
stained gel showing elution fractions from Co2+ column (5ml Talon FF GE life sciences) 
as an increasing concentration of imidazole was passed through. All wells shown were 
pooled as it was not clear which contained EBNA3C HD. B. Coomassie stained gel 
showing elution fractions from size exclusion purification step. N-terminally His tagged 
EBNA3C100-356 was loaded onto a Superdex S200 10/300 calibrated in EB3C Buffer C. C. 
Samples from the size exclusion step were boiled and run on a 4-12% Tris SDS page gel, 
then probed with anti-His antibody.  A His-tagged PU.1 construct was used as the 
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3.3.4.1 : Conclusions of the structural studies of EBNA-RBP-Jκ complexes 
We were unable to obtain crystals of EBNA2.14aa-RBP-Jκ-DNA complex that were 
suitable for X-ray diffraction. We showed that the EBNA2 peptide was not present in 
the crystal structure and had not been incorporated into the complex (Figure 3.49). 
This was likely caused by the contact points of the crystal that were over the BTD of 
RBP-Jκ forcing the peptide out of the WФP binding pocket. In addition to this the 
crystal produced low resolution data. This was likely caused by the free space that was 
between the complexes in the lattice reducing resolution and the fact that the crystal 
contained two crystals stacked on top of each other. This generated shadow spots of 
intensity when we were exposing the crystal to the X-ray source. Shadow spots make 
resolving structures difficult as they create diffractions that do not represent the 
structure you are attempting to resolve yet are incorporated into Fourier transform 
calculations making the scatter data challenging to process.  
One potential issue with our protocol for preparing the EBNA2.14aa-RBP-Jκ-DNA 
complex was that we concentrated the RBP-Jκ-DNA before adding the peptide. This 
potentially could have made the solution congested and sterically prevented the 
EBNA2.14aa peptide from binding to the RBP-Jκ. However, this was dismissed when a 
postdoc from Michelle West’s group incubated EBNA2.14aa with RBP-Jκ-DNA before 
concentrating and showed that this did not improve crystallisation of the EBNA2.14aa-
RBP-Jκ-DNA complex. 
We then attempted to co-crystalise EBNA peptides with RBP-Jκ expressed in E.coli. 
With the higher and more consistent yields of RBP-Jκ expressed in E.coli we were able 
to broaden the range of crystallisation strategies. We also switched using EBNA2.26aa 
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peptide to EBNA2.14aa as amino acid chains not bound to RBP-Jκ were thought to be 
one of the reasons for the low quality resolution of the RAM domain of Notch in the 
structure of the Notch ternary complex (Wilson and Kovall, 2006). Even after testing 
large numbers of different crystallisation conditions to crystallise EBNA2.14aa-RBP-Jκ-
DNA expressed in E.coli we were not able to discourage the crystals from forming 
crystal showers (Figure 3.57, 3.58, 3.60 and 3.62). 
Finally, we attempted to express constructs of the EBNAs individually and in co-
expression vectors. Again, based on previous studies of the EBNA TΦGC and WΦP RBP-
Jκ binding motifs by and we chose to express the EBNAs in insect cells (Zhao et al 1996, 
Calderwood et al 2011)(Figure 3.69). We also tried to co-express the EBNAs with RBP-
Jκ as we hypothesised that RBP-Jκ would confer stability to the EBNAs as they were 
being expressed (Figure 3.69). We also utilised StrepII-tag as it is eluted from 
StrepTactin resin using desthiobiotin which is significantly less harmful to proteins than 
imidazole. Time constraints and unsuccessful transfections meant we were only able to 
produce a baculovirus that could express his-tagged EBNA3C100-356 (3CHD.1)(Figure 
3.69 and 3.70). However, EBNA3C100-356 expressed poorly and due to time constraints 








Chapter 4 : Discussion 
4.1 : Future strategies for the crystallisation of EBNA peptides bound to RBP-Jκ  
The largest obstacles we encountered when optimising crystallisation conditions whilst 
expressing RBP-Jκ in insect cells was that the production of recombinant baculovirus, 
expression and purification processes were slow. Inconsistent yields also meant that 
planning crystallisation strategies was also difficult. It is possible that the quality of the 
RBP-Jκ expressed in insect cells was likely of a higher quality than the RBP-Jκ expressed 
in E.coli, due to processing by eukaryotic folding machinery. However, the extra time 
that it took to express RBP-Jκ in insect cells largely negated this benefit. Additionally, 
we showed using ITC that the ability of the EBNA2.14aa peptide to bind to RBP-Jκ was 
not affected by which expression system had been used to produce RBP-Jκ (Figure 
3.27). Therefore for the purpose of crystallising the EBNA2.14aa-RBP-Jκ-DNA complex, 
the RBP-Jκ expressed in E.coli was suitable.  
Even after testing large numbers of different crystallisation strategies we were not 
able obtain crystals of EBNA RBP-Jκ complexes. We were able to produce a 3.63Å 
structure of RBP-Jκ8-435 bound to DNA where the crystal packing forces had appeared 
to displace EBNA2 peptide from the BTD of RBP-Jκ. This may have occurred due to the 
EBNA2 peptide having significantly weaker affinity for RBP-Jκ than Notch peptide 
(Figure 3.24).   
Novel constructs of RBP-Jκ could be generated for future trials to prevent crystal 
packing forces from displacing EBNA2 peptide from the crystal. Adding tags to RBP-Jκ 
and binding RBP-Jκ to different DNA nucleotides could also encourage an EBNA2-RBP-
Jκ-DNA to crystallise into different lattices and symmetries. This could potentially 
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prevent crystal showers from growing, encourage tighter packing to improve 
resolution and prevent crystal contact points being established over the hydrophobic 
WΦP binding pocket of the BTD.  
A potential way of co-crystallising RBP-Jκ-EBNA2 peptide complex would be to 
reproduce the crystallisation strategy that produced structure of Hairless bound to 
Suppressor of hairless (Su(H)) complex (Figure 4.1)(Yuan et al., 2016). Su(H) is the D. 
melanogaster homologue of RBP-Jκ and hairless, which there is no known human 
homologue, binds to Su(H) to silence notch signalling. Traditionally Maltose binding 
Protein (MBP) tags are cleaved off and are only attached to proteins to improve 
solubility however, in this structure the MBP tag was not cleaved off hairless as the 
MBP-tag formed key contact points in the crystal lattice. The lattice that was produced 
consisted of very tightly packed complexes, which produced a 2.14Å resolution 
structure, one of the highest resolution structures of a RBP-Jκ homologue (Figure 4.1). 
The crystallisation strategy used to produce the structure of the Notch1 transcription 
complex could also be attempted by substituting the RAM domain peptide for EBNA2 
peptide in the Notch complex. However, our SwitchSense data indicated that the 
EBNA2 peptide induced conformational changes to RBP-Jκ, which may differ to the 
conformation induced by Notch RAM domain binding, potentially disrupting the 
assembly of the Notch transcription complex when attempting to co-crystallise it with 
the EBNA2 peptide. 
Another potential solution to ensuring that the EBNA2.14aa peptide remained bound 
to RBP-Jκ during crystallisation would be to produce a fusion protein of RBP-Jκ and 
EBNA2 CR6, which contains the WΦP RBP-Jκ binding motif. A significant challenge to 
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designing a RBP-Jκ fusion protein is that the N and C termini of RBP-Jκ are shown in the 
structure of the Notch 1 transcription complex to protrude from the NTD and CTD 
away from the BTD (Choi et al., 2012). This would mean a flexible linker chain would 
have to be introduced to allow the EBNA2 CR6 to interact with the BTD of RBP-Jκ. 
However, in the structure of the Notch transcription activation complex the amino acid 
linker that connects the RAM domain to the ANK repeats was suggested to contribute 
to the low resolution of the structure (Nam et al., 2003, Choi et al., 2012). Also 
increasing the length of the amino acid chain linker that connects the Notch ANK and 
RAM domains has been shown to reduce the strength of RBP-Jκ-Notch interactions 







Figure 4.1. Crystal Structure of MBP-tagged Hairless bound to the Suppressor of 
Hairless-Hes-1 site complex. MBP-tag shown in pink, Hairless shown in yellow and 
Suppressor of Hairless shown in blue. Structure resolved by Yuan et al 2016 to 2.14Å 










4.2 : Production of recombinant EBNAs 
An ongoing problem that was encountered during attempts to express recombinant 
EBNAs was there poor solubility in vitro. This is likely due to the EBNAs being predicted 
to have predominantly disordered folding (Yenamandra et al., 2009). We attempted to 
express the EBNA3C homology domain in insect cells due to it being predicted to fold 
(Yenamandra et al., 2009) but despite this it expressed poorly and was unstable 
suggesting it relied on distal parts of the EBNA3C protein for stability. In LCLs EBNA3 
levels were not affected by the addition of cyclohexamide or interferon-γ, suggesting a 
low turnover and were suggested to be very stable in cells (Touitou et al., 2005, West, 
2006). Additionally pulse chase experiments and cycloheximide treatment also showed 
that EBNA2 was stable in cells for over 24 hours (Grässer et al., 1991). It has been 
suggested that the EBNAs rely on interactions with host cell folding proteins to achieve 
this. For example, EBNA3A induces the expression of and interacts in vitro with Hsp70 
(Young et al., 2008).   
We did not attempt to express EBNA2 and EBNA3C HD in E.coli as previous studies 
showed that EBNA-RBP-Jκ interactions are influenced by whether they were expressed 
in eukaryotic or prokaryotic expression systems (Henning, 2006, Johnson et al., 2010, 
Calderwood et al., 2011). However, Dr Rajesh Ponnusammy, working in the group in 
parallel, did attempt to express EBNA2 and EBNA3C homology domain in E.coli and 
yeast expression systems. He also found that the EBNA3s and EBNA2s were insoluble 
and expressed at low levels.   
One solution to improve solubility of the EBNAs in vitro would be to co-express them 
with binding partners such as host transcription factors they interact with. Although 
241 
 
we attempted to co-express the EBNAs with RBP-Jκ in insect cells we were unable to 
produce a recombinant virus capable of this and due to time constraints we were 
unable to repeat the transfections. However SKIP could be co-expressed with EBNA2 to 
improve stability as it has been shown to interact with EBNA2 in pull downs and 
mammalian two hybrid assays, and play a role in EBNA2 transactivation of RBP-Jκ 
mediated genes in reporter assays (Sifang Zhou, 2000). However, SKIP has not been 
expressed and purified in large quantities in vitro and not much is known about its 
stability. 
Another solution to finding a truncation of the each of the EBNAs that expresses well 
and is soluble in buffer would be to process cDNA encoding EBNA2 and the EBNA3s at 
the Oxford Protein Production Facility UK (OPPFUK). This research facility will initially 
produce an array of constructs capable of expressing a multitude of iterations of your 
protein of interest. The cDNA produced from this PCR step are cloned into vectors 
capable of being transformed or transfected into a host of E.coli strains and eukaryotic 
expression systems. In addition to this they have a library of tags to add to your 
protein of interest, such as MBP-tags and TRX-tags, to improve solubility. The precise 
mechanism to how MBP tags improve solubility of fusion proteins is not well 
understood and MBP tags ability to improve solubility is suggested to be dependent on 
the protein fused to the MBP tag (Nallamsetty and Waugh, 2006). TRX tags improve 
solubility and prevent the formation of inclusion bodies of their fusion partners with 
their oxido-reductase activity (LaVallie et al., 1993, Yasukawa et al., 1995, LaVallie et 
al., 2000). From here different constructs are expressed in plates in a multitude of 
expression hosts which can be probed for successful expression to provide a list of hits 
of successful constructs. Finally, the hits can be tested for solubility in a range of stock 
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lysis buffers the OPPFUK have designed. This broad screen could provide the key to 
finding a soluble and highly expressible truncation of the EBNAs suitable for 
thermodynamic and structural studies.  
4.3 : EBNA interactions with RBP-Jκ. 
4.3.1 : The Role of TFGC and WTP RBP-Jκ motifs in EBNA-RBP-Jκ interactions 
Our ITC data showed that, in the context of the peptide, Notch2 bound to RBP-Jκ an 
order of magnitude tighter than EBNA2. This suggests that in the context of an EBV 
infection it is unlikely that EBNA2 directly competes with Notch for RBP-Jκ for binding. 
However Notch1 is also expressed in B cells at different stages of B cell development 
and should also be tested to quantify how tightly it binds to RBP-Jκ to compare its 
affinity to EBNA2-RBP-Jκ interactions (He and Pear, 2003b). Additionally, our 
Switchsense data indicated that the EBNA2 peptide induced more severe 
conformational changes to RBP-Jκ than Notch induced. During an EBV infection this 
could allow EBNA2 to drive dynamic RBP-Jκ to bind specific promoters that aid the 
establishment of a persistent EBV infection. This unique conformation of RBP-Jκ 
induced by EBNA2 could also provide a unique platform to recruit transcriptional and 
epigenetic factors, not recruited by Notch, to manipulate host gene expression during 
an EBV infection.  
Surprisingly we found that in the context of a peptide that the TΦGC EBNA3 RBP-Jκ 
binding motif did not contribute to RBP-Jκ binding and did not compete with an EBNA2 
peptide for RBP-Jκ binding. We also showed that in vitro the WΦP motif in the EBNA3C 
peptide was essential for RBP-Jκ binding. In addition to this, we showed that residues 
in EBNA3A that mimicked the chemistry of the WΦP motif facilitated weak binding to 
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RBP-Jκ. This suggests that TΦGC motif may bind indirectly to RBP-Jκ via another host 
transcription factor or be essential to EBNA3 folding and the presentation of the WФP 
or a WΦP-like motif. However, the EBNA3 peptides we tested did not include two 
regions, which flank the TΦGC and WΦP motif, which are predicted to fold in to β-
sheets. If these regions had been included in the EBNA3 peptide designs they may 
have facilitated EBNA3 TΦGC motif binding to RBP-Jκ and should be tested in future 
studies (Yenamandra et al., 2009, Calderwood et al., 2011). 
However, we suggest that the scanning alanine mutations that were used to identify 
the TΦGC motif as directly binding to RBP-Jκ in past studies may have in fact perturbed 
the folding of EBNA3C and the presentation of WΦP motif rather than knocking out 
specific RBP-Jκ binding interactions (Robertson et al., 1996a). Most of the EBNA3C-
RBP-Jκ interaction studies were undertaken before research had showed that alanine 
mutations and truncations can have serious consequences for the overall folding of the 
protein interest (Studer et al., 2013). In addition to this mutating glycine residues is 
often avoided as they rotate freely allowing the protein to fold into tight turns. Glycine 
residues have been shown to be evolutionary conserved in kinases as they facilitate 
turns in protein loops essential for kinase folding but are not directly involved in 
protein-protein interactions (Barouch-Bentov et al., 2009).  
Rajesh Ponnusamy from our group produced a 3D model of the EBNA3C HD using 
RaptorX online modelling software (Figure 4.2). The EBNA3C model predominantly 
folds in to clusters of α-helices connected by disordered linkers with the TFGC and 
WTP motifs presented in a loop above anti-parallel β-sheets (Figure 4.2). In this model, 
the TFGC and the WTP RBP-Jκ binding motifs are in close proximity to each other and 
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presented on the surface of the protein on a loop. The two motifs appear close enough 
to form hydrogen bonds between the threonine residues from both motifs and could 
potentially have hydrophobic interactions between organic rings of the phenylanine 
and tryptophan residues from each of the RBP-Jκ binding motifs. We speculate from 
this model of the EBNA3C HD structure that the TFGC residues could play a role in the 
presentation of the WTP RBP-Jκ binding motif. Therefore, when the TFGC residues are 
mutated to alanines, EBNA3C is no longer correctly presenting the WTP motif 
preventing EBNA3C-RBP-Jκ binding. What this model cannot show is the effect of the 
TFGC-AAAA mutation on the overall structure of EBNA3C. However, it would be 
interesting to see if raptorX models of the EBNA3A and EBNA3B homology domains 
were predicted to fold in a similar conformation to the EBNA3C model and whether 
the RBP-Jκ binding motifs would be presented in similar positions. 
We also wanted to test whether the TFGC-AAAA mutations affected EBNA3Cs ability to 
bind other host targets. We intended to cross-link the DG75 cells transfected with wild 
type and TFGC mutants of EBNA3C. This would have fixed host transcription factors 
known to bind EBNA3C. We then intended to pull down full length EBNA3C, with an 
anti EBNA3C antibody conjugated to beads, and probe the pulldowns products for 
RBP-Jκ and other known binding targets of EBNA3C using western blot analysis. We 
hypothesised that if the EBNA3C TFGC-AAAA mutation was deleterious to the folding 
of EBNA3C we would have seen that EBNA3C interactions with other host target 














Figure 4.2. A 3D model of the EBNA3C homology domain produced on RaptorX 
software. Model was produced by Dr Rajesh Ponnusamy from Michelle West’s group. 
Shown in grey is EBNA3C HD with the TFGC and WTP motifs shown in green pink 
respectively. Highlighted in the box is the TFGC and WTP EBNA3C RBP-Jκ binding 











4.3.2 : Modelling peptides of the EBNAs binding to the Beta-trefoil domain  
As we were unable to obtain structures of EBNA bound to RBP-Jκ we modelled 
peptides of EBNA2, EBNA3A, EBNA3B and EBNA3C on to the structure of the Lag1-
Lin12 RAM-DNA complex (the worm Notch complex homologue)  by mutating the 
residues of the lin12 RAM domain to EBNA residues using WinCoot software 
(Friedmann et al., 2008)(Figure 4.3). We chose to use the Lag1-Lin12 RAM-DNA 
complex structure due to Lag-1 having a proline residue proceeding the WTP motif as 
the EBNAs do (Friedmann et al., 2008). Whether the WTP is proceeded by a proline or 
not has been shown in other structures to dictate which direction the RAM domain 
binds to RBP-Jκ after the WΦP motif. Although the biological consequence of this has 
not been investigated. The tryptophan residue of the EBNA2 and EBNA3C WΦP RBP-Jκ 
binding motif, in the model, fits well in the a hydrophobic pocket of the BTD (Figure 
4.3). This was not surprising as mutation of this tryptophan to serine ablates Notch and 
EBNA2 binding to RBP-Jκ (Johnson et al., 2010, Calderwood et al., 2011)(Figure 4.3). 
Even though EBNA3A lacks a WΦP RBP-Jκ binding motif we showed using ITC that FKL 
residues in the same position as the EBNA3C WΦP motif bound weakly to RBP-Jκ. The 
model of EBNA3A bound to CSL reveals that the phenylanine ring fits well into the 
same hydrophobic pocket the tryptophan in the WФP motif binds (Figure 4.3). The 
EBNA3B Valine residue, despite being hydrophobic, does not appear to fit so tightly 
into the hydrophobic pocket in the BTD (Figure 4.3). This may explain why we were 
able to measure binding using ITC for the EBNA3A.33a-RBP-Jκ interaction but not for 
the EBNA3B.33a-RBP-Jκ interaction. If this interaction is shown to be biologically 
relevant then it may offer an explanation of the differences between each of the 
EBNA3s abilities to inhibit EBNA2 transactivation of RBP-Jκ mediated genes. The 
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evidence comparing how EBNA3s bind to RBP-Jκ is conflicting though. EBNA3A 
expressed in EBV infected B cells was shown to co-immunoprecipitate transfected RBP-
Jκ more so than EBNA3C and EBNA3B (Robertson et al., 1996a, Waltzer et al., 1996). 
However GST-tagged EBNA3A expressed in E.coli pulled down RBP-Jκ less efficiently 



















Figure 4.3. Models of peptides of the EBNA RBP-Jκ WΦP binding motifs bound to 
CSL. Models were generated by mutating the residues of the Lin-12 peptide, on Wilson 
et al 2007 structure of C.Elegans Lag-1-DNA-lin-12 structure, to residues of EBNA2, 
EBNA3A, EBNA3B or EBNA3C aligned to the WTP motif of Lin-12 using WinCoot 
software. RBP-Jκ, lin-12, EBNA2, EBNA3A, EBNA3B and EBNA3C are shown in blue, 











4.3.3 : Finding potential host candidates that could facilitate indirect EBNA3C binding to 
RBP-Jκ. 
To find potential host proteins that bridge EBNA3C and RBP-Jκ via EBNA3Cs TFGC motif 
ChIP-mass spectroscopy or ChroP could be used to probe latency III EBV infected cell 
lines such as GM1278, MutuIII or LCLs to identify chromatin interacting proteins in EBV 
cells. Cross-linking these cells, pulling down EBNA complexs using antibodies specific to 
EBNA3C and identifying the proteins bound using mass spectroscopy may identify host 
proteins which aid EBNA3C gene mediation and stability. In order to focus on RBP-Jκ 
interactions it would be useful to carry out parallel experiments using an anti-RBP-Jκ 
antibody to allow identification of proteins bound by both factors.  
The SwitchSwense bioassay allowed us to investigate how RBP-Jκ interacts with 
peptides of the EBNAs containing RBP-Jκ binding motifs whilst being bound to DNA. 
We showed that EBNA2 peptide caused the conformation of RBP-Jκ to compact more 
so than Notch2 peptide. Notch Ram domain has previously been shown to be integral 
to Notch complex assembly as it causes conformational changes to RBP-Jκ that provide 
a platform for the rest of the complex to assemble upon (Friedmann et al., 2008). This 
more compact EBNA2 induced RBP-Jκ conformation could provide a unique platform 
for different array host factors to bind to, to enhance EBV induced B cell 
immortalisation, and potentially a novel site for EBNA3C to associate with. However, 
this would need to be confirmed with in vitro assays such as the EMSA used to study 
the assembly of the CSL-Notch complex (Friedmann et al., 2008). 
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4.3.4 : Potential mechanisms and alternative RBP-Jκ binding pockets for EBNA3C to 
facilitate inhibition of EBNA2 transactivation 
Recent publications have shed light on how Notch signalling maybe turned off by 
proteins such as KyoT2 (mouse) and MINT (human) competing off Notch from RBP-Jκ 
via a WΦP motif (Kuroda et al., 2003, VanderWielen et al., 2011, Collins et al., 2014). 
Our ITC data would suggest EBNA3A and EBNA3C may also compete with EBNA2 for 
RBP-Jκ binding via a WΦP/ WΦP-like motif in a similar manner to these regulators of 
Notch signalling. However more research needs to be carried to confirm whether 
EBNA3A and EBNA3C bind directly to RBP-Jκ via WΦP/ WΦP-like motifs in vivo. 
Our ITC data also suggests that the EBNA3 TΦGC motif may require folding to interact 
with RBP-Jκ directly. So far no homologues of the EBNA3 TΦGC motif or the EBNA3 
homology domain have been identified in humans (White et al., 2010). This suggests 
that EBNA3s may interact with RBP-Jκ via a binding site not yet identified in mammals. 
Active Suppressor of hairless (Su(H)), the drosphila homologue of RBP-Jκ, is silenced by 
Hairless binding to a cluster of leucines which form a hydrophobic pocket in the CTD of 
Su(H) (Figure 4.1) (Yuan et al., 2016). We had intended to investigate whether this 
pocket was utilised by EBNA3C to silence EBNA2 transactivation of RBP-Jκ. We 
designed and produced His-tagged RBP-Jκ8-435 with alanine mutants of the CTD hairless 
binding pocket to use as bait to see if it was still able to pull down EBNA3C expressed 
in DG75 cells. However, due to time constraints we were unable to optimise this 
pulldown. However, this CTD hairless pocket is gaining interest as a potential 
therapeutic target for small molecule inhibitors to attempt to treat cancers which have 
deregulated Notch signalling (Yuan et al., 2016).  
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4.3.5 : Connotations of TFGC-AAAA mutation not knocking out specific RBP-Jκ binding 
interactions to the study of EBV 
The TFGC motif not contributing to direct EBNA3C-RBP-Jκ binding not only changes the 
model of how we think the EBNA3s interact with RBP-Jκ but potentially affects how we 
study EBV. The EBNA3C TFGC-AAAA mutant has often been used as a negative control 
for studying EBNA3-RBP-Jκ interactions in vitro and is increasingly being used a 
negative control in studies studying the global changes EBV elicits on host chromatin 
conformation and host gene expression. EBV research groups are using increasingly 
more complex techniques such as Chip-Seq, Capture Hi-C and SILAC Mass Spectroscopy 
to map the EBV-induced global changes to host chromatin conformation, gene 
expression and proteasome (McClellan et al., 2013a, Ohashi et al., 2015, Traylen et al., 
2015, Kalchschmidt et al., 2016, Wood et al., 2016). RBP-Jκ regulates genes, which 
control B cell maturation and growth making it a key target for EBV induced 
immortalisation of B cells and a significant area of interest to EBV researchers (Bigas et 
al., 2010, Kalchschmidt et al., 2016, Lu et al., 2016).  If EBNA3CTFGC-AAAA mutants are to 
be used as negative controls we need to fully understand the contributions TФGC 
motif makes to EBNA3-RBP-Jκ interactions as researchers risk drawing misleading 
conclusions.  
4.4 : Fluorescent Polarisation binding assay could be used to screen for inhibitors of 
EBNA-RBP-Jκ interactions. 
Targeting the WTP binding pocket in the BTD of RBP-Jκ as a therapeutic strategy has 
not been pursued due to the Notch signalling pathway role in the development of 
many cells in the body that have a high turnover such as lymphocytes (Bigas et al., 
2010, Bray, 2016). However, we showed with ITC that the EBNA2 WTP motif binds to 
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RBP-Jκ with 10-fold weaker affinity than Notch 2 does. The FP assay, adapted to 
function in a drug screen machine such as a FlexStation PHERAStar FS, could be used to 
screen compounds that compete off the fluorescein tagged EBNA2 peptide from RBP-
Jκ but do not interfere with binding between fluorescein tagged Notch peptide and 
RBP-Jκ. If such a compound was discovered in these screens it would at least serve as a 
useful tool to study how EBV infected cell lines without EBNA2 transactivated RBP-Jκ 
expression function, whilst avoiding the difficulties associated with inserting or 
deleting genes using electroporation or lentiviral techniques. In addition to this 
EBNA2s has a half-life of over 24 hours in immortalised B cell lines whereas Notch is 
turned over rapidly to tightly control notch signalling which may reduce the likelihood 
of an EBNA2 inhibitor interfering with Notch signalling (Grässer et al., 1991, Oberg et 
al., 2001).  If compounds were considered effective at selectively inhibiting EBNA2-
RBP-Jκ interactions they could be used to study EBV induced Post transplant 
lymphoproliferative disorder (PTLD). Patients who receive allogeneic hematopoetic 
stem cell transplants are at a particularly high risk of EBV associated PTLD due to their 
T cell count, including EBV specific T cells, being low and the high likelihood of donor 
cells being infected with EBV creating an environment permissive for EBV cancers to 
develop (Ruf et al., 2011). Screening for EBV in donor stem cells and pre-emptive 
prescription of anti-CD23 antibodies (Rituximab) to patients with low T cell counts can 
greatly reduce the risk of PTLD developing (Styczynski et al., 2009, Tomblyn et al., 
2009). In addition to this immunotherapy involving EBV specific T cells has been shown 
to be an effective treatment for PTLD malignancies (Heslop et al., 2010). However for 
patients receiving cord blood transplants there is rarely more donor sample to derive 
EBV-specific T cells from and some patients do not respond to rituximab (Muramatsu 
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et al., 2011, Rasche et al., 2014). A small molecule inhibitor that targeted EBNA2-RBP-
Jκ interactions to disrupt EBV malignancies could be used as a preventative strategy for 
stem cell transplant patients or potentially as a treatment for cord blood transplant 
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Appendix 1 : Table of primers 
Primer  Primer Target Sequence 5’ to 3’ 
RBP-Jκ 8-435 Forward SmaI RBP-Jκ (aa8-435) with 
the C-terminal His-tag 
cDNA 
TAACCCGGGATGGGTGAGCGGCCTCCA 
RBP-Jκ 8-435 Reverse XbaI GCGAAGCTTTCAGTGGTGGTGGTGGTG 
pUC/M13 Forward * 
 
Diagnostic PCR of 
Transposition site of 
Bacmid 
CCCAGTCACGACGTTGTAAAACG 
pUC/M13 Reverse * 
 
AGCGGATAACAATTTCACACAGG  
EBNA3C T>A Forward 
 
Mutagenesis of TFGC 
RBP-Jκ binding motif of 
EBNA3C 
TTAACTGCCGCATTTGGATGCCAAAAT 
EBNA3C F>A Forward 
 
TTAACTGCCACAGCTGGATGCCAAAAT 
EBNA3C TF>AA Forward 
 
TTAACTGCCGCAGCTGGATGCCAAAAT 
EBNA3C TFGC mutant Reverse CATGATGCTGTCAGCCCCAACC 
EBNA3C STP Forward 
 
Mutagenesis of WTP 
RBP-Jκ binding motif of 
EBNA3C 
ACCGTGTCGACACCACCC 
EBNA3C STP Reverse GGCAGAGAAGGTGTTTAGAGTTCGTGC 
T7 sequencing primer ** Sequence pSG5 vector 
from T7 promoter 
TAATACGACTCACTATAGGG 










EBNA2 fragment Reverse BamHI TATGGATCCTTAGGGTTGCGGGGGGTCG 
EBNA2FL Reverse SalI 
 
Full length EBNA2 
cDNA 
TATGTCGACTTACTGGATGGAGGGGCGA 
EBNA2FL Forward NheI, XbaI *** CGGACGGAGCTCTCTAGAGCTAGCATG 
CCTACATTCTATCTTGCG 




destined for p10 MCS  
ATAGCTAGCCACGACATCACACCATAT      
3CHD.1 p10 Reverse NheI 
 
AATAAGCTTTCACGTTGCTAACATTGATAA 
3CHD.2 p10 Reverse NheI 
 
AATAAGCTTTCATGCAGGCACACGGCTCAC 
3CHD polyhed Forward XbaI EBNA3C100-356 and 
EBNA3C100-413 cDNA 
destined for polyhed 
MCS 
TAATCTAGACACGACATCACACCATAT 
3CHD.1 polyhed Reverse BamHI ATTGGATCCTCACGTTGCTAACATTGATAA 
3CHD.2 polyhed Reverse BamHI AATGGATCCTCATGCAGGCACACGGCTCAC 
pFastBac F sequencing primer ** Sequence DNA inserted 
into pFastBac p10 MCS 
TCCGGATTATTCATACCGTCCC 
pFastBac R sequencing primer ** CCTCTACAAATGTGGTATGGCTG 
Polyhed_fwd Sequence DNA inserted 
into pFastBac polyhed 
MCS 
AAAATGATAACCATCTCG 
Polyhed reverse *** GTCGAGAAGTACTAGAGGAT 
*primers designed by Invitogen Bac-to-Bac expression kit 
** designed by Eurofins sequencing service 










Appendix 2 : Table of vectors  
Vector  Inserts 
pET28B.JK.8-435* 
 
RBP-Jκ8-435 with a C terminal His tag 
pFastBac.CP17.2 pFastBac co-expression vector produced by Dr Christomous Prodromou with a p10 MCS with 
a N-terminal His-tag, a polyhed MCS with a N-terminal StrepII-tag and a LoxP site for 
combining two pFastBac.CP17.2 vectors. 
pF.JK.V1 
 
p10 MCS: Full length RBP-Jκ Variant 1 with an 
N-terminal His-tag 
polyhed MCS: Empty 
pF.JK.V2 
 
p10 MCS: Full length RBP-Jκ Variant 2 with an 
N-terminal His-tag 
polyhed MCS: Empty 
pF.JK.8-435 
 
p10 MCS: RBP-Jκ (aa8-435) with a C-terminal 
His-tag  
polyhed MCS: Empty 
pSG5 Vector that can be transfected into DG75 cell line to overexpress insert 
 
pSG53C** Full length EBNA3C Cdna 
 
pSG53C.Jκ** Full length EBNA3C cDNA with TFGC mutated to AAAA 
 
pSG53C.STP Full length EBNA3C cDNA with WTP mutated to STP 
 
pSG53C.Jκ.STP Full length EBNA3C cDNA with TFGC mutated to AAAA and WTP mutated to STP 
pSG53C.TA Full length EBNA3C cDNA with TFGC mutated to AFGC 
 
pSG53C.FA Full length EBNA3C cDNA with TFGC mutated to TAGC 
 
pSG53C.TFAA Full length EBNA3C cDNA with TFGC mutated to AAGC 
 
pF.CP17.272*** p10 MCS: EBNA2272-333 with an N-terminal His-
tag 
polyhed MCS: Empty 
pF.JK.V1.272*** 
 
p10 MCS: Full length RBP-Jκ Variant 1 with an 
N-terminal His-tag 




p10 MCS: Full length RBP-Jκ Variant 2 with a 
N-terminal His-tag 




p10 MCS: RBP-Jκ8-435 with a C-terminal His-tag  polyhed MCS: EBNA2272-333 with an N-
terminal StrepII-tag 
pF.CP17.EB2*** p10 MCS: Full length EBNA2 with an N-
terminal His-tag 
polyhed MCS: Empty 
pF.JK.V1.EB2 p10 MCS: Full length RBP-Jκ Variant 1 with an 
N-terminal His-tag 
polyhed MCS: Full length EBNA2 with an N-
terminal StrepII-tag 
pF.JK.V2.EB2 p10 MCS: Full length RBP-Jκ Variant 2 with a 
N-terminal His-tag 
polyhed MCS: Full length EBNA2 with an N-
terminal StrepII-tag 
pF.JK.8-435.EB2 p10 MCS: RBP-Jκ (aa8-435) with a C-terminal 
His-tag 
polyhed MCS: Full length EBNA2 with an N-
terminal StrepII-tag 
pcDNA3.EBNA3C**** pcDNA3 vector containing full length EBNA3C cDNA  
 
pF.EB3C.HD1 p10 MCS: EBNA3C100-356 with an N-terminal 
his-tag 
polyhed MCS: Empty 
pF.EB3C.HD2 p10 MCS: EBNA3C100-413 with an N-terminal 
his-tag 
polyhed MCS: Empty 
pF.JK.8-435. 
EB3C.HD1 
p10 MCS: RBP-Jκ (aa8-435) with a C-terminal 
His-tag 




p10 MCS: RBP-Jκ (aa8-435) with a C-terminal 
His-tag 
polyhed MCS: EBNA3C100-413 with a N-
terminal StrepII-tag 
* pET28B.JK.8-435 was produced by a summer student in Michelle West’s Group. 
**pSG53C and pSG53C.Jκ were produced by Dr Helen Webb from Michelle West’s Group. 
***pF.CP17.272 and pF.CP17.EB2 vectors were produced by a  masters student from Dr Christomous Prodromou group. 






Appendix 3 : Table of Buffers and Reagents 
Agarose Gel 
TBE Tris base, Boric acid and EDTA 
Agarose tablets Bioline 0.5g DNase and RNAse free agarose tablets 
DNA loading dye Bromothenol blue and cyanol F 
Gel red Biotium Gel RedTm Nucleic acid gel stain  
SDS-PAGE, Coomassie and Western blotting 
Gel sample buffer (GSB) 50mM Tris pH6.8, 4% SDS, 10% β-Mercaptoethanol, 0.01% Bromophenol blue, 10% 
Glycerol, 1mM EDTA 
SDS-PAGE gel (10% and 4-12% Bis-tris 
gel) Supplied by Novex (LifeTechnologies) 
SDS running buffer (MOPS) 
Simply blue stain  Supplied by Invitrogen 
Ponceau Supplied by Sigma Bioreagents 
ECL Solution 1: Luminol Stock, Coomaric acid, 1M tris pH8.5 
Solution 2: H2O2, 1M tris pH8.5 
Mixed immediately prior to use 
Milk powder The Co-operative powdered milk 
Transfer buffer 4 litre dH2O, 1 litre methanol (Fisher), 75g Glycine (Fisher), 15g Tris(hydroxymethyl)-
methylamine (Fisher) 
PBS Tween 100 tablets PBS (Fisher) in 10 litre of water, Tween 20 (Fisher)  
Antibodies 
Anti-His tag Target: 6xHis-tag, Species: mouse, Supplied by Sigma Aldrich 
Anti-StrepII tag Target: strepII-tag, Species mouse, Supplied by Life Technologies 
Anti EBNA2 Target: EBNA2, Species: mouse, Produced in Lab 
Anti EBNA3C Target: EBNA3C, Species: mouse, Supplied by Sigma Aldrich 
Insect cell culture 
SF900II medium 
Supplied by LifeTechnologies 
Sf9 cells 
Trypan Blue Supplied by Invitrogen 
Bacmid preparation 
MAX Efficiency DH10Bac™ 
Competent E.coli 
Supplied by LifeTechnologies 
SOC medium 
Gentamicin 
Tetracyclin Supplied by Thermo-Scientific 
Kanamycin 
Supplied by Fisher Bioreagents  IPTG 
X-Gal 
70% ethanol 
Supplied by Fisher Scientific 
3M potassium acetate pH 5.5 
Transfection and baculvirus plaque assay  
CellfectinII 
Supplied by LifeTechnologies Neutral red 
High purity agar  
EMSA 
EMSA stock buffer 5 x Buffer: 50mM Tris pH7.5, 5mM MgCl, 2.5mM EDTA, 2.5mM DTT, 250mM NaCl, 
0.25µg/µl PolydIdC, 20% glycerol 
6% DNA retardation gel Supplied by Novex (LifeTechnologies) 
E.coli Cells 
DH5α compotent cells  Supplied by Invitrogen 
LB 
Supplied by Fisher Scientific 
LB Agar 
Competent Rosetta ply5 De3 Supplied by Invitrogen 
NEB DH5α competent E.coli Supplied by NEB 
Enzymes and Buffers 
Phosphatase Alkaline Supplied by Roche 
DNA T4 Ligase Supplied by New England Biolabs 
Ligase Buffer (10x buffer) Supplied by New England Biolabs : 50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 10mM 
DTT, pH 7.5 
High fidelity Phusion DNA Polymerase 
Supplied by New England Biolabs 
Phusion HF buffer (5x) 
Phusion GC buffer (5x) 
Taq DNApolymerase 
Standard Taqpol (10x buffer) 
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Purification of RBP-Jκ expressed in insect cells 
Buffer A (lysis) 50mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP 
Buffer B (elution) 50mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP, 1M imidazole 
Buffer C (low salt buffer) 20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP 
Buffer D (high salt buffer) 20mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP 
Purification of RBP-Jκ expressed in E.coli 
Buffer A (lysis) 50mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP, 10mM imidazole 
Buffer B (elution) 50mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP, 1M imidazole 
Buffer C (low salt buffer) 20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP 
Buffer D (high salt buffer) 20mM Tris pH8.8, 500mM NaCl, 0.5mM TCEP 
Thermodynamic assay buffers 
Dialysis Buffer  20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP, 0.5mM EDTA 
ITC Buffer 20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP, 0.5mM EDTA, 2% DMSO 
FP (fluorescent polarisation assay) 
Buffer 
20mM Tris pH8.8, 100mM NaCl, 0.5mM TCEP, 0.5mM EDTA, 2% DMSO, 1% IPEGAL 
SwitchSense Buffer  20mM Tris pH8.8, 50mM NaCl, 0.5mM TCEP, 0.5mM EDTA 
Purification of EBNA3C homology domain expressed in insect cells 
Buffer A (lysis) 50mM Tris pH8.0, 500mM NaCl, 0.5mM TCEP, 20mM imidazole, 5% glycerol 





Hot start Q5 high fidelity mix 
KLD mix 
λ-phosphatase Supplied by Sigma Aldrich 
Competent cells 
Buffer I 100mM RbCl, 50mM MnCl2.4H2O, 30mM KOAc, 10mM CaCl2, 15% v/v Glycerol, pH to 
5.8 with 0.2M Acetic Acid 
Buffer II 10mM RbCl, 10mM MOPS, 75mM CaCl2,15% v/v Glycerol 
pH to 6.8 with 1M NaOH 
In-gel digestion and Mass spectroscopy 
Coomassie destain 50% MeCN, 25 mM NH4HCO3 
Reduction buffer 10 mM DTT, 25 mM NH4HCO3 
Alkylation buffer 50 mM iodoacetamide, 25 mM NH4HCO3 
Trypsin solution 12.5 ng/ul trypsin, 25 mM NH4HCO3 
Formic acid Supplied by Fisher Bioreagents 
MeCN Supplied by Fisher Bioreagents 
Mass Spectrometer loading buffer 0.1% Trifluoroacetic acid (TFA) 
NanoLC buffer A 0.1% Formic acid 
NanoLC buffer B MeCN, 0.1% Formic acid 
Crystallisation trials 
PacT 96 deep well block 
Supplied by Molecular Dimensions JCSG plus 96 deep well block 
Proplex 96 deep well block 
Natrix 96 deep well block Supplied by Hampton Research 
Additive screen 96 deep well block Supplied by Molecular Dimensions 
CsCl prep and pull downs 
SolI 50 mM Glucose, 25 mM Tris HCl pH8,10 mM EDTA 
SolII 0.2M NaOH, 1% SDS 
SolIII 5M K acetate, Glacial Acetic Acid  
Buffer PD 50mM Tris pH7.5, 150mM NaCl, 20mM MgCl2, 1% NP-40, 0.5% Na Deoxycholate 
DG75 Cell culture 
RPMI 1640 Medium 
Supplied by LifeTechnologies 
100X Penicillin/ streptomycin  
PBS 
Foetal Bovine serum (FBS) 
DG75 cell line Maintained by Michelle West Laboratory 
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Appendix 4 : Table of peptides 
Peptides were ordered from Peptide Synthetics and arrived purified to 98% purity, in 
powder form and were stored at -20oC. The peptides were dissolved in DMSO and 
stocks were flash frozen in liquid nitrogen and stored at -80oC. 














EBNA3A.14aa    
 
VHLQATLGCTGGRR 
EBNA3B.14aa    
 
VLVTATLGCDEGTR 
EBNA3C.14aa    
 
IMLTATFGCQNAAR 
EBNA3C.Phos.14aa    
 
IMLTAT(P)FGCQNAAR 















EBNA3C.33aa.mTFGC.mWTP   TAAAAAQNAARTLNTFSATVAAAPHAGPREQER 
 
 
 
